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Summary  
Due to modern high-throughput technologies, large numbers of compounds are 
produced by parallel synthesis and combinatorial chemistry.  The pharmaceutical 
industry therefore requires rapid and accurate methods to screen new drugs leads for 
membrane permeability potential in the early stages of drug discovery.  Around 50 % 
of all investigational new drugs fail in pre-clinical and clinical phases of development 
due to inadequate absorption/permeation, distribution, metabolism, excretion and/or 
unacceptable toxicity.  This may be decreased by applying in vitro screening methods 
early in the discovery process.  Reliable in vitro models can be applied to determine 
permeation of the test compounds, which will help avoid the wasting of valuable 
resources for the development of drugs that are destined to fail in preclinical and 
clinical phases due to insufficient permeability properties.  It is important to decide as 
early as possible on the most promising compound and physical formulation for the 
intended route of administration. 
   
With awareness of the increasing importance of in vitro models in the investigations 
of the permeability properties of drug compounds, this research project was 
specifically devoted to determine the suitability of our in vitro model to evaluate and 
predict drug permeability.  A continuous flow-through diffusion system was employed 
to evaluate the permeability of nine different compounds/drugs with different 
chemical properties, across three biological membranes.  The biological membranes 
chosen for the present study were human vaginal mucosa, human skin tissue and 
human small intestine mucosa.  The continuous flow-through diffusion system was 
furthermore utilised to investigate the effects of de-epithelialisation of mucosal 
surfaces, chemical enhancers, temperature, permeant concentration and formulation 
on the permeability of the test compounds/drugs.  The in vitro permeability 
information and data from the flow-through diffusion model were compared to in vitro 
and in vivo literature studies and drug profile.  An in vitro model that is able to reliably 
predict in vivo data will shorten the drug development period, economise resources 
and may potentially lead to improved product quality. 
 
In this thesis research results are reported on the permeability of the mentioned 
biological membranes to the various chemical markers, including anti-HIV (human 
immunodeficiency virus) drugs.  The permeability studies will be discussed in three 
sections: vaginal mucosa, skin tissue, small intestine mucosa.   
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The results of the vaginal permeability studies showed that the three peptides (MEA-
5, MDY-19 and PCI) readily penetrated the vaginal mucosa.  MDY-19 had a higher 
flux rate than MEA-5, commensurate with its smaller molecular size (weight).  The 
surfactant enhanced the flux rate of MDY-19 approximately 1.3 times and decreased 
the lag time of the peptide.  Removal of the vaginal epithelium increased the flux 
rates of the peptides across the mucosa and may have implications for a more rapid 
uptake of these and other microbicides in vivo.  The permeability of 1 mM MDY-19 
and PCI at 37 °C were significantly (p<0.05) higher than at 20 °C.  At 37 °C the AUCs 
of the overall mean flux values of MDY-19 and PCI increased with concentration 
according to well-established diffusion theory. 
 
The experiments on the permeability of different terbinafine hydrochloride 
formulations through human skin demonstrated that the terbinafine hydrochloride 
formulations used in this study, readily diffused into the skin tissue.  However, no flux 
values for any of the terbinafine hydrochloride formulations through the skin into the 
acceptor fluid were found.  The mean terbinafine concentrations in the skin after 24 h 
exposure to the three commercial, terbinafine hydrochloride formulations were 3.589, 
1.590 and 4.219 µg/ml respectively.  The mean terbinafine concentration in the skin 
exposed to the 10 mg/ml PBS/Methanol solution was higher than those from the 
three commercial formulations.   
 
The results of the temperature study demonstrated that an increase of 5 ºC caused a 
significant increase in flux values of tritiated water across skin.  The flux values for 
tritiated water across skin at 37 ºC were on average double those at a temperature of 
32 ºC. 
 
The permeability of excised human small intestine mucosa to different oral dosage 
drugs was investigated over a 24 h period.  The four drugs selected were zidovudine, 
propranolol hydrochloride, didanosine and enalapril maleate.  They were selected as 
representative model compounds of drug classes 1 (high solubility, high permeability) 
and 3 (high solubility, low permeability) according to the Biopharmaceutics 
Classification System.  The flux rates of the four chosen test drugs were influenced 
by the length of the experiment.  Between the time periods 2-4 h and 4-6 h, 
zidovudine’s mean flux values across small intestine tissue were respectively 1.8 and 
2.0 times higher than didanosine and 2.3 and 2.2 times higher than enalapril. 
Propranolol’s mean flux values were respectively 1.2 and 1.4 times higher than 
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didanosine and 1.6 higher than enalapril during both the 2-4 and 4-6 h time periods.  
Between both the time periods 2-4 and 4-6 h AZT’s mean flux values were 1.4 times 
higher than propranolol and didanosine’s mean flux values were respectively 1.3 and 
1.1 times higher than enalapril during the mentioned time periods.  Class 1 drugs 
showed a significantly higher flux rate across the jejunal mucosa compared to the 
class 3 drugs and these results are in line with their Biopharmaceutics Classification 
System classification.  The in vitro model has proved to be reliable to predict 
permeability of class 1 and 3 drugs and also showed correlation with human in vivo 
data. 
 
It seems that the in vitro flow-through diffusion model used in the present study have 
the potential to overcome some of the problems and limitations demonstrated by 
other in vitro techniques and may potentially serve as a future tool for pharmaceutical 
companies to predict the diffusion characteristics of new drugs and different 
formulations, across different biological membranes.  Furthermore, it may serve as a 
prospective method for assessing the bioequivalence of alternative (generic) vehicles 
or formulations containing the same drug/compound.    
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Opsomming 
As gevolg van moderne hoë spoed tegnologie kan groot hoeveelhede middels 
vervaardig word deur ooreenkomende sintese en kombinasieleer chemie.  Die 
farmaseutiese industrie benodig dus vinnige en akkurate metodes om nuwe 
geneesmiddels te evalueer t.o.v. membraan deurlaatbaarheid.  Hierdie evaluasie 
moet verkieslik so vroeg moontlik in die geneesmiddel se ontwikkelingsproses 
geskied.  Ongeveer 50 % van alle potensiële geneesmiddels misluk in pre-kliniese en 
kliniese fases van geneesmiddelontwikkeling.  Die mislukte pogings kan toegskryf 
word aan onvoldoende absorbsie/deurlaatbaarheid, distribusie, metabolisme, 
ekskresie en/of onaanvaarbare middel toksisiteit.  Dit is daarom belangrik om so 
vroeg moontlik in die geneesmiddelontwikkelingsproses te besluit op die mees 
belowende middel, asook die geskikte formulasie vir die spesifieke roete van 
toediening van die middel.  Die farmaseutiese industrie benodig tans in vitro modelle 
met die potensiaal om die deurlaatbaarheid van geneesmiddels te bepaal en te 
voorspel.  Betroubare in vitro modelle kan aangewend word om die deurlaatbaarheid 
van potensiële geneesmiddels te toets.  Sodoende sal die onnodige uitgawes op die 
ontwikkkeling van geneesmiddels wat in elk geval later gaan faal in pre-kliniese en 
kliniese fases van geneesmiddelproewe a.g.v. deurlaatbaarheidseienskappe, vermy 
word. 
 
Hierdie navorsingsprojek was dus spesifiek onderneem om die waarde en 
toepaslikheid van ‘n in vitro deurlopende-vloei perfusie model te ondersoek.  Die 
model se potensiaal om geneesmiddels se deurlaatbaarheid en absorpsie te 
voorspel was geëvalueer.  Die deurlopende-vloei perfusie apparaat was gebruik om 
die deurlaatbaarheidsvloede van drie verskillende biologiese membrane t.o.v. nege 
chemiese stowwe (MEA-5, MDY-19, PCI, terbinafien hidrochloried, getritieerde 
water, zidovudien, propranolol, hidrochloried, didanosien, enalapril maleaat) te 
bepaal.  Die drie biologiese membrane wat gebruik was, was vaginale weefsel, vel 
en klein intestinale weefsel.  Al drie weefsel tipes was van menslike oorsprong.  Die 
deurlopende-vloei perfusie apparaat was ook gebruik om die effek wat verwydering 
van die mukosa se epiteellaag op deurlaatbaarheidsvloede het, te ondersoek.  
Verder was navorsing gedoen op die effek van temperatuur en die konsentrasie en 
formulasie van die toetsmiddels op hulle diffusie vloedwaardes.  Daar was ook gekyk 
na die invloed van ander chemiese stowwe op die toetsmiddels se diffusie 
vloedwaardes.  Die in vitro deurlaatbaarheidsinformasie en -gegewens was vergelyk 
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met ander in vitro en in vivo literatuurstudies en geneesmiddel databasisse.  ‘n In 
vitro model wat in staat is om in vivo resultate betroubaar te voorspel, het die 
potensiaal om die tyd wat dit neem om geneesmiddels te ontwikkel, te verkort, 
finansiële uitgawes te besnoei en om geneesmiddelkwaliteit te verseker. 
 
In die tesis word dan die resultate gerapporteer van die deurlaatbaarheidsvloede van 
die verskillende tipes weefsel ten op sigte van verskeie chemiese stowwe, 
insluitende anti-MIV (menslike immuniteitsgebreksvirus) middels.  Die 
deurlaatbaarheidstudies word bespreek in drie afdelings: vaginale mukosa, vel en 
klein intestinale mukosa. 
 
Die resultate van die deurlaatbaarheidstudies op die vaginale weefsel dui daarop dat 
die drie peptiede (MEA-5, MDY-19 and PCI) die vaginale mukosa goed penetreer.  
Soos verwag, het MDY-19 hoër diffusie vloedwaardes as MEA-5 gehad.  Dit kan 
toegeskryf word aan MDY-19 se kleiner molekulere grootte (gewig).  Surfaktant het 
die diffusie vloedwaardes van MDY-19 1.3 keer vergroot en het ook die tyd na vaste 
vlak verminder.  Die verwydering van die vaginale epiteel het die diffusie 
vloedwaardes van die peptiede verhoog en mag dus dui op die vinniger opname van 
peptiede en moontlike ander mikrobisiede in vivo, wanneer die belyning van die 
epiteel onderbreek.  Die deurlaatbaarheid van 1 mM MDY-19 en PCI by 37 °C was 
satisties beduidend (p<0.05) hoer as teem 20 °C.  Die area onder die kurwe (AOK) 
van die gemiddelde vloedwaardes van MDY-19 en PCI by 37 °C, het toegeneem met 
‘n toename in die konsentrasie van hierdie peptiede. Die toename vloedwaardes 
ondersteun dus die alombekende diffusie teorie.   
 
Die transdermale diffusie eksperimente van verskillende terbinafien formulasies het 
getoon dat terbinafien geredelik vrygestel word vanuit hierdie formulasies na die vel.  
Geen terbinafien vloedwaardes, van enige van die formulasies, was egter gevind in 
die ontvangselle van die deurlopende-vloei perfusie apparaat nie.  Die gemiddelde 
terbinafien konsentrasies in die vel na 24 h se blootstelling aan drie kommersiële 
terbinafien hidrochloried formulasies was onderskeidelik 3.589, 1.590 en 4.219 
µg/ml.  Die gemiddelde terbinafien konsentrasie in die vel wat aan 10 mg/ml 
PBS/metanol blootgestel was, was hoër as die konsentrasies in die vel wat aan die 
drie kommersiële formulasies blootgestel was. 
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Die resultate van die temperatuurstudie op vel het aangetoon dat ‘n temperatuur 
toename van 5 ºC  ‘n statisties beduidende toename in vloedwaardes van 
getritieerde water oor vel veroorsaak.  Die vloedwaardes van die getritieerde water 
oor vel teen ‘n temperatuur van 37 ºC was gemiddeld dubbeld so veel as teen 32 ºC. 
 
Die deurlaatbaarheidsvloede van klein intestinale mukosa ten opsigte van 
verskillende geneesmiddels (wat oraal toegedien word) was ondersoek gedurende ‘n 
24 h eksperiment.  Die vier geneesmiddels wat gebruik was, was zidovudine, 
propranolol hidrochloried, didanosien en enalapril maleaat.  Hierdie geneesmiddels is 
verteenwoordigers van die Biofarmaseutiese Klassifikasie Sisteem se klas 1 (hoë 
oplosbaarheid, hoë deurlaatbaarheid) en klas 3 (hoë oplosbaarheid, lae 
deurlaatbaarheid) geneesmiddels.  Die vloedwaardes van die vier geneesmiddels het 
gewissel na aanleiding van die tydsverloop in die eksperiment.  Zidovudien se 
gemiddelde vloedwaardes tussen 2-4 en 4-6 h was onderskeidelik 1.8 en 2.0 keer 
hoër as didanosien se gemiddelde vloedwaardes vir hierdie tyd periodes en 
onderskeidelik 2.3 en 2.2 keer hoër as enalapril se gemiddelde vloedwaardes.  
Tydens hierdie selfde periodes was propranolol se gemiddelde vloedwaardes 1.2 en 
1.4 keer hoër as didanosien en vir beide periods 1.6 keer hoër as enalapril se 
gemiddelde vloedwaardes.  Gedurende beide genoemde tyd periodes was 
zidovudien se gemiddelde vloedwaardes 1.4 keer hoer as propranolol en didanosien 
se gemiddelde vloedwaardes was onderskeidelik 1.3 en 1.1 keer hoër as enalapril 
tydens 2-4 en 4-6 h.  Die klas 1 geneesmiddels het statisties beduidende hoër 
vloedwaardes gehad as die klas 3 geneesmiddels.  Hierdie resultate stem ooreen 
met die geneesmiddels se Biofarmaseutiese Klassifikasie Sisteem klassifikasie.  Dit 
wil dus voorkom asof die in vitro model wat gebruik was in die studie, gebruik kan 
word om die deurlaatbaarheidsvloede van klas 1 en 3 te voorspel.  Die resultate van 
hierdie studie stem ooreen met ander in vivo studies. 
 
Dit wil voorkom asof die in vitro deurlopende-vloei perfusie apparaat die potensiaal 
het om sommige van die probleme en tekortkominge van ander in vitro modelle te 
oorkom en dat dit moontlik die potensiaal het om die diffusie-eienskappe van nuwe 
geneesmiddels en verskillende formulasies oor verskillende biologiese membrane te 
voorspel.  Die model kan verder moontlik dien as ‘n potensiële toestel om 
biogelykbaarheid van alternatiewe (generiese) formulasies, wat dieselfde 
geneesmiddel/chemiese stof bevat, te bepaal. 
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A    membrane area exposed (cm2) 
ACE   angiotensin converting enzyme  
ANN  artificial neural network 
API   active pharmaceutical ingredient 
AUC  area under curve  
AZT   zidovudine 
BA/BE  bioavailability/bioequivalence 
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BCS   Biopharmaceutics Classification System 
Capp   the applied concentration 
Cs,v and Cs,m  the solubility of the drug in the vehicle and in the barrier respectively 
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CV   coefficient of variation 
D    the diffusion coefficient of skin 
dATP   deoxyadenosine triphosphate 
DNA   deoxyribonucleic acid 
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EMPRO  European Microbicides Project 
FDA   Food and Drug Administration 
FITC   fluorescein isothiocyanate 
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GI    gastrointestinal 
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H     the diffusional pathlength 
HIV   human immunodeficiency virus 
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MALT   mucosal-associated lymphoid tissues 
MDCK  Madin–Darby canine kidney  
MDY-19  FITC (fluorescein isothiocyanate)-labelled peptide, Mw = 2409.5 Da.  
It is a transport peptide that has potential applications for transporting 
therapeutically active compounds into cells. 
MEA-5  FITC (fluorescein isothiocyanate)-labelled peptide, Mw = 2911.4 Da.  
It is an antibacterial peptide that binds to cell surfaces. 
MEM   minimum essential medium 
MIC   minimum inhibitory concentration 
MW  molecular weight 
P450  cytochrome P450 
PBS   phosphate buffered saline 
PCI  FITC (fluorescein isothiocyanate)-labelled peptide, Mw = 2325 Da.  It 
is a transport peptide that has potential applications for transporting 
therapeutically active compounds into cells. 
PG   1,2-dipalmitoyl-L-α-phophatidylglycerol 
pKa  negative logarithm of the acid dissociation constant 
PNP   purine nucleoside phosphorylase  
Q    quantity of drug crossing membrane (μg) 
QSAR   quantitative structure-permeability relationship 
QSPR   quantitative structure-activity relationship 
ROF   rule-of-five  
RSD  relative standard deviation 
RT   retention time 
SC   stratum corneum 
SD   standard deviation 
SEM  standard error of the mean 
t    time of exposure (min) 
TEER  transepithelium electrical resistance  
USP   United States Pharmacopeia  
UV    ultraviolet 
WHO   World Health Organisation  
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Chapter 1: Introduction of literature review 
The traditional drug administration routes used were oral administration for systemic 
effects and topical for local effects.  Drugs could also be self-administered by inhalation, 
suppository and sometimes injections.  The other routes of delivery usually required the 
intervention of a healthcare provider and the pain, fear and the possibility of infections 
associated with injections often resulted in low patient compliance and therefore have 
aided the development of suitable non-parenteral routes of administration.  Technology 
advancement in drug delivery has allowed for a wider choice of sites for drug 
administration.  During the last two decades attention has shifted to alternative drug 
administration routes, which allowed a single intervention by a healthcare provider to 
provide sustained therapy (Alexander et al., 2004).  Suitable non-parenteral routes 
include mucosal surfaces of the vagina and skin (Starokadomskyy and Dubey, 2006; 
Pettit and Gombotz, 1998).   
 
Increasing attention is therefore given to using mucosae or skin as a non-invasive drug 
administration route for systemic delivery.  The high vascularity and accessibility of the 
mucous membranes, as well as the relative absence of proteolytic enzymes, have made 
this tissue a potential route for administration of peptides and proteins.  The skin has a 
surface area of approximately 2 m2 and receives about a third of the body‟s blood 
circulation (MacKie, 1987).  Since it is the biggest organ (that of an average adult male 
weighs 4.5 to 5 kg) and easily accessible, it offers great opportunities for the 
administration of therapeutic compounds (Williams, 2003).   
   
Unfortunately, all of these approaches have some limitations, particularly in view of the 
fact that mucosal linings and stratum corneum of the skin have important protective 
functions in the body.  Mucosae protect the deeper lying tissues and organs from 
mechanical damage, act as barriers against the many potentially invasive organisms 
colonizing the tissue, prevent fluid loss from underlining tissues and prevent the ingress 
of many harmful chemical agents.  The skin regulates heat and water loss from the body 
and protects the body from the penetration of harmful chemicals or microorganisms, 
including agents applied to the skin.  The stratum corneum seems to be the main 
permeability barrier of the skin and provides an incredibly effective barrier to penetration, 
even though it is merely 15-20 µm thick (Hadgraft, 2001b).   
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Oral administration still dominates drug therapy and more than 60 % of marketed drugs 
are oral products (Masaoka et al., 2006).  This type of drug administration is preferred 
due to its convenience, high patient compliance, less stringent production conditions and 
lower costs.  Unfortunately, this traditional drug delivery method has its limitations, due 
to gastrointestinal permeability, metabolism and elimination of drugs by the liver or 
gastrointestinal mucosa (first-pass effect).  The main drawback of the oral route is that 
only those compounds that are stable in the gastrointestinal tract can be administered in 
this way.  For this reason, the oral route has been used for mainly non-peptide drugs 
(Starokadomskyy and Dubey, 2006).  
 
Investigation of the passage of chemical substances across various biological 
membranes is of high importance in devising systems for optimal drug delivery.  
Estimates of the permeability across biological membranes provide a valuable tool for 
determining the factors limiting the potential absorption and bioavailability of drugs 
(Katneni et al., 2006).  Numerous methods for drug administration exist and an 
increasing amount of research is focused on optimising delivery as a method of 
improving pharmacotherapy.  The availability of effective, highly reproducible, economic 
and rapid in vitro permeation assays for prediction of the drug absorption properties in 
humans is highly desirable for the preliminary screening of new drug compounds in the 
early stages of the drug discovery process, thus improving efficiency and the probability 
of success in the development of efficacious pharmaceutical formulations. 
 
The aim of the presented research project was to assess the suitability of an in vitro 
permeation simulation model based on the use of human tissue. The actual predictive 
power of the flow-through diffusion system will be tested on a wide range of 
compounds/drugs with different properties, including the model drugs belonging to two 
classes of the BCS.  Moreover, the accuracy of our method in assessing drug 
permeation potential and in establishing in vitro-in vivo correlations will be compared with 
that of the other principal in vitro methods available at present.   
 
The tissues selected were human vaginal mucosa, skin tissue and small intestine 
mucosa.   A diverse set of 9 test compounds/drugs were selected and the permeability of 
the different biological membranes to these compounds/drugs were investigated, to 
ensure a reliable model. 
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Due to the artificial milieu to which the excised tissues are exposed, it is crucial to ensure 
tissue viability and integrity during the experiment.  Previous studies with the in vitro 
flow-through diffusion system have shown that skin tissue, vaginal and intestinal mucosa 
can be frozen and banked without their permeability properties to a number of different 
permeants being changed.  In view of the foregoing, the assumption of using 
frozen/thawed vaginal mucosa, skin tissue and small intestine mucosa for the current 
permeability study was considered to be a reasonable one (Van der Bijl et al., 2003; Van 
der Bijl and Van Eyk, 2002; Van der Bijl et al., 1998a; Swarbrick et al., 1982; Franz, 
1975).  
 
1.1  In vitro permeability studies for drug testing  
Penetration of chemicals through vaginal mucosa, skin and gastrointestinal mucosa can 
be characterised using both in vivo and in vitro methods.  In vitro studies are generally 
conducted using a diffusion cell system with either a static or a flow-through cell.  There 
are several benefits of utilising an in vitro flow cell system for the initial testing of drug 
diffusion in the laboratory, prior to undertaking studies in human volunteers.  The 
environment, specific permeation parameters and variables may be controlled in an 
attempt to reveal specific factors affecting the kinetic processes of the transmembrane 
diffusion/penetration.    
 
Different types of diffusion equipment are available for the study of in vitro tissue 
permeability.  The different flow cells include the conventional static Franz cells (Fig. 1), 
the Ussing chamber (Fig. 2), as well as flow-through diffusion cells (Fig. 3) (Hug, 2002; 
Cόrdoba-Diaz et al., 2000).  All three types of cells contain a donor and acceptor 
compartment, between which a membrane/cell layer can be sandwiched.  Different 
variations of these designs are also available. Membranes/cell layers that are frequently 
used for permeability determination of the drug substance include excised human or 
animal intestinal tissue, monolayer of cultured epithelial cells (e.g. Caco-2 that are 
commonly used for intestinal permeability studies), artificial membranes and isolated 
membrane vesicles (Martinez et al., 2002; Ungell et al., 1998; Waclawski and Sinko, 
1996; Corti et al., 2006; Press and Di Grandi, 2008).  
 
Since Hans Ussing (Ussing, 1949) described the measurement of ion transport across 
frog skin held between two half chambers in 1949, numerous modifications of this 
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apparatus have been proposed for examining the in vitro permeability of a variety 
tissues.  The Ussing chamber may contain an additional amplifier and data acquisition 
system and can therefore be used for either electrophysiology- and/or diffusion-based 
studies.  One of the disadvantages of the original side-by-side arrangement of the 
Ussing chambers for measurements of skin permeability was the need to immerse both 
sides of the tissue in an aqueous environment, leading to hydration of the normally dry 
skin surface.  In 1975, Franz proposed a vertical design that allowed the membrane 
surface to remain dry and also facilitated the direct application (and removal) of different 
agents (Franz, 1975).        
 
Even though Franz cells and the Ussing system are regularly used in permeability 
studies it has certain shortcomings.  Both these models are labour intensive, since an 
accurate volume of sample must be removed at fixed time intervals from the acceptor 
compartment with a simultaneous media replacement to maintain sink conditions in the 
cells.  The manual sampling requires constant attention and is therefore often limited to 
the normal laboratory hours which mean a less accurate fitting of the curve. Also, air 
bubbles are easily formed in the receptor compartments while withdrawing samples, 
interfering with permeability results.     
 
 
  
 
 
 
 
 
 
 
 
 
 
 Fig. 1.  Schematic drawing of a Franz cell 
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   Fig. 2.  An Ussing chamber 
 
It is important to select an in vitro model design where the diffusion of the test compound 
is limited by the tissue and not in any stagnant diffusion (non-stirred) layers adjacent to 
the tissue‟s surface (Hadgraft and Lane, 2005).  A flow-through diffusion apparatus was 
used in the present study (Figs. 3 and 4).  The flow-through diffusion system has a 
constant flow of buffer and therefore does not have the problem of an unstirred water 
layer in the acceptor and donor wells, like the Franz and Ussing in vitro models, which 
may influence the permeability results.    It contains 7 flow-through diffusion cells.  Each 
cell contains an acceptor chamber through which there is a continuous flow of buffer.  
Since the flow-through diffusion apparatus has a constant flow (1.5 ml/h) of PBS through 
the acceptor chamber, any drug absorbed across the biological membrane is 
immediately carried away, preserving the concentration gradient as driving force for drug 
transport.  It was therefore accepted that sink conditions were maintained (at the 
completion of each run the concentration of permeant in the acceptor chamber never 
reached 10 % of that in the donor compartment), since there is not a method to measure 
concentration in the acceptor chamber.  In contrast to the static Franz and Ussing 
chamber cells, the flow-through diffusion cells offers automation with the addition of a 
pump that offers an accurate, constant flow rate of buffer.  The only other requirement is 
the addition of a fraction collector (Cόrdoba-Diaz et al., 2000).  A flow-through diffusion 
cell method, by virtue of continuous replenishment of perfusion medium, helps in 
maintaining the viability of the skin tissue/mucosa and thus would mimic better a 
physiological environment than a static cell.  The drug is added to the donor 
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compartment of the flow cell and collected by means of a fraction collector from the 
acceptor compartment of the flow cell.  This is done for the required time period of the 
experiment, at a constant flow rate.  The drug in the effluent may be detected by various 
means e.g. scintillation counting, UV spectroscopy, fluorospectroscopy, high-
performance liquid chromatography or LC/MS (Liquid Chromatography/Mass 
Spectrometry).  The use of small tissue samples (4 mm Ø for mucosa and 1 cm Ø for 
skin tissue) and the maintenance of a continuous high gradient of permeant across the 
biological membrane are major benefits of this system. The system has also potential for 
automatisation on a larger scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Fig. 3.  Schematic drawing of a flow-through diffusion cell 
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   Fig. 4.  Flow-through diffusion apparatus used in the present study 
 
 
 
 
Pump 
Fraction collector 
Flow-through diffusion cells (7x) 
   
                                 Chapter 1: Introduction of literature review                                13  
           
1
3
 
1.2  Primary aim 
Recent advances made in molecular biology and combinatorial chemistry have changed 
the way in which pharmaceutical companies conduct drug discovery research.  The 
biggest challenges are in screening a large number of drug candidates (synthesised in 
very small quantities, 1-10 mg) in a very short period of time.  Due to modern high-
throughput technologies, large numbers of compounds are produced by parallel 
synthesis and combinatorial chemistry.  The fields of miniaturisation and automation 
have made remarkable advancements to meet these challenges.  In contrast to the 
successful use of miniaturisation and automation in biological activity screening, 
intestinal permeability and absorption screening have not made similar progression.  
One of the most important challenges facing the pharmaceutical industry at present is to 
develop high-throughput, cost-effective and highly predictive screening models for drug 
absorption/permeation that can be used during the decision making process early in 
drug discovery.  Even though, physicochemical parameters such as lipophilicity, charge, 
molecular weight, etc. are often used as initial indicators of absorption, they are not 
entirely reliable because of their inability to incorporate the in vivo conditions. 
Furthermore, the available experimental methods for assessing the permeation and 
absorption characteristics of compounds have various disadvantages.  
 
With awareness of the increasing importance of the role played by in vitro models in 
investigations of the permeability properties of drug compounds, this research project‟s 
primary aim was to determine the suitability of our in vitro flow-through diffusion model to 
evaluate and predict drug permeability.  Towards this primary aim, a flow-through 
diffusion system was employed to evaluate the permeability of various biological 
membranes e.g. human vaginal mucosa, skin tissue and small intestine mucosa to a set 
of 9 different compounds/drugs with different solubility and permeability properties.  To 
serve as a suitable in vitro model with versatile applications, different test conditions 
were applied to evaluate the suitability of the in vitro flow-through diffusion system.  The 
different test conditions included the effect of epithelial stripping, chemical enhancers, 
temperature, concentration and formulation on the permeability of compounds/drugs.  
Four secondary aims were therefore set to achieve the primary aim.  The secondary 
aims are discussed in more detail in the three sections of the thesis (vaginal mucosa, 
skin tissue and small intestine mucosa). 
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Human vaginal tissue was used to test the in vitro flow-through diffusion model‟s 
suitability to evaluate the permeability of vaginal mucosa to three different peptides and 
to evaluate it‟s value to examine test conditions such as different temperatures and 
concentrations, removal of epithelium and the use of a surfactant.  The three different 
peptides were chosen since they were manufactured to serve as potential microbicides 
or as transporters of microbicides against viruses such as HIV, which portal of entry is 
often the vaginal mucosa.   
 
Secondly, human skin tissue was utilised to assess the in vitro flow-through diffusion 
model‟s ability to evaluate the permeability of skin to terbinafine hydrochloride and 
tritiated water.  Terbinafine hydrochloride is often used as a topical drug and the target 
site of this drug is the skin, therefore the test condition included the use of different 
formulations and concentrations.  Furthermore, the effect of different temperatures on 
the permeability of skin to tritiated water was investigated. 
 
Thirdly, human small intestine mucosa was employed to assess the in vitro flow-through 
diffusion model‟s ability to evaluate the permeability of small intestine to 4 oral drugs 
(zidovudine, propranolol HCl, didanosine, enalapril maleate) and to investigate the 
system‟s ability predict of BCS permeability classification. 
 
Fourthly, correlation of the in vitro permeability information from the in vitro flow-through 
diffusion apparatus to the in vivo drug profile was performed for the three membrane 
models.  A model that reliably predicts in vivo data shortens the drug development 
period, economises resources and leads to improved product quality. 
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Chapter 2: Vaginal mucosa 
2.1  Summary 
Due to an absence of an effective prophylactic anti-HIV vaccine or therapy, there has 
been a current surge in interest at the development of a topical intravaginal formulation 
to combat the mucosal and perinatal HIV or microbicide transmission (D‟Cruz and 
Uckun, 2004).  Mucosal surfaces of the vagina are the portals for heterosexual 
transmission of HIV and therefore play a fundamental role in the pathogenesis of the 
primary infection.  Topical microbicides, including peptides, are being developed for 
blocking the transfer of this virus, but little is known about the diffusion of these 
compounds into and through vaginal mucosal epithelium (Hussain and Ahsan, 2004).  
Although the vagina has been used since ancient times for drug delivery, it still remains 
a relatively unexplored route for drug administration.  Some studies have suggested that 
the vagina‟s molecular weight cut-off point for absorption may be higher than that of 
other mucosal surfaces.  Experience with a variety of compounds demonstrates that the 
vagina is a highly effective site for drug administration and particularly in women‟s health 
(Justin-Temu et al., 2004).  Data on human vaginal permeability to drugs with different 
physiochemical properties is very limited and therefore much research is necessary to 
establish the effects of physicochemical parameters of drugs on vaginal absorption 
(Hussain and Ahsan, 2004).  It was therefore decided to include vaginal tissue in the 
present study. 
 
Currently a resurgence of interest in peptide and protein drugs exists.  The unusual 
characteristics of peptides and proteins present considerable challenges to 
pharmaceutical scientists in selecting a suitable route for their administration and 
formulation.  Peptides and proteins cannot readily be given orally because of enzymatic 
breakdown in the gastrointestinal tract, their sensitivity to the acidic pH in the stomach 
and poor intrinsic permeability across intestinal epithelium (Maggio, 2005).  In the past, 
the most commonly used route for protein and peptide delivery has been by parenteral 
administration.  Most proteins and peptides have a relatively short half-life and therefore 
repeated administrations (injections) are often required (Veuillez et al., 2001). 
Development of suitable nonparenteral routes (such as the vagina) for introducing these 
agents into humans could significantly enhance patient compliance and increase the 
benefit derived from certain peptide or protein therapy. 
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Topical microbicide peptides are being developed to combat the transfer of HIV, but little 
is known about the permeation of these compounds through vaginal epithelium.  
Cationic peptides have activity against malaria parasites, and viruses (including HIV, 
HSV, influenza A virus and vesicular stomatitis virus).  These properties make them 
promising candidates as new therapeutic agents.  It was decided to investigate the 
permeation kinetics of three novel, synthetic FITC (fluorescein isothiocyanate)-labelled 
peptides MEA-5 (Mw = 2911.4 Da), MDY-19 (Mw = 2409.5 Da) and PCI (Mw = 2325 Da) 
across human vaginal mucosa by means of a continuous flow-through diffusion system.  
The FITC-labelled peptides were provided by EMPRO (European Microbicides Project).  
MEA-5 is an antibacterial peptide that binds to cell surfaces, but cannot be internalised.  
MDY-19 and PCI are transport peptides that have potential applications for transporting 
therapeutically active compounds into cells. 
 
Permeability studies were conducted at concentrations of 1 mM, 0.75 mM and 0.5 mM in 
phosphate buffered saline (PBS) at 20 °C and 37 °C, respectively, and over a time 
period of 24 h, using fluorospectrophotometery as detection method.  Effects of a 
surfactant on MDY-19 permeation and de-epithelialisation of the vaginal mucosa were 
also studied.   
 
All three peptides readily penetrate vaginal mucosa.  Microbicides may be coupled to 
MDY-19 and PCI to be transported transmucosally. Although increased size of the 
peptide/microbicides complex may decrease mucosal permeability this could possibly be 
overcome by the addition of a permeation enhancer, e.g. a surfactant. Removal of the 
vaginal epithelium increased the flux rates of the peptides across the mucosa and may 
have implications for a more rapid uptake of these and other microbicides in vivo.  
Concentration- and temperature dependency of peptide flux rates must be taken into 
consideration when performing in vitro permeability studies.  The results of the vaginal 
mucosa study improved the understanding of the permeation characteristics of peptides 
through vaginal mucosal barriers. It demonstrated the usefulness of the in vitro flow-
through diffusion model to study the absorption characteristics of vaginal epithelium, to 
investigate the effect of an absorption enhancer and to study the effect of different 
permeant concentrations and temperature on the diffusion kinetics of the peptide 
permeants.   
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2.2  Introduction 
2.2.1  Peptides 
Proteins are the most abundant organic molecules in animals, playing important roles in 
all aspects of cell structure and function.  They are biopolymers of α-amino acids and the 
physical and chemical properties of a protein are determined by its constituent amino 
acids.  Proteins are synthesised as a linear sequence of individual amino acids subunits 
linked together by peptide bonds, but they assume complex three-dimensional shapes in 
performing their function.  There are approximately 300 amino acids present in various 
animal, plant, and microbial systems, but DNA which may potentially appear in proteins 
codes for only 20 amino acids, called standard amino acids.  Many proteins also contain 
modified amino acids and accessory components termed prosthetic groups (Wade, 
2003; Bhagavan, 1992). 
 
The standard amino acids differ from each other in the structure of the side chains 
bonded to their α-carbon atoms.  Each amino acid has a central carbon, called the α-
carbon, to which four different groups are attached: 
 A basic amino group (-NH2) 
 An acidic carboxyl group (-COOH) 
 A hydrogen atom (-H) 
 A distinctive side chain (-R) 
 
All amino acids, except for glycine, contain at least one asymmetric carbon atom (the α-
carbon atom), resulting in two isomers that are optically active.  These 
isomers/enantiomers are chiral.  The two amino acid configurations are called D- and L-
configurations.  All amino acids in proteins are of L-configurations, because proteins are 
biosynthesised by enzymes that insert only L-amino acids to chains. 
 
The properties of each amino acid are dependent on its side chain (-R).  The side chains 
are the functional groups that are the major determinants of the conformation and 
function of proteins.  Amino acids with charged, polar or hydrophilic side chains are 
usually exposed on the surfaces of proteins, while the nonpolar hydrophobic residues 
are usually buried in the hydrophobic interior of a protein and are out of contact with 
water.  Due to their varying amino acid composition, proteins have a wide range of 
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structural and catalytic properties.  Because of this versatility, proteins serve an 
extensive variety of functions in living organisms (Wade, 2003; Bhagavan, 1992).  
 
Currently a resurgence of interest in peptide and protein drugs exists (Veuillez et al., 
2001).  Many of the latter are related to endogenous compounds regulating endocrine 
and other physiological processes in the body and are generally found at low 
concentrations in the tissues of mammals, but several different peptides can be found in 
a single type of tissue (Hancock and Rozek, 2002).  These amino acid polymers are 
increasingly used in major research and development programs, especially due to 
advances in genetic engineering and biotechnology (Yu and Chien, 1997).  They may 
act synergistically with each other and with other agents in the host, e.g. magainin 2 
shows synergistic antimicrobial effects with the peptide PGLa.   
 
The unusual characteristics of peptides and proteins present considerable challenges to 
pharmaceutical scientists in selecting a suitable route for their administration and 
formulation.  In the past, the most commonly used route for protein and peptide delivery 
has been by parenteral administration.  Most proteins and peptides have a relatively 
short half-life and therefore repeated administrations (injections) are often required 
(Veuillez et al., 2001).  Development of suitable nonparenteral routes for introducing 
these agents into humans could significantly enhance patient compliance and increase 
the benefit derived from peptide or protein therapy. 
 
Peptides and proteins cannot readily be given orally because of enzymatic breakdown in 
the gastrointestinal tract, their sensitivity to the acidic pH in the stomach and poor 
intrinsic permeability across intestinal epithelium (Maggio, 2005).  The fraction of intact 
peptide reaching the systemic circulation will depend on its ability to cross the mucosal 
barrier and also on its resistance to degradation by peptidases present at both the site of 
administration and in the mucosal barrier.  Proteolysis can rapidly metabolise peptides at 
most mucosal routes of administration.  Protein-like compounds are generally not well 
absorbed through mucosae, due to their molecular size, hydrophilicity and metabolism 
occurring at the site of absorption.  Permeation enhancers and/or delivery vehicles can 
also be used to enhance membrane transport of proteins, peptides and other chemical 
compounds across biological membranes (Veuillez et al., 2001).  
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Most small peptides, however, do not diffuse readily through mucosal membranes and 
diffusion enhancers must be added to increase their absorption. Currently much 
research involves studying the diffusion of small peptide molecules through biological 
membranes in the presence of chemical permeation enhancers.  
 
2.2.1.1  Structure of peptides and physico-chemical properties 
2.2.1.1.1  Molecular weight and size 
The diffusion of a drug through the epithelial layer is influenced by its molecular weight 
and size.  In general smaller molecules (<75-100 Da) appear to cross the mucosa barrier 
more readily than very large molecules (Veuillez et al., 2001).  
 
The apparent permeability coefficient of fluorescein isothiocyanate dextrans (FITCD), a 
neutral polysaccharide, decreases as molecular weight increase (Donovan et al., 1990; 
Maiani et al., 1989; Tavakoli-Saberi and Audus, 1989).  Proteins and peptides have a 
very large dispersion in molecular weight (Mw) compared to most conventional drugs, 
ranging from less than 600 to greater than 100 000 Da (Sandow et al., 1990).  An in vivo 
study on humans showed that peptides such as protirelin (Mw: 362) and oxytocin (Mw: 
1007) crossed the human buccal mucosa barrier, whereas buserelin (Mw: 1239) and 
calcitonin (Mw: 3500) did not (Veuillez et al., 2001).  In another study Merkle et al. (1992) 
proposed that the transfer of peptides with molecular weights above 500-1000 Da 
through buccal mucosa would require the use of an absorption enhancer.   
 
2.2.1.1.2  Conformation, stereospecifity and immunogenicity 
Peptides have unique structures and their diffusion characteristics are therefore different 
from other conventional drugs.  Peptides have primary, secondary and tertiary structures 
and in solution may adopt different conformations depending on their size, which may 
present difficulties in preserving the pharmacologically active conformation (Bunrham, 
1999; Delie et al., 1995; Green et al., 1991).  During the processes of formulation and 
sterilisation of a peptide drug, the stereospecificity of the peptide must be reserved since 
this may influence membrane permeability and permeation systems are thought to be 
stereoselective (Palm et al., 1996; Ho et al., 1990). 
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Peptides may be immunogenic and the use of inert polymers such as polyethylene glycol 
(PEG), dextran, polyvinylpyrrolidone (PVP) and albumin for peptide delivery may 
increase resistance to proteolysis and simultaneously decrease peptide immunogenicity 
(Veuillez et al., 2001).  
 
2.2.1.1.3  Electrostatic charges 
Charge distribution on the peptide or protein chain may also play an important role in 
predicting their permeability through mucosae, since terminal charges on zwitterionic 
peptides decrease their membrane permeability (Ho et al., 1990).  The effect of charge 
density can be modified by altering the pH of the medium and therefore the degree of 
ionisation of the permeant to promote peptide absorption (Liaw et al., 1992).  It seems as 
if mucosae are considered to be permeability-selective towards positively charged 
peptides (Rojanasakul et al., 1992). 
 
2.2.1.1.4  Solubility, hydrophilicity and partition coefficient 
Peptides are amphoteric and therefore usually have complex solubility versus pH 
profiles.  The aqueous solubility is dependent on pH, metallic ions, ionic strength and 
temperature.  The drug is usually neutral at the isoelectric point and therefore the 
aqueous solubility of the peptide is minimal at this point.  Peptides are normally very 
hydrophilic, unless the N- and C-termini are blocked through cyclization, amide formation 
or esterification.  These compounds have a low octanol-water partition coefficient and 
peptide absorption by passive diffusion can be enhanced by increasing their lipophilicity 
(Hansen et al., 1992; Corbo et al., 1989; Siegel et al., 1981).  Permeation properties may 
also be modified to a significant extent by the formation of hydrogen-bonds between 
peptides and the mucosal tissue (Saitoh and Aungst, 1997; Burton et al., 1996).  The 
pKa and the local pH at the mucosal surface strongly influence the degree of ionisation of 
a permeant.  Absorption of peptides is maximal at a pH at which they are mostly non-
ionised, tailing off as the degree of ionisation increases.  However, it has also been 
shown in an in vitro study that the permeability coefficient of protirelin through rabbit 
buccal mucosa was independent of the pH of the peptide solution (Dowty et al., 1992). 
 
2.2.1.1.5  Aggregation, self-association and hydrogen bonding 
Self-aggregation may modify the intrinsic properties of peptides.  Insulin usually exhibits 
aggregation.  Ionic ingredients and phenolic preservatives may accelerate this 
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aggregation (Touitou, 1992).  Therefore, zinc insulin complexes are more stable than 
zinc-free insulin.  In another extensive study, it has been reported that non-ionic 
surfactants such as Pluronic F68 appear to be promising stabilisers (Massey and 
Shelga, 1989). 
 
Another predictor of peptide absorption is the capacity of some peptides to form 
intermolecular hydrogen bonds with water.  Selfassociation may involve formation of 
intermolecular H-bonds and hydrophobic interactions.  The addition of hydroxyl groups 
generally promote hydrogen bonding with solvating water, leading to a decrease in the 
partition coefficient and a decrease in the permeation of a lipid membrane.  However, the 
presence of hydroxyls can sometimes lead to an increased permeability.  This is usually 
due to the formation of cyclic intermolecular hydrogen bonds, which appear to reduce 
hydrogen bonding and therefore increasing lipophilicity.  Cyclisation of peptides appears 
to reduce hydrogen bonding and therefore increase lipophilicity (Veuillez et al., 2001).  
 
2.2.1.2  Peptides as microbicides 
About 20 years ago it was discovered that the lymph of insects, the granules of human‟s 
neutrophils and the skin of frogs contain peptides that could kill bacteria in culture.  
Since then more than 600 different cationic peptides have been observed in almost all 
species (Hancock, 2001).  This class of small, positively charged peptides, namely 
cationic antimicrobial peptides, is known for its broad-spectrum antimicrobial activity and 
is found throughout nature.  Cationic peptides are characterised by an overall positive 
charge and contain multiple lysine and arginine residues and 50 % or more hydrophobic 
residues.  They are produced by most living organisms, from plants and insects to 
human beings, and form a major part of their immediate defences against infections.  
These peptides also have anti-viral and anti-cancer activity and the ability to modulate 
the innate immune responses.  The main requirements for their antimicrobial activities 
are a cationic charge and an induced amphipathic conformation (Powers and Hancock, 
2003).  Interactions with membranes often induce the peptides to fold into an amphipatic 
or amphiphilic conformation (Powers and Hancock, 2003).  The disulphide bridges cause 
them to fold into three-dimensional amphiphilic structures in which the positively charged 
and hydrophilic domains are well separated from the hydrophobic domains.  This 
structural conformation equips the molecule to interact with membranes, especially with 
   
Chapter 2: Vaginal mucosa                                            22 
           
2
2
 
bacterial membranes with their negatively charged and hydrophilic head groups and 
hydrophobic cores.  The four structural classes of peptides include β-sheet molecules 
established by two or three disulphide bonds, amphipatic α-helices, extended molecules 
and loops due to a single bond (Hancock, 2001).  
 
Due to the development of resistant pathogens, it is important to consider new classes of 
antibiotics, such as cationic peptides (Hancock, 2001).  After the development of 
quinolones there were for more than 30 years no new antibiotic chemical structures, until 
the release of synercid and linezolid.  An advantage of the cationic peptides over the 
traditional antibiotics is that cationic peptides have a wide variety of antimicrobial 
activities that include action against most Gram-positive and Gram-negative bacteria, 
fungi, enveloped viruses and protozoa.  Most traditional antibiotics do not have activity 
against fungi and antifungal drugs do not act against bacteria.  Cationic peptides are 
bactericidal and also able to combat the antibiotic-resistance mechanisms that limit the 
use of other antibiotics such as meticillin-resistant staphylococcus aureus.  They kill 
bacteria very rapidly compared with conventional bactericidal antibiotics and there are 
only a few antibiotic-resistant mechanisms that affect antimicrobial peptides, but most 
only have a moderate effect on the MIC (Hancock, 2001; Zhang et al., 2000).  
   
These peptides may have minimal inhibitory concentrations (MIC) as low as 0.25-4 
μg/ml against microorganisms (Powers and Hancock, 2003).  Some peptides have 
activity against malaria parasites and viruses (including HIV, HSV, influenza A virus and 
vesicular stomatitis virus).  Examples of such peptides are defensins, indolicidin, 
polyphemusin and melittin (Zhang and Hancock, 2000).  Mechanisms of action have 
been reported to include blockage of virus-cell fusion and inhibition of the activity of HIV 
long terminal repeats (Hancock, 2001).  Cationic peptides may also possess anticancer 
activity and promote wound healing.  There is still uncertainty as to whether the peptides 
have selectivity for malignant over normal cells.  Recent studies have also shown their 
function as effectors of innate immune responses.  These properties make cationic 
peptides exciting candidates as new therapeutic agents (Powers and Hancock, 2003).  
Where antibiotics only have activity against bacteria, cationic peptides have an extensive 
range of activities against bacteria, fungi, enveloped viruses and eukaryotic parasites.  
The pharmacological applications of cationic peptides to treat infections have therefore 
received much interest and are being developed for clinical trials (Hancock, 2001). 
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 2.2.1.2.1  Mechanisms of action 
The mechanism of action of cationic antimicrobial peptides is continuously investigated 
and information about their structures keeps expanding.  Despite the enormous amount 
of investigations, there is still a disagreement in the literature on the role of membrane 
disruption/permeabilisation in determining the mechanism of action of cationic peptides.  
It seems that these peptides mainly exert their action by disrupting cytoplasmic 
membranes and may be cytotoxic by virtue of disturbing the bacterial inner or outer 
membranes (Hancock and Rozek, 2002).  However, there is still uncertainty about 
precisely how these peptides perturb membranes and whether the latter process is 
related to the antimicrobial activities of these compounds (Epand and Vogel, 1999).  It 
seems that two types of molecules exist: membrane disruptive and non-membrane 
disruptive antimicrobial peptides.  Another proposal is that cationic antimicrobial peptides 
have multiple actions on cells including membrane permeabilisation, cell wall and 
division effects and macromolecular synthesis inhibition.  It also seems as if the 
mechanism of action varies between different peptides and between different bacteria 
for a given peptide.  
 
2.2.2  Vaginal mucosa 
The safety and efficacy of vaginal administration have been well established (Alexander 
et al., 2004).  Although the vagina has been used since ancient times for drug delivery, it 
still remains a relatively unexplored route for drug administration.  Some studies have 
suggested that the vagina‟s molecular weight cut-off point for absorption may be higher 
than that of other mucosal surfaces.  Experience with a variety of compounds 
demonstrates that the vagina is a highly effective site for drug administration and 
particularly in women‟s health (Justin-Temu et al., 2004).  Advantages of vaginal 
administration of drugs include: the administration of lower doses, maintenance of 
steady drug levels, less frequent administration than with e.g. the oral route, avoidance 
of the first-pass effect and no effect of gastrointestinal (GI) disturbances on the 
absorption of the drug (Alexander et al., 2004; Sanders and Matthews, 1990).  This route 
also allows a woman to self-administer medication continuously for prolonged periods of 
time.   
 
Modern technology has yielded vaginal drug delivery systems that provide optimised 
pharmacokinetic profiles, which make the vagina an excellent route for drug delivery.    
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The rate and extent of drug absorption after intravaginal administration may vary 
depending on formulation factors, vaginal physiology, age of the patient and menstrual 
cycle. Suppositories, creams, gels, tablets and vaginal rings are commonly used vaginal 
drug delivery systems for both systemic and local effects.  In recent years, the vaginal 
route has been rediscovered as a potential route for systemic delivery of peptides and 
other therapeutically important macromolecules (Hussain and Ahsan, 2004). 
 
2.2.2.1  Anatomy of vagina 
The vagina is a muscular, tubular organ connecting the uterus to the exterior of the 
body.  In adults the vagina varies from 8-12 cm, with the posterior wall approximately 
1.50-2 cm longer than the anterior wall (Alexander et al., 2004; Ahuja et al., 1997).  It is 
a collapsed organ with the anterior and posterior walls in contact with each other 
(Alexander et al., 2004).  Radiographic colpography has shown that the vagina has two 
distinct portions: a lower convex portion and a wider upper portion that lies in an almost 
horizontal plane when the woman is standing.  The angle between the upper and lower 
axes is 130 degrees (Funt et al., 1978).  The vagina contains numerous folds called 
rugae, which provide distensibility and support and also increase the surface area of the 
vaginal wall (Namnoum and Murphy, 1997). 
 
The vagina is provided by a nerve supply from two sources namely the peripheral, which 
primarily supplies the highly sensitive lower quarter of the vagina and the autonomic, 
which primarily supplies the upper three quarters. Autonomic fibres are not very sensitive 
to pain or temperature and responds mainly to stretch.  Woman rarely feel localised 
sensations or discomfort when using vaginal products such as suppositories or vaginal 
rings and are often unaware of the presence of these products when used (Alexander et 
al., 2004).  
 
The vagina has an extensive blood vascular supply.  Blood is supplied from different 
sources such as the uterine artery, the pudendal artery and the middle and inferior 
haemorrhoidal arteries.  It also has an extensive venous system with the primary 
drainage through the pudendal veins.  The vaginal, uterine, vesical and rectosigmoid 
veins from the middle and upper vagina provide drainage to the inferior vena cava and 
has the advantage that it bypass the hepatic portal system (Namnoum and Murphy, 
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1997).  A so called “first uterine pass effect” has been hypothesised when hormones are 
administered vaginally, due to the extensive vascular connections between the vagina 
and uterus (De Ziegler et al., 1997).  Several groups have demonstrated that the 
endometrial concentrations of some compounds such as progesterone and estradiol 
(E2), were higher than the vaginal concentrations, with both vaginal and oral 
administration (Cicineli et al., 2000; Tourgeman et al., 1999; Fanchin et al., 1997). 
 
2.2.2.2  Histology of vagina 
During the fertile period of a woman‟s life the vaginal mucosa consists of 4 main 
epithelial layers (Fig. 5).  The most superficial layer consists of nonsecretory stratified 
squamous epithelium, which is non-keratinised and contains pycnotic nuclei.  The next 
layer is the lamina propria or tunica, made of collagen and elastin, which also contains a 
rich supply of vascular and lymphatic channels.  The muscle layer is the third layer, with 
smooth muscle fibres running in both circular and longitudinal directions.  The final layer 
consists of areolar connective tissue and a large plexus of blood vessels.  Vaginal tissue 
does not contain fat cells, glands or hair follicles (Herbst et al., 1992).  The thickness of 
the vaginal epithelial layer changes by approximately 200-300 μm during the menstrual 
cycle (Hussain and Ahsan, 2004).  Although the vagina does not possess any glands, it 
does secrete a large amount of fluid (Paavonen, 1983).  Secretions from the vaginal wall 
are transudate in nature and are produced by the engorgement of the vascular plexus 
that encompasses the vagina (Herbst et al., 1992).  The amount and composition of the 
vaginal fluid changes throughout the menstrual cycle (Hussain and Ahsan, 2004).  Adult 
woman produce fluid at a rate of 3-4g/4h, while the discharge produced by 
postmenopausal women is 50 % less (Bergh, 1988).  The contents of the fluid may 
include enzymes, enzyme inhibitors, proteins, carbohydrates, amino acids, alcohols, 
hydroxyl-ketones and aromatic compounds (Wagner and Levin, 1978).  The volume and 
composition of the vaginal fluid may also be influenced by sexual arousal and this may 
lead to an alteration in the drug release pattern from a vaginal delivery system.  
Lactobacilli acidophilus are present in the vagina and produce lactic acid from glycogen.  
The lactic acid acts as a buffer to maintain the vaginal pH between 3.8 and 4.2.  During 
menstruation, the pH of vaginal fluid increases and frequent acts of coitus may also 
cause an increase in the vaginal pH, because both ejaculate and vaginal transudate are 
   
Chapter 2: Vaginal mucosa                                            26 
           
2
6
 
alkaline.  The vaginal pH is also influenced by the presence of cervical mucus and the 
amount of vaginal transudate.   
 
The epithelium contains densely packed cells present in the superficial layer with narrow, 
cycle-independent, intercellular spaces.  The intercellular spaces widen and become 
deeper in the epithelium. 
 
Paracellular diffusion barriers in non-keratinised epithelia can be represented by different 
types of junctional complexes.  Lipids or glycoconjuagates present in the upper levels of 
the vaginal epithelium may play a role in the inhibition of intercellular channels.  
Keratinised epithelia were found to have a different barrier function to the non-
keratinised superficial epithelial cell layers of the vaginal mucosa.  The intraepithelial 
transport system allows larger molecules, e.g. proteins, to pass (Forsberg, 1996). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.  Non-keratinised human vaginal epithelium (By courtesy of Prof. IOC  
Thompson)  
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2.2.2.3  Physiology of vagina and drug administration 
Drugs administered via the vaginal route are absorbed similar to other mucosal routes.  
Compounds are absorbed through mucosa transcellularly via concentration dependent 
diffusion through cells; paracellularly by mediation of tight junctions and vesicularly or 
through receptor mediated transport.  Absorption of the drug from the vaginal delivery 
system occurs through two main steps: drug dissolution in the vaginal lumen and 
membrane penetration.  The absorption profile of vaginal drug delivery systems is 
therefore affected by any biological formulation factor that affects drug dissolution and 
membrane transport (Woolfson et al., 2000). 
 
The mucosal linings in the body have important protective functions and the vaginal 
defences include the epithelium, florae, immune cells and pH.   
 
2.2.2.4  Vaginal enzymes 
Most enzyme activity exists in the external layers and the basal cell layers of the vagina 
(Woolfson et al., 2000; Wendel-Smith and Wilson, 1991; Schmidt and Beller, 1978). 
Different enzymes are present of which the proteases seem to be the prominent barrier 
for the absorption of intact peptide and protein drugs into the systemic circulation.  
Acatürk et al. (2001) did a comparison of enzymatic activities of four different 
aminopeptidases (aminopeptidase N, leucine aminopeptidase, aminopeptidase A and 
aminopeptidase B) in vaginal homogenates of various species.  These authors reported 
that the enzyme activity in rat, rabbit, and human was significantly lower than that of 
sheep and guinea-pig.  The aminopeptidase activity in the species studied showed the 
following order of activity: sheep>guinea-pig>rabbit≥human≥rat and they concluded that 
rat and rabbit vaginal tissue could be used as potential models for vaginal enzymatic 
activity studies and for the determination of degradation of protein and peptide drugs in 
the vagina.  
 
2.2.2.5  Epithelium 
When estrogen is present, the vaginal epithelium consists of 25 layers, which forms a 
physical barrier together with cervical mucus, vaginal secretions and local flora (Miller et 
al., 2000).  It is difficult for organisms to invade or access the basement membrane or 
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capillary bed, because the stratified squamous epithelium is continually renewing and 
shedding (Alexander et al., 2004).  
 
An example of the effect of vaginal epithelium thickness on drug transport has been 
shown in a study with vidarabine.  Vidarabine has a 5-100 times higher permeability 
coefficient during the early dioestrous stage, than during the oestrus stage in guinea pigs 
(Pschera et al., 1989).  The vaginal absorption of estrogen is also higher in 
postmenopausal women compared to premenopausal women (Pschera et al., 1989).  
Vaginal absorption is influenced by the thickness of vaginal epithelium (Carlsrom et al., 
1988).  There are conflicting reports in the literature on the effect of an increase in 
vaginal epithelium on drug absorption through the mucosa.  In women who received 
vaginal estrogen therapy, the vaginal progesterone absorption was found to be 
increased, even though prior estradiol therapy should have caused an increase in the 
vaginal epithelium (Villanueva et al., 1981).  This anomalous finding was explained by 
the fact that the absorption of progesterone was increased with increased vascularity of 
the vagina (Katz and Dunmire, 1993).  The presence of cervical mucus could serve as a 
possible permeability barrier.  The short- and long-term stability of intravaginal delivery 
systems and devices may be affected by the high activity of enzymes in the vaginal 
epithelium (Hussain and Ahsan, 2004).  
 
2.2.2.6  Florae 
Lactobacilli proliferate near the epithelium and use desquamated cells as a source of 
intracellular glycogen that can be converted to lactic acid.  These organisms play an 
important role in vaginal health, because they compete with exogenous microbes for 
nutrients and produce lactic acid and hydrogen peroxide, which regulate the growth of 
other flora.  An absence of hydrogen-producing lactobacilli in the normal vaginal flora 
may result in the overgrowth of catalase-negative organisms, resulting in vaginosis 
(Alexander et al., 2004).  
 
Estradiol stimulates glycogen production in the epithelial cells and therefore promotes 
the presence of lactobacillus.  During pregnancy the high levels of estrogen may result in 
thick epithelium, proliferation of lactobacilli and a low pH.  Other factors that may disrupt 
the vaginal milieu are antibiotics and some diseases e.g. diabetes.  Healthy women of 
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reproductive age have vaginal secretions that contain a mixture of aerobic and 
anaerobic bacterial flora (Roy, 1994).  The numbers and prevalence of different bacteria 
vary according to a woman‟s menstrual cycle (Priestley et al., 1997; Schwebke et al., 
1997).  Numbers decrease 10-fold to 100-fold in the week before menstruation, followed 
by dramatic increase in the number of bacteria as menstruation commences (Larsen and 
Galask, 1980). 
 
2.2.2.7  Immune cells 
The cellular and humoral systems provide protective immunity.  The Langerhans' cells 
play an important role in the local immune system.  It has dendritic extensions exposed 
to the lumen of the vaginal epithelium and these cells can pass antigens to dendritic 
cells that migrate to the lymph nodes, where they activate B and CD4+ T cells.  The 
activated B lymphocytes return to the subepithelium, where they become IgA-secreting 
cells.  The IgA is taken up by the epithelial cells and made into a dimer prior to release 
into the lumen.  
 
The cervical mucus contains IgG and IgM, as well as IgA antibodies (McGhee et al., 
1993).  Intraepithelial T lymphocytes, dendritic cells and a subepithelial population of B 
lymphocytes that synthesize IgA locally, all constitute to the protective immunity of the 
vagina.  
 
Martin et al. (1998) have shown that long-term use of depot-medroxyprogesterone 
acetate results in thinning of the vaginal epithelium and increased susceptibility to HIV 
infection.  Animal studies indicated that in progestogen-dominant environments 
infections such as chlamydia trachomatis and herpes simplex might also be worsened 
(Kaushic et al., 2003; Kaushic et al., 2000).  
 
A recent human study demonstrated that changes in leukocyte subtype concentrations 
varied depending on whether depot-medroxyprogesterone acetate or levonorgestrel was 
administered.  Estrogen treatment in monkeys made them completely resistant to simian 
immunodeficiency virus (SIV), whereas progestogen treatment made them susceptible.  
The presence of estrogen or exogenous products keeps the vagina‟s pH low and 
enables this organ to resist infection.  It is still unclear whether the beneficial effects of 
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estrogen are due to its effect on the integrity and thickness of the cervicovaginal 
epithelium, or whether they are due to the inaccessibility of certain immune cells 
(Alexander et al., 2004).  
2.2.2.8  PH 
The production of lactic acid by vaginal microflora maintains the vaginal pH at 3.8 to 4.2 
(Herbst et al., 1992).  The pH may be rapidly influenced by the presence of semen, 
which is slightly alkaline (pH 7.0 to 8.0) and the effect may last for several hours (Voeller 
and Anderson, 1992).  Female hygiene products may wash away a variety of the vaginal 
defences and can promote colonisation of bacteria or alter vaginal pH.  This may lead to 
the proliferation of pathogenic bacteria and yeast.  The absorbent material may also 
become media for bacterial colonisation and growth (Ness et al., 2002).  Therefore, 
products that will be used in the vagina for days, weeks, or months, must be made of a 
material that does not damage the surrounding tissue, should not interfere with the 
normal immune functions and must be non-absorbent (Alexander et al., 2004).  
 
2.2.2.9  Drug delivery systems and physiochemical properties of 
drugs 
Gels, foams, solutions, suppositories and tablets have been traditionally used as vaginal 
formulations.  The vaginal ring has also been introduced recently for hormone 
replacement and contraceptive therapy.  Drug absorption, distribution and residence 
time may vary according to the delivery system used.  Solutions, suspensions and foam 
show better distribution and coverage of vaginal tissue over a tablet form (Johnson and 
Masters, 1962).  A vaginal drug delivery system that is intended for a local effect, should 
distribute uniformly throughout the vaginal cavity to be effective.  A semi-solid 
formulation and a fast dissolving system are therefore required.  Generally a bioadhesive 
dosage form or intravaginal ring system would be more preferable to attain a topical 
effect.  It has been difficult for researchers to quantify the distribution of a drug after 
intravaginal administration, since it is uncertain if the administered formulation coated the 
whole organ (Hussain and Ahsan, 2004).  Vaginal enzymes, cyclic changes in the 
thickness of vaginal epithelium, fluid volume and composition, pH and sexual arousal 
potentially affect drug release from intra vaginal delivery systems.  Vaginal drug 
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absorption is also influenced by physiochemical properties of drugs such as molecular 
weight, lipophilicity, ionisation, surface charge and chemical nature. 
 
The vaginal permeability of straight chain aliphatic alcohols increases in a chain 
dependant manner and similarly vaginal permeability is much greater to lipophilic 
steroids e.g. progesterone and estrone than to hydrophilic steroids such as 
hydrocortisone and testosterone (Brannon-Peppas, 1992; Hwang et al., 1977).  It is 
generally accepted that the absorption of low molecular weight lipophilic drugs is higher 
than large molecular weight lipophilic or hydrophilic drugs.  A study on vaginal absorption 
of polyvinyl alcohol suggested that the vagina may absorb higher molecular weight 
compounds than other mucosal surfaces (Sanders and Matthews, 1990).  Vaginal fluid 
contains a large amount of water and therefore any drug intended for vaginal delivery 
requires a certain degree of water solubility.  Data on human vaginal permeability to 
drugs with different physiochemical properties is very limited and therefore much 
research is necessary to establish the effects of physicochemical parameters of drugs on 
vaginal absorption (Hussain and Ahsan, 2004).  
 
A hydrophobic drug‟s absorption may increase when the vaginal fluid volume is higher, 
but the presence of overly viscous cervical mucus may present a barrier to drug 
absorption.  Increased fluid volume may remove the drug from the vaginal cavity and 
subsequently reduce the absorption of the drug.  Absorption of a drug by the vaginal 
epithelium is also influenced by the pH of the vaginal fluid since it determines the degree 
of ionisation of weak electrolyte drugs.  An in vitro study has shown that the pH of the 
vaginal preparations affects the release of PGE2 from the media (Johnson et al., 1992).  
A change in the vaginal pH may therefore affect the release profiles of pH sensitive 
drugs from vaginal drug delivery systems (Hwang et al., 1977).  
 
2.2.2.9.1  Creams and gels 
For creams and gels to be feasible as a drug delivery system, it has to be easy to use, 
non-toxic and non-irritating to the mucous membrane. 
 
Creams and gels are often used for topical delivery of contraceptives and anti-bacterial 
drugs.  Unfortunately, these products may have disadvantages of being uncomfortable, 
messy to apply and sometimes embarrassing when they leak into the undergarment.  
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These delivery methods may also not provide an exact dose, because of nonuniform 
distribution and leakage.  
 
Applying a cream and gel may compare well with oral delivery of drug, such in the 
treatment of bacterial vaginosis, where metronidazole and clindamycin vaginal cream 
were found to be nearly as effective as orally administered drugs (DuBouchet et al., 
1998). 
 
A gel formulation has also been used for intravaginal vaccine delivery, for cervical 
ripening and induction of labour.  The cholera vaccine showed a greater mucosal 
response in female genital tract compared with the oral administration of the drug.  
Oxytocin, dinoprostone and misoprostone are examples of drugs commonly used for 
cervical ripening and induction of labour.  There have been several studies done to 
compare the efficacy of intravaginal administration versus oral delivery.  The dose 
required for the oral delivery of misoprostol is usually 4 times that of an intravaginal 
dose.  There have been conflicting reports in the literature with respect to the efficacy of 
the route of misoprostol administration.  Shetty et al. (2003) reported that vaginal 
administration of misoprostol was more efficacious than the oral route, but Hall et al. 
(2002) found that oral delivery of the drug had the potential to induce labour as safely 
and effectively as oral administration.  This difference in findings occurred even though 
both researchers used the same oral and vaginal dose and the same intervals of drug 
administration.  The disparity in their observation may be explained to their different 
principal outcome criteria assessed in each of the studies.  From an analysis of different 
studies performed employing the oral and vaginal routes of misoprostol administration, it 
appears that the currently recommended vaginal routes of misoprostol dose (25 μg) is 
efficacious and safer than the 100 μg oral dose (Hussain and Ahsan, 2004).  
 
Due to an absence of an effective prophylactic anti-HIV vaccine or therapy, there has 
been a current surge in interest at the development of a topical intravaginal formulation 
to combat the mucosal and perinatal HIV or microbicide transmission (D‟Cruz and 
Uckun, 2004).   
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2.2.2.9.2  Vaginal rings 
Vaginal rings are generally approximately 5.5 cm in diameter with a circular cross 
section diameter of 4-9 mm and are designed to release a drug in a controlled fashion 
after insertion in the vagina.  They are usually made of a polymeric material such as the 
most commonly used polymer, poly (dimethylsiloxane) or silicone devices.  Other 
elastomeric polymers such as ethylene vinyl acetate and styrene butandiene block 
copolymer have also been tested recently (Van Laarhoven et al., 2002; Roumen and 
Dieben, 1999).  The ethylene vinyl acetate polymers are classified by the content of vinyl 
acetate.  Addition of vinyl acetate units in the polyethylene provides the following 
advantages: increased flexibility, improved optical properties, greater adhesion, 
increased impact and puncture resistance.  The clinical acceptability of rings made of 
ethylene vinyl acetate is very high (Novák et al., 2003; Roumen and Dieben, 1999).  
Roumen and Dieben (1999) evaluated the tolerability of ethylene vinyl acetate of a non-
medicated vaginal ring.  The ring had a diameter 54 mm and was inserted for 21 
consecutive days, permitting temporary removal during coition.  Most of the women 
judged the ring easy to insert and remove.  No adverse effects were experienced among 
the test group during the study period and the ring received a 91 % acceptability.  
 
Vaginal rings are most frequently used for contraceptive and hormone replacement 
therapy (Dezarnaulds and Fraser, 2002; Ballagh, 2001; Harwood and Mishell, 2001).  
When used for contraceptive applications, the rings are placed in vagina for 21 days 
followed by ring free period of a week.  NuvaRing® was the first combined contraceptive 
vaginal ring available in the US market. It contains two active compounds, etonogestrel 
and ethinyl estradiol.  The ring releases 120 μg/day of etonogestrel and 15 μg/day of 
ethinyl estradiol over a 3-week period of use.  Clinical trials showed that NuvaRing® is 
an effective contraceptive ring with good cycle control and user acceptability (Novák et 
al., 2003).  
 
Femring® and Estring® are estrogen releasing rings used for hormone replacement 
therapy.  Femring® is placed in the vagina once every trimester and releases acetate 
derivate of estradiol.  The estradiol acetate is then hydrolysed to estradiol after being 
released from the delivery device.  The vaginal ring Estring® contains estradiol (Hadgraft 
and Lane, 2005). 
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Advantages of vaginal rings are that it is user controlled, does not interfere with coition, 
does not require daily intake of pills and allows continuous delivery of low dose 
hormones (Hussain and Ahsan, 2004).  In simple vaginal rings, the active compound is 
homogeneously dispersed within a polymeric ring.  The drug at the surface of the ring is 
released more rapidly than the drug in the inner layer of the ring.  This may lead to an 
initial burst release of the drug in the outermost layer and therefore sandwich or reservoir 
type rings have been developed to obtain a constant release of drug from the ring.  
Sandwich type devices consist of a narrow drug-containing layer located below the 
surface of the ring and positioned between a non-medicated central core and a 
nonmedicated outer band.  In reservoir type rings, drugs are dispersed in a centralised 
core, which is then encapsulated by a drug free layer of polymer.  It is possible to have 
several cores of different drugs in a single ring; allowing administration of several drugs 
from the same device.  Changing the core diameter or thickness of the non-medicated 
coating can modify the rate of drug release (Hussain and Ahsan, 2004).  
 
2.2.2.9.3  Suppositories and vaginal tablets 
Some authors use the terms suppositories and pessaries interchangeably and consider 
vaginal tablets as a separate dosage form.  Large numbers of vaginal medications are 
available in the form of tablets or suppositories.  These formulations are designed to melt 
in the vaginal cavity and release the drug for several hours. Suppository systems are 
commonly used to administer drugs for cervical ripening prior to childbirth and for local 
delivery of drugs e.g. dehydroepiandrosterone sulphate for ripening effect on the uterine 
cervix, miconazole for vaginal candidacies and progesterone for hormonal replacement 
therapy (Yamashita et al., 1991; Abrams and Weintraub, 1983; Vukovich et al., 1977).  
Binders, disintegrants and other excipients that are used to prepare conventional oral 
tablets may also be used in vaginal tablets.  It has the advantage of ease of manufacture 
and insertion. Mucoadhesive polymers are sometimes used in vaginal tablet formulation 
to increase vaginal residence time.  Drugs that are administered as vaginal tablets 
include itraconazole, clotrimazole and prostaglandins.  The presence of hydrophobic and 
release retarding materials may decrease the absorption of a drug from a vaginal 
formulation.  Hydrophobic drugs may not be suitable for vaginal tablets, but the presence 
of penetration enhancers such as surfactants and bile salts may significantly enhance 
absorption. 
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2.2.2.9.4  Bioadhesive delivery systems 
Bioadhesive drug delivery systems have been developed to circumvent the problems of 
leakage, low retention of the vaginal epithelium and unpleasantness of the conventional 
vaginal formulations.  Polymers that have been used for vaginal formulation include 
polycarbohil, hydroxypropylcellulose and polyacrylic acid.  The developed formulations 
showed good adhesive properties and the ability to hold the dosage form at the 
application site (Hussain and Ahsan, 2004).  Various peptide and protein drugs have 
been hosted using this delivery system.  An example of such a peptide is calcitonin, a 
polypeptide, which is used in the treatment of postmenopausal osteoporosis (Richardson 
and Armstrong, 1999).  Other examples include nonoxynol-9, a spermicidal agent and 
the antimycotic agent, clotrimazole (Ceschel et al., 2001; Lee and Chien, 1996). 
 
2.2.2.9.5  User acceptability 
Misperceptions and poor education about vaginal anatomy and physiology among 
patients may lead to reluctance to use vaginal medications.  Counselling and educating 
of patients and health care workers may overcome this problem and help to establish the 
vaginal route of drug administration as safe, effective and convenient so that more 
women can experience the potential benefits. 
 
2.2.2.9.6  Vaginal immunisation 
Immunisations are conventionally administered via the oral or parenteral route, resulting 
in systemic rather than mucosal immunity.  The mucosal-associated lymphoid tissues 
(MALT) of the gastrointestinal, respiratory, female and male genital tracts are the primary 
sites of entry of pathogens into the human body.  They are structured to provide 
protection against pathogen transmission across the body surfaces and reduce 
dissemination to submucosal tissues, draining lymph nodes and blood.  Mucosal 
immunisations therefore have the advantage of providing mucosal as well as systemic 
immunity by a non-invasive route (Hussain and Ahsan, 2004; Hobson et al., 2003).  In 
recent years, there have been several reports of successful immunisation with DNA 
vaccines delivered to a variety of mucosal surfaces (Kaneko et al., 2000; Kanellos et al., 
2000; Klavinskis et al., 1999; Roy et al., 1999; Kuklin et al., 1997).  
 
Vaginal vaccine formulations have been researched to combat HIV.  Bodgers et al. 
(2004) have reported a novel HIV-CCR5 receptor vaccine strategy in the control of 
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mucosal SIV/HIV infection and may serve as a novel strategy in the prevention of HIV 
transmission.  A vaccine which targets both the virus and its CCR5 receptor was 
administered to female rhesus monkeys either by the vaginal route or by a para-mucosal 
route, targeting the proximity of the draining lymph nodes. 
 
2.2.3  Permeation enhancers 
Protein-like compounds are generally not well absorbed through mucosae, due to their 
molecular size, hydrophilicity and metabolism occurring at the site of absorption.  
Permeation enhancers and/or delivery vehicles can also be used to enhance membrane 
transport of proteins, peptides and other chemical compounds across biological 
membranes (Veuillez et al., 2001).   
 
Permeation enhancers promote the transport of drugs through a mucosal membrane.  
Several classes of enhancers have been evaluated for potential use in enhancing 
transmucosal delivery.  It is clear from the literature that the choice of a permeation 
enhancer must be based on the following characteristics: effectiveness, safety, chemical 
inertness, lack of biological activity and rapidly reversibility of toxic and/or 
pharmacological effects, if any. 
 
Examples of strategies to improve peptide absorption include the following: chemical 
enhancers, enzyme inhibitors, lipophilicity modification and formulation design (Veuillez 
et al., 2001). 
 
2.2.3.1  Chemical enhancers 
Examples of chemical enhancers often studied or used are surfactants, bile salts, 
chelators, alcohols and fatty acids.  Chemical enhancers may exert their effect by: 
1. altering the rheological properties of the mucus layer 
2. increasing the thermodynamic properties of the peptide 
3. enhancing transcellular transport by interacting with phospholipids and/or 
proteins to increase membrane fluidity 
4. enhancing paracellular transport 
5. inhibiting enzyme activity 
(Veuillez et al., 2001) 
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2.2.3.1.1  Surfactant 
Currently much research involves studying the diffusion of small peptide molecules 
through biological membranes in the presence of chemical permeation enhancers, such 
as surfactant.  
 
Surfactants are used as emulsifier and as physical stabilising, wetting and suspending 
agents in many topical pharmaceutical formulations, cosmetic and food products.  
Surfactants may enhance partitioning by reducing the surface tension between the 
vehicle and the membrane surface and by influencing the barrier potential of the 
membrane and the tight junctions.  It may also disrupt the barrier layers of the 
membrane (Fig. 6) (Barry and El Eini, 1976).   
 
Furthermore, the use of surfactants or complexation agents is associated with a 
reduction in the thermodynamic activity of the drug due to micellar association or 
complexation. In turn, this leads to changes in the free concentration of drug available 
for transport or diffusion across the membrane (Poelma et al., 1991). 
 
 
 
 
 
 
 
 
 
Fig. 4.  
 
Fig. 6.   
A: Permeation of drugs through the epithelial layer via the intercellular route. 
B: Permeation of drugs through the epithelial layer via the transcellular route        
     following disordering of the lipid layers by surfactant. 
 
  
B:   Transcellular Route 
       (Fast Diffusion and Short Path) 
         Disordered 
Bilayers 
A:   Intercellular Route 
       (Slow Diffusion and Tortuous Path)              
 
 
 
 Ordered Lipid Bilayers 
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2.2.3.1.2  Vehicles and adjuvants (co-solvent) 
A drug can be dissolved or dispersed in a solvent to improve transport by changing the 
thermodynamic activity and/or increasing the drug‟s solubility in the epithelial barrier of 
the mucosa (Veuillez et al., 2001). 
2.2.3.2    Enzyme inhibitors 
Peptidase inhibitors may be employed to overcome both enzymatic barriers to 
permeation.  It may be used alone or in combination with other permeation enhancers 
(Aungst, 1994). 
 
2.2.3.3  Lipophilicity modification 
The lipophilicity plays an important role in the diffusion of a peptide through a biological 
membrane.  Acylation or alkylation may be used to conjugate the N-terminal with 
lipophilic molecules or prodrugs may be used to enhance lipophilicity and the diffusion of 
peptides (Veuillez et al., 2001).   
 
2.2.3.4  Formulation design 
Formulation may have a dramatic impact on transmucosal absorption rates.  The clinical 
efficacy of the formulation depends on the ability of the vehicle to release the drug in a 
controlled manner and to penetrate the mucosa in sufficient concentrations. 
 
Liposomal formulations have shown to increase the local and decrease the systemic 
concentrations of peptides.  
 
2.2.4  Transmembrane diffusion processes 
Free diffusion or passive transport of substances through liquids, solids and membranes 
is an important process in pharmaceutical science.  Transvaginal diffusion is a passive 
process, requiring a concentration differential as the driving force and each molecule 
requires kinetic energy to achieve a net movement down this gradient.  The diffusion of a 
molecule through a membrane, biological or synthetic, in vivo or in vitro, would normally 
occur as follows (Smith, 1987).  The molecule diffuses through the vehicle in which it is 
contained to the membrane interfaces and partition from the vehicle into the upper 
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lamina of the membrane.  The molecule then diffuses within the membrane, equilibrating 
laterally and emerges under steady state conditions, from the distal surface of the 
medium.  Absorptive interaction may be extensive in this layer, forming a reservoir of the 
molecule.  It then partitions into the adjacent membrane strata or into the acceptor fluid 
under the influence of the concentration gradient and adsorption may occur once again.  
Diffusion through any of the layers or any of the partitioning events may control the 
overall rate of permeation. 
 
There are two general mechanisms by which soluble macromolecules can be absorbed 
from the vaginal mucosa into the body.  The molecules can pass either through the cells 
(transcellular transport/absorptive transcytosis) or between the cells (paracellular or 
intercellular transport).  Transcellular transport may occur independently of a plasma 
membrane receptor (fluid phase or adsorptive transcytosis) or it may involve receptor 
mediated binding, followed by vesicular transport (receptor mediated transcytosis).  
Paracellular transport occurs through the junctional complex between two or three cells.   
 
The physicochemical properties of a drug such as molecular weight, lipophilicity, 
ionisation, surface charge and chemical nature influence drug absorption.  The 
governing factor for which pathway a molecule will follow when it diffuses through a 
membrane, is the partition coefficient.  Hydrophilic molecules are expected to 
predominantly permeate through the paracellular route, while lipophilic molecules are 
expected to permeate mainly through the transcellular route (Williams, 2003).  A mixed 
permeation model has been proposed for drugs that predominantly diffuse through 
tissue via the continuous intercellular lipid domains.  Both the lipid and polar regions of 
the lipid bilayers could thus provide a micro-route through which the permeant diffuses, 
depending on the drug‟s partition coefficient (Williams, 2003).  
  
The rate of absorption of a drug molecule is also a function of its molecular size and 
shape.  An inverse relationship exists between the permeant flux and its molecular 
weight.  Smaller molecules diffuse through the vaginal tissue at a faster rate than larger 
molecules.  Organic molecules, which have a high melting point, have lower aqueous 
solubility at normal temperatures and pressures.  This leads to the assumptions that the 
more lipophilic the molecule, the faster it would permeate through any tissue.  Topical 
medication is usually applied from an aqueous formulation and the permeant should 
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contain some aqueous solubility to minimise the depletion of the permeant from the 
formulation over the time course of the application.  Because many drug substances are 
weak acids or weak bases, the ionisation state of the drug will be important in its 
diffusion through membranes.  Weak acids and weak bases will dissociate to various 
degrees depending on the pH of the formulation used and the pH of the membrane 
through which it diffuses.  In the non-ionised state, the drugs will be more lipid soluble 
and will diffuse through membranes at a higher rate than in the ionised state (Williams, 
2003).  
 
2.2.5  Aim 
Due to an absence of an effective prophylactic anti-HIV vaccine or therapy, there has 
been a current surge in interest at the development of a topical intravaginal formulation 
to combat the mucosal and perinatal HIV or microbicide transmission (D‟Cruz and 
Uckun, 2004).  Mucosal surfaces of the vagina are the portals for heterosexual 
transmission of HIV and therefore play a fundamental role in the pathogenesis of the 
primary infection.  Topical microbicides, including peptides, are being developed for 
blocking the transfer of this virus, but little is known about the diffusion of these 
compounds into and through vaginal mucosal epithelium (Hussain and Ahsan, 2004).  
 
The use of small peptide molecules as drugs has therefore gained a lot of interest in the 
last few years.  These molecules, however, cannot readily be given orally, because they 
are metabolised by enzymes in the gastrointestinal tract and they are sensitive to the 
acidic pH in the stomach.  They can be applied topically on mucosal membranes e.g. 
vaginal mucosa, thus bypassing first-pass metabolism and making them available to the 
systemic circulation directly.  Most of these small peptides do not diffuse readily through 
the mucosal membranes and diffusion enhancers must be added to increase absorption.  
Currently, the research direction involves the diffusion of small peptide molecules 
through biological membranes, as well as the enhancement of their diffusion by using 
enhancers.   
 
This study involves the investigation of diffusion in kinetics of three synthetic and novel 
peptides (MEA-5, MDY-19 and PCI) through human vaginal mucosa.  Furthermore, the 
study entails an evaluation of the flow-through diffusion system‟s value to examine test 
conditions such as different temperatures, removal of epithelium and the use of a 
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surfactant.  The three different peptides were chosen since they were manufactured to 
serve as potential microbicides or as transporters of microbicides against viruses such 
as HIV, which portal of entry is often the vaginal mucosa.  MEA-5 is an antibacterial 
peptide that binds to cell surfaces, but cannot be internalised.  It bears structural 
similarity to Maigainin 2 and can act synergistically with other existing microbicides.  
MDY-19 is a transport peptide that strongly binds to cell surfaces and can be 
internalised.  This peptide has potential applications for transporting therapeutically 
active compounds into cells, where the active microbicides can be released and exert its 
activity against e.g. viruses such as HIV.  The transport peptide PCI is comparable in 
size and has an amino acid sequence similar to MDY-19.  However, it contains less of 
the basic acid, arginine (4 vs. 7 residues), thereby reducing the overall positive charge of 
the peptide. 
 
The outcomes will hopefully improve the understanding of the permeation characteristics 
of peptides through vaginal mucosal barriers and the usefulness of the in vitro flow-
through diffusion model to study the absorption characteristics of vaginal epithelium.   It 
will also help to investigate the effect of an absorption enhancer, different permeant 
concentrations and temperature on the diffusion kinetics of the peptide permeants.   
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2.3  Materials and Methods 
2.3.1  Human vaginal mucosa 
Specimens were obtained from excess tissue removed from 43 postmenopausal 
patients, ages 40-81 years (mean age 58±11 yr SD), following vaginal hysterectomies at 
the Louis Leipoldt Hospital, Bellville, South Africa.  All surgical specimens obtained were 
immediately placed in a transport fluid and transferred to our laboratory within 1 h.  The 
transport fluid consisted of a stock solution of Eagle‟s Minimum Essential Medium (MEM) 
without L-glutamine and sodium bicarbonate (Gibco, Paisley, Scotland), to which the 
latter as well as an antibiotic (penicillin/streptomycin, 100 IU/ml) and an antimycotic 
(amphotericin-B, 2.5 μg /ml) were added prior to using it for the transport of tissue 
specimens. Excess connective and adipose tissue were trimmed away and all 
specimens were snap-frozen in liquid nitrogen and stored at -85°C for periods up to 6 
months, as previously prescribed (Van der Bijl and Van Eyk, 2004; Van der Bijl and Van 
Eyk, 1999; Van der Bijl et al., 1998b; Van der Bijl et al., 1997).  No specimens were 
obtained where there was clinical evidence of any disease that might have influenced 
the permeability characteristics of the different specimens.  The Ethics Committee of 
Stellenbosch University and the Tygerberg Academic Hospital approved the study.  
Project number:  95/019 (resubmitted and approved on 28/7/03).  
 
2.3.2  Peptides 
The three synthetic FITC (fluorescein isothiocyanate)-labelled peptides MEA-5 (Mw = 
2911.4 Da), MDY-19 (Mw = 2409.5 Da) and PCI (Mw = 2325 Da) were obtained from the 
EMPRO (European Microbicides Project) consortium partner PEPSCAN, Lelystad, The 
Netherlands (Fig. 7).  EMPRO is a European based research network investigating and 
developing new microbicides for the prevention of HIV infection.  It is funded by the 
European Union.  The EMPRO program is divided into different activities, e.g. covering 
development of new microbicides in the laboratory and also testing these candidates‟ 
permeability through different membranes.   MEA-5 is an antibacterial peptide that binds 
to cell surfaces, but cannot be internalised.  It bears structural similarity to Maigainin 2 
and can act synergistically with other existing microbicides.  MDY-19 is a transport 
peptide that strongly binds to cell surfaces and can be internalised.  This peptide has 
potential applications for transporting therapeutically active compounds into cells, where 
the active microbicides can be released and exert its activity against e.g. viruses such as 
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HIV.  The transport peptide PCI is comparable in size and has an amino acid sequence 
similar to MDY-19.  However, it contains less of the basic acid, arginine (4 vs. 7 
residues), thereby reducing the overall positive charge of the peptide. 
 
 
MEA-5 (2922.4 Da) 
FITC-Ahx-GIGKFLHSAGKFGKAFVGEIMKS-NH2 
 
MDY-19 (2409.5 Da)  
FITC-Ahx- GRQLRIAGRRLRGRSR-NH2 
 
PCI (2325 Da) 
FITC-Ahx-GQQLRIAGRRLRGQSQ-NH2 
 
 
 
Symbol Amino Acid 
A Alanine 
R Arginine 
E Glutamic Acid 
Q Glutamine 
G Glycine 
H Histidine 
I Isoleucine  
L Leucine  
K Lycine 
M Methionine  
F Phenylalanine  
S Serine 
V Valine  
 Hydrophobic amino acids 
 
   Fig. 7. Chemical structures of MEA-5, MDY-19, PCI (By courtesy of PEPSCAN) 
 
Ahx (6-Aminohexanoic acid) was used to attach FITC-moiety into the peptides.  A spacer 
between the peptide and the ligand (Figs. 8 and 9) minimises the inference in the folding 
of the peptide and/or it‟s binding to the receptor.   
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Fig. 8.  FITC = Fluorescein isothiocyanate (Fluka/Riedel-de Haën Catologue, 
2007/2008) 
 
 
 
 
 
 
 
 Fig. 9.  Ahx = Aminohexanoic acid (Fluka/Riedel-de Haën Catologue, 2007/2008)  
 
2.3.3  Surfactant 
A novel surfactant Biopolsurf (prepared in our laboratory by Prof. JM van Zyl) was used 
as an enhancer.  It was decided to use this surfactant, since it was readily available and 
we wanted to investigate its effect on transvaginal peptide permeability.  Initial studies on 
the effect of Biopolsurf on the bronchial, vaginal, buccal and rectal permeability of 
different chemicals showed that it significantly enhanced the permeability of most of the 
selected drugs across the different epithelia (Viljoen et al., 2005).   
 
Biopolsurf preparations were prepared by mixing DPPC (dipalmitoyl-L-α-
phophatidylcholine), cetyl alcohol and PG (1,2-dipalmitoyl-L-α-phophatidylglycerol) in a 
10:1.1:1 ratio (w/w) in chloroform.  The organic solvent was then removed by rotary 
evaporation and the mixture was dried under a continuous stream of nitrogen at room 
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temperature.  The dried phospholipids film was then hydrated with 0.1 M NaCl.  A 
Branson B-15P ultrasonicater fitted with a microtip was then used to sonicate the mixture 
on ice under a stream of nitrogen (power of 20 watts for 7 x 13 s; 60 s intervals).  
Hereafter, tyloxapol was added to the preparation to a final concentration of 1 mg/ml and 
the tube was sealed under nitrogen before use.  The Biopolsurf suspension contained 
13.5 mg/ml DPPC and 1.35 mg/ml PG.  
 
2.3.4  Permeability Experiments  
Prior to each permeability experiment, vaginal tissue specimens were thawed at room 
temperature in phosphate buffered saline (PBS, pH 7.4). The diffusion kinetics of FITC-
labelled peptides through thawed, frozen vaginal mucosa were then determined (Basson 
et al., 2007).  After equilibration of the specimens in PBS, they were carefully cut, so as 
not to damage the epithelial surfaces, into sections (4 mm in diameter) and then 
mounted in flow-through diffusion cells (exposed areas 0.039 cm2) with the epithelial 
surfaces facing upwards.  Previous studies showed that the vaginal mucosa could be 
harvested without damaging the underlying connective tissue layer. Histological 
examination of formalin-fixed specimens of fresh, thawed frozen and post 24 h 
experiment vaginal mucosa showed that the structural integrity of it was preserved after 
harvesting and freezing.  Individual epithelial cells, however, demonstrated early signs of 
autolysis and some minor degenerative changes.  In spite of these degradative changes, 
there was no evidence of a break-down in properties as barriers to the various 
permeants tested (Van der Bijl and Van Eyk, 2004; Van der Bijl et al., 1998).  
   
Six permeation studies were performed for each investigation, on 7 tissue replicates for 
each of the six patients‟ tissue. Prior to commencing each permeability experiment, 
tissue disks were equilibrated for 10 min with PBS (pH 7.4) at 20 °C in both the donor 
and acceptor compartments of the diffusion cells. Following equilibration, the PBS was 
removed from the donor compartment and replaced with 0.5 ml of PBS containing the 
FITC-labelled peptide.  PBS at 20 °C was pumped through the acceptor chambers at a 
rate of 1.5 ml/h and collected, by means of a fraction collector, at 2 h intervals for 24 h.  
FITC-labelled peptides in the acceptor chambers were quantified by means of 
fluorospectrophotometry.  Intra- and inter-experiment variations were calculated for the 
peptide experiments (CV= SD/mean x 100). 
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 2.3.5  Methodology 
Various test conditions were applied such as different temperatures, different 
concentrations of the test peptides, the use of a surfactant and the de-epithelisation of 
the mucosa. 
 
The in vitro permeation of a FITC-labelled synthetic transport peptide (MDY-19) and a 
FITC-labelled microbicidal peptide (MEA-5) through human vaginal mucosa was studied.  
Permeability studies of MDY-19 and MEA-5 were conducted at a concentration of 1 mM 
(in PBS) at a temperature of 20 °C and over a time period of 24 hours.  The permeation 
enhancing effects of a phospholipid surfactant on MDY-19 permeation and the effect of 
vaginal de-epithelisation on MEA-5 flux rates were also studied.  De-epithelisation 
mimics the situation when integrity of vaginal epithelium is breached due to disease or 
local trauma.   
 
Initially de-epithelisation was conducted by two methods to establish the most effective 
and convenient method.  The one method involves the vaginal tissue being submerged 
in 80 ˚C water for 30 s and the quick stripping of the epithelial layer with tweezers (heat 
stripping).  The second method entailed the removal of the epithelial cells by scraping 
the tissue with a scalpel (mechanical stripping).  Concentrations of 1 mM (in PBS) were 
used for the forgoing mentioned permeability studies. 
 
Initial experiments were conducted at 20 °C (room temperature), since it is less 
expensive to have a flow-through system without a waterbath to control temperature and 
previous vaginal permeability studies in our laboratory with selected chemicals showed 
that permeability data of experiments at 20 °C could be extrapolated and correlated with 
experimental data at temperatures of 37 °C (Van der Bijl and Van Eyk, 2004; Van der Bijl 
and Van Eyk, 1999; Van der Bijl et al., 1997).  Precipitation of peptides on the vaginal 
mucosa during the permeability experiments at room temperature (20 °C) and at a 
concentration of 1 mM was noticed.  For this reason, further permeability studies of 
MDY-19 and PCI were conducted at a temperature of 37 ˚C.  PEPSCAN stopped the 
production of MEA-5 and therefore studies with MEA-5 could not be repeated at 37 °C.   
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Permeability studies of MDY-19 and PCI were conducted at concentrations of 1, 0.75 
and 0.5 mM (in PBS) at a temperature of 37 ˚C and the respective extraction ratios were 
calculated.   
 
Only limited amounts of MDY-19 and PCI were manufactured by PEPSCAN and it was 
then decided to conduct further experiments with FITC-labelled peptides at 37 °C and at 
a concentration of 0.75 mM to prevent precipitation and to economise the use of the 
peptides. The effect of vaginal de-epithelisation on MDY-19 and PCI flux rates were also 
studied. 
 
2.3.6  Detection of FITC-labelled peptides  
Fluorospectrophotometry (emission: 520 nm and excitation: 497 nm) using a Perkin-
Elmer spectrophotometer (Perkin-Elmer, MA, USA), was used for the detection of FITC 
peptides (Figs. 10-15).  The standards of the three selected peptides were dissolved in 
the same PBS as the drug containing samples collected from the flow-through diffusion 
system.  Fresh or new standards were made for each experiment and all the samples 
were analysed on one day.  The coefficient of determination was better than 0.99 for all 
the peptides (R2) and the reproducibility of 3 injections from standards from 3 different 
vials were better than a % RSD of 2 % for all analytes.  The stability of the peptides was 
not tested in the carrier medium and no information is available on the stability of the 
peptides at the temperatures used in the experiment. 
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       Fig. 10.  Calibration curve of MEA-5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     Fig. 11. Excitation and fluorescence spectra of MEA-5 
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       Fig. 12.  Calibration curve MDY-19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
  
                    Fig. 13. Excitation and fluorescence spectra of MDY-19 
 
 
 
   
Chapter 2: Vaginal mucosa                                            50 
           
5
0
 
0.00 0.05 0.10 0.15 0.20 0.25
0
200
400
600
800
Concentration (M)
F
lo
re
s
c
e
n
c
e
 
 
 
 
 
 
 
 
 
 
 
 
                    Fig. 14.  Calibration curve of PCI 
 
 
                    
 
 
 
 
 
   
 
     
 
 
 
 
 
 
                  Fig. 15. Excitation and fluorescence spectra of PCI 
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2.3.7  Calculation of flux values 
Flux (J) values of the various chemicals compounds across the different membranes 
were calculated by means of the relationship: J = Q/(A x t), where Q = quantity of 
compound crossing membrane (pmoles), A = membrane area exposed (cm2) and t = 
time of exposure (min) (Basson et al., 2005).  The trapezoid method of obtaining area 
under curve (AUC) was used.    
 
2.3.8  Steady state kinetics and statistical analysis of data 
Repeated measure ANOVA over all time periods and a Bonferroni multiple comparison 
procedure was used to determine steady state.  If at consecutive time periods p-values 
exceeded 0.05, these flux values do not differ significantly, therefore indicating steady 
state.  Non-linear regression analyses (third-order polynomial) were performed using 
GraphPad Prism, version 4, 2003 computer programme.  A F-test was used to compare 
entire curves (Motulsky, 1995).  A significant level of 5 % was used for all tests and 
comparisons. 
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2.4  Results 
The overall mean flux values of MEA-5 and MDY-19 versus time across vaginal tissue 
(20 ˚C) are shown in Fig. 16.  Both MEA-5 and MDY-19 permeated vaginal mucosa well.  
MDY-19 had a significantly higher (p<0.05) flux rate than MEA-5, commensurate with its 
smaller molecular size (weight).  Both MEA-5 and MDY-19 reached steady state at 18 h 
(Fig. 16a).    
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 AUC/24 h of MEA-5: 55.63 ± 7.65 pmoles.cm-2.min-1 
 AUC/24 h of MDY-19: 77.88 ±10.00 pmoles.cm-2.min-1 
 
 
Fig. 16.  The overall mean flux values at 20 ˚C of MEA-5 and MDY-19 versus time 
across vaginal tissue 
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Bonferroni test; variable DV_1 (MEA-5)
Error: Within MS = 726.11, df = 451.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
4.926 18.106 30.205 42.351 51.909 62.052 67.398 74.995 81.355 89.542 94.204 100.54
1 2 1 0.00139 0 0 0 0 0 0 0 0 0
2 4 1 1 0.00294 1E-06 0 0 0 0 0 0 0
3 6 0.00139 1 1 0.01655 7E-06 0 0 0 0 0 0
4 8 0 0.00294 1 1 0.05771 0.00165 3E-06 0 0 0 0
5 10 0 1E-06 0.01655 1 1 0.57585 0.00659 5.2E-05 0 0 0
6 12 0 0 7E-06 0.05771 1 1 1 0.07314 0.00026 5E-06 0
7 14 0 0 0 0.00165 0.57585 1 1 1 0.01241 0.00044 2E-06
8 16 0 0 0 3E-06 0.00659 1 1 1 0.90625 0.07725 0.00114
9 18 0 0 0 0 5.2E-05 0.07314 1 1 1 1 0.07825
10 20 0 0 0 0 0 0.00026 0.01241 0.90625 1 1 1
11 22 0 0 0 0 0 5E-06 0.00044 0.07725 1 1 1
12 24 0 0 0 0 0 0 2E-06 0.00114 0.07825 1 1
Bonferroni test; variable DV_1 (MDY-19)
Error: Within MS = 1603.7, df = 462.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
17.665 19.382 38.347 55.635 71.481 82.669 94.307 105.77 114.74 126.98 137.21 140.96
1 2 1 1 0.0009 0 0 0 0 0 0 0 0
2 4 1 1 0.00214 0 0 0 0 0 0 0 0
3 6 1 1 1 0.00938 2.8E-05 0 0 0 0 0 0
4 8 0.0009 0.00214 1 1 0.12261 0.00063 1E-06 0 0 0 0
5 10 0 0 0.00938 1 1 0.56073 0.00549 5.1E-05 0 0 0
6 12 0 0 2.8E-05 0.12261 1 1 0.51068 0.01514 2.8E-05 0 0
7 14 0 0 0 0.00063 0.56073 1 1 1 0.01159 6.3E-05 7E-06
8 16 0 0 0 1E-06 0.00549 0.51068 1 1 0.9541 0.02003 0.00358
9 18 0 0 0 0 5.1E-05 0.01514 1 1 1 0.63243 0.167
10 20 0 0 0 0 0 2.8E-05 0.01159 0.9541 1 1 1
11 22 0 0 0 0 0 0 6.3E-05 0.02003 0.63243 1 1
12 24 0 0 0 0 0 0 7E-06 0.00358 0.167 1 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Fig. 16a.  Both MEA-5 and MDY-19 reached steady state at 18 h  
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The overall mean flux values of MDY-19 across vaginal tissue (20 ˚C) with and without 
surfactant as a penetration enhancer are shown in Fig. 17.  The surfactant significantly 
(p<0.05) enhanced the flux rate of MDY-19.  The surfactant increased the AUC of the 
mean flux values (average flux over 24 h experiment) of MDY-19 1.3 times and also 
decreased the lag time of the peptide.  The control group reached steady state after 18 h 
and the group with the surfactant enhancer had a lag time of 16 h (Fig. 17a).   
 
 
 
 
 
 
 
 
 
 
 
 
  
 AUC/24 h of MDY-19: 77.88 ± 10.00 pmoles.cm-2.min-1 
 AUC/24 h of MDY-19 & Surfactant: 104.54 ± 14.52 pmoles.cm-2.min-1 
 
Fig. 17.  The overall mean flux values at 20 ˚C of MDY-19 across vaginal tissue 
with and without surfactant as a penetration enhancer 
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Bonferroni test; variable DV_1 (MDY-19)
Error: Within MS = 1603.7, df = 462.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
17.665 19.382 38.347 55.635 71.481 82.669 94.307 105.77 114.74 126.98 137.21 140.96
1 2 1 1 0.0009 0 0 0 0 0 0 0 0
2 4 1 1 0.00214 0 0 0 0 0 0 0 0
3 6 1 1 1 0.00938 2.8E-05 0 0 0 0 0 0
4 8 0.0009 0.00214 1 1 0.12261 0.00063 1E-06 0 0 0 0
5 10 0 0 0.00938 1 1 0.56073 0.00549 5.1E-05 0 0 0
6 12 0 0 2.8E-05 0.12261 1 1 0.51068 0.01514 2.8E-05 0 0
7 14 0 0 0 0.00063 0.56073 1 1 1 0.01159 6.3E-05 7E-06
8 16 0 0 0 1E-06 0.00549 0.51068 1 1 0.9541 0.02003 0.00358
9 18 0 0 0 0 5.1E-05 0.01514 1 1 1 0.63243 0.167
10 20 0 0 0 0 0 2.8E-05 0.01159 0.9541 1 1 1
11 22 0 0 0 0 0 0 6.3E-05 0.02003 0.63243 1 1
12 24 0 0 0 0 0 0 7E-06 0.00358 0.167 1 1
Bonferroni test; variable DV_1 (MDY-19 & Surfactant)
Error: Within MS = 991.95, df = 209.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
9.895 37.66 72.805 89.755 107.7 121.17 129.63 142.65 150.74 150.2 158.19 168.21
1 2 0.38261 0 0 0 0 0 0 0 0 0 0
2 4 0.38261 0.03388 2.7E-05 0 0 0 0 0 0 0 0
3 6 0 0.03388 1 0.03705 0.00016 3E-06 0 0 0 0 0
4 8 0 2.7E-05 1 1 0.12185 0.00572 1.8E-05 0 0 0 0
5 10 0 0 0.03705 1 1 1 0.03633 0.00158 0.00198 5.8E-05 0
6 12 0 0 0.00016 0.12185 1 1 1 0.22024 0.26053 0.01712 0.00028
7 14 0 0 3E-06 0.00572 1 1 1 1 1 0.30143 0.00947
8 16 0 0 0 1.8E-05 0.03633 1 1 1 1 1 0.72447
9 18 0 0 0 0 0.00158 0.22024 1 1 1 1 1
10 20 0 0 0 0 0.00198 0.26053 1 1 1 1 1
11 22 0 0 0 0 5.8E-05 0.01712 0.30143 1 1 1 1
12 24 0 0 0 0 0 0.00028 0.00947 0.72447 1 1 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
      
 
 
 
 
 
 
 
 
 
 
 
Fig. 17a.  MDY-19 and MDY-19 with surfactant (MDY-19 & Surfactant) as a penetration enhancer, reached steady state 
respectively at 18 and 16 h
Chapter 2: Vaginal mucosa                                            56 
 
           
5
6
 
Vaginal mucosal surfaces were de-epithelialised by means of mechanical and heat 
stripping.  The overall mean flux values of MEA-5 across human vaginal mucosa across 
intact vaginal tissue and after heat and mechanical de-epithelialisation are shown in Fig. 
18.  Both heat and mechanical de-epithelialisation of mucosa significantly (p<0.05) 
enhanced flux values of MEA-5 (heat de-epithelialisation: 1.9 x; mechanical de-
epithelialisation: 1.8 x) compared with controls (20 ˚C), although no marked significant 
differences (p>0.05) or advantages could be discerned between the two methods.  MEA-
5 across intact vaginal tissue reached steady state after 18 h, but de-epithelialisation 
(heat and mechanical) of the vaginal tissue caused MEA-5 not to reach steady state 
during the 24 h experiment (Figs. 18a and b).  Precipitation of MEA-5 and MDY-19 was 
noted with the initial experiments, therefore further permeability studies were conducted 
at 37 °C.  The overall mean flux values of MDY-19 and PCI across intact vaginal tissue 
(control group) versus de-epithelialised tissue are respectively shown in Figs. 19 and 20.  
De-epithelialisation of the vaginal mucosa significantly (p<0.05) enhanced flux values of 
MDY-19 (1.5 x) and PCI (1.3 x) compared with the controls (37°C) and it also decreased 
the lag time of the two peptides (Figs. 19a and 20a). 
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 AUC/24 h of Control: 55.63 ± 7.65 pmoles.cm-2.min-1 
 AUC/24 h of Mechanical de-epithelialisation: 105.54 ± 7.21 pmoles.cm-2.min-1 
 AUC/24 h of Heat de-epithelialisation: 101.08 ± 11.00 pmoles.cm-2.min-1 
 
Fig. 18.  Overall mean flux values at 20 ºC of MEA-5 versus time across intact 
vaginal mucosa (control) and de-epithelialised mucosa by means of heat and 
mechanical stripping 
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Bonferroni test; variable DV_1 (MEA-5)
Error: Within MS = 726.11, df = 451.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
4.926 18.106 30.205 42.351 51.909 62.052 67.398 74.995 81.355 89.542 94.204 100.54
1 2 1 0.00139 0 0 0 0 0 0 0 0 0
2 4 1 1 0.00294 1E-06 0 0 0 0 0 0 0
3 6 0.00139 1 1 0.01655 7E-06 0 0 0 0 0 0
4 8 0 0.00294 1 1 0.05771 0.00165 3E-06 0 0 0 0
5 10 0 1E-06 0.01655 1 1 0.57585 0.00659 5.2E-05 0 0 0
6 12 0 0 7E-06 0.05771 1 1 1 0.07314 0.00026 5E-06 0
7 14 0 0 0 0.00165 0.57585 1 1 1 0.01241 0.00044 2E-06
8 16 0 0 0 3E-06 0.00659 1 1 1 0.90625 0.07725 0.00114
9 18 0 0 0 0 5.2E-05 0.07314 1 1 1 1 0.07825
10 20 0 0 0 0 0 0.00026 0.01241 0.90625 1 1 1
11 22 0 0 0 0 0 5E-06 0.00044 0.07725 1 1 1
12 24 0 0 0 0 0 0 2E-06 0.00114 0.07825 1 1
 
 
 
 
 
 
 
 
 
       
 
        Fig. 18a.  MEA-5 across intact vaginal mucosa (control) reached steady state at 18 h  
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Bonferroni test; variable DV_1 (Heat de-epithelialisation)
Error: Within MS = 316.40, df = 165.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
7.495 25.446 65.129 90.156 103.32 115.65 127.82 141.76 152.28 164.78 177.65 190.24
1 2 0.32118 0 0 0 0 0 0 0 0 0 0
2 4 0.32118 0 0 0 0 0 0 0 0 0 0
3 6 0 0 0.00681 1E-06 0 0 0 0 0 0 0
4 8 0 0 0.00681 1 0.00511 1E-06 0 0 0 0 0
5 10 0 0 1E-06 1 1 0.00939 0 0 0 0 0
6 12 0 0 0 0.00511 1 1 0.00348 2E-06 0 0 0
7 14 0 0 0 1E-06 0.00939 1 1 0.0096 1E-06 0 0
8 16 0 0 0 0 0 0.00348 1 1 0.02238 3E-06 0
9 18 0 0 0 0 0 2E-06 0.0096 1 1 0.00552 1E-06
10 20 0 0 0 0 0 0 1E-06 0.02238 1 1 0.00522
11 22 0 0 0 0 0 0 0 3E-06 0.00552 1 1
12 24 0 0 0 0 0 0 0 0 1E-06 0.00522 1
Bonferroni test; variable DV_1 (Mechanical de-epithelialisation)
Error: Within MS = 648.85, df = 165.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
23.17 38.31 59.958 77.335 89.234 101.87 117.48 134.02 146.8 162.33 168.99 186.83
1 2 1 0.00453 1E-06 0 0 0 0 0 0 0 0
2 4 1 1 0.00168 4E-06 0 0 0 0 0 0 0
3 6 0.00453 1 1 0.09208 0.00044 0 0 0 0 0 0
4 8 1E-06 0.00168 1 1 0.47108 0.00101 0 0 0 0 0
5 10 0 4E-06 0.09208 1 1 0.13359 0.00011 0 0 0 0
6 12 0 0 0.00044 0.47108 1 1 0.03089 0.0001 0 0 0
7 14 0 0 0 0.00101 0.13359 1 1 0.09082 0.00011 3E-06 0
8 16 0 0 0 0 0.00011 0.03089 1 1 0.13085 0.00983 2E-06
9 18 0 0 0 0 0 0.0001 0.09082 1 1 0.97337 0.00106
10 20 0 0 0 0 0 0 0.00011 0.13085 1 1 0.47651
11 22 0 0 0 0 0 0 3E-06 0.00983 0.97337 1 1
12 24 0 0 0 0 0 0 0 2E-06 0.00106 0.47651 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 18b.  MEA-5 across de-epithelialised mucosa by means of both heat (heat de-epithelialisation) and mechanical 
stripping (mechanical de-epithelialisation) did not reach steady state during the 24 h period  
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 AUC/24 h of Control: 124.00 ± 13.76 pmoles.cm-2.min-1 
 AUC/24 h of Heat de-epithelialisation: 180.00 ± 21.73 pmoles.cm-2.min-1 
 
Fig. 19.  Overall mean flux values at 37 ˚C of MDY-19 versus time across intact 
vaginal mucosa and de-epithelialised mucosa by means of heat 
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Bonferroni test; variable DV_1 (MDY-19)
Error: Within MS = 4049.0, df = 451.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
12.64 33.445 63.248 89.405 113.37 134.98 158.13 171.69 184.97 202.16 212.97 221.68
1 2 1 0.01973 4E-06 0 0 0 0 0 0 0 0
2 4 1 1 0.00432 1E-06 0 0 0 0 0 0 0
3 6 0.01973 1 1 0.02252 2.4E-05 0 0 0 0 0 0
4 8 4E-06 0.00432 1 1 0.07331 6.9E-05 0 0 0 0 0
5 10 0 1E-06 0.02252 1 1 0.08957 0.00212 2.5E-05 0 0 0
6 12 0 0 2.4E-05 0.07331 1 1 0.55911 0.02329 0.00012 2E-06 0
7 14 0 0 0 6.9E-05 0.08957 1 1 1 0.10725 0.00599 0.0004
8 16 0 0 0 0 0.00212 0.55911 1 1 1 0.20518 0.02336
9 18 0 0 0 0 2.5E-05 0.02329 1 1 1 1 0.56037
10 20 0 0 0 0 0 0.00012 0.10725 1 1 1 1
11 22 0 0 0 0 0 2E-06 0.00599 0.20518 1 1 1
12 24 0 0 0 0 0 0 0.0004 0.02336 0.56037 1 1
Bonferroni test; variable DV_1 (Heat de-epithelialisation)
Error: Within MS = 9739.3, df = 198.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
19.183 71.227 113.08 144.96 163.21 189.29 210.83 237.56 255.89 269.39 318.53 333.37
1 2 1 0.24809 0.0078 0.00077 1.9E-05 1E-06 0 0 0 0 0
2 4 1 1 1 0.29783 0.01932 0.00138 3.3E-05 2E-06 0 0 0
3 6 0.24809 1 1 1 1 0.17003 0.00911 0.0009 0.00014 0 0
4 8 0.0078 1 1 1 1 1 0.28084 0.04297 0.00916 1.1E-05 1E-06
5 10 0.00077 0.29783 1 1 1 1 1 0.27864 0.07162 0.00016 1.9E-05
6 12 1.9E-05 0.01932 1 1 1 1 1 1 0.86887 0.00512 0.00076
7 14 1E-06 0.00138 0.17003 1 1 1 1 1 1 0.06098 0.01147
8 16 0 3.3E-05 0.00911 0.28084 1 1 1 1 1 0.80701 0.20591
9 18 0 2E-06 0.0009 0.04297 0.27864 1 1 1 1 1 1
10 20 0 0 0.00014 0.00916 0.07162 0.86887 1 1 1 1 1
11 22 0 0 0 1.1E-05 0.00016 0.00512 0.06098 0.80701 1 1 1
12 24 0 0 0 1E-06 1.9E-05 0.00076 0.01147 0.20591 1 1 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19a.  MDY-19 across intact vaginal mucosa and de-epithelialised mucosa by means of heat (heat de-epithelialisation) 
reached steady state respectively after 18 and 16 h  
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 AUC/24 h of Control: 172.21 ± 14.93 pmoles.cm-2.min-1 
 AUC/24 h of Heat de-epithelialisation: 226.46 ± 21.38 pmoles.cm-2.min-1 
 
Fig. 20.  Overall mean flux values at 37 ˚C of PCI across intact vaginal mucosa and 
de-epithelialised mucosa by means of heat. 
 
            
6
3
 
Bonferroni test; variable DV_1 (PCI)
Error: Within MS = 3856.5, df = 484.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
18.079 57.992 102.5 140.33 170.62 195.62 217.31 237.37 252.78 264.53 270.95 277.05
1 2 0.16002 0 0 0 0 0 0 0 0 0 0
2 4 0.16002 0.04821 0 0 0 0 0 0 0 0 0
3 6 0 0.04821 0.26571 1.9E-05 0 0 0 0 0 0 0
4 8 0 0 0.26571 1 0.00191 1E-06 0 0 0 0 0
5 10 0 0 1.9E-05 1 1 0.02629 3.2E-05 0 0 0 0
6 12 0 0 0 0.00191 1 1 0.10019 0.00102 1.4E-05 1E-06 0
7 14 0 0 0 1E-06 0.02629 1 1 0.4608 0.02257 0.00323 0.00042
8 16 0 0 0 0 3.2E-05 0.10019 1 1 1 0.70052 0.16952
9 18 0 0 0 0 0 0.00102 0.4608 1 1 1 1
10 20 0 0 0 0 0 1.4E-05 0.02257 1 1 1 1
11 22 0 0 0 0 0 1E-06 0.00323 0.70052 1 1 1
12 24 0 0 0 0 0 0 0.00042 0.16952 1 1 1
Bonferroni test; variable DV_1 (Heat de-epithelialisation)
Error: Within MS = 12476., df = 286.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
28.097 96.786 143.81 171.99 215.8 253.61 294.12 349.7 336.54 327.26 327.98 343.52
1 2 1 0.01138 0.00023 0 0 0 0 0 0 0 0
2 4 1 1 0.92003 0.00746 3.1E-05 0 0 0 0 0 0
3 6 0.01138 1 1 1 0.02369 8.6E-05 0 0 0 0 0
4 8 0.00023 0.92003 1 1 0.50696 0.00497 1E-06 9E-06 3.9E-05 3.5E-05 3E-06
5 10 0 0.00746 1 1 1 0.69174 0.00099 0.00596 0.01935 0.01771 0.00234
6 12 0 3.1E-05 0.02369 0.50696 1 1 0.11495 0.44651 1 0.99232 0.22167
7 14 0 0 8.6E-05 0.00497 0.69174 1 1 1 1 1 1
8 16 0 0 0 1E-06 0.00099 0.11495 1 1 1 1 1
9 18 0 0 0 9E-06 0.00596 0.44651 1 1 1 1 1
10 20 0 0 0 3.9E-05 0.01935 1 1 1 1 1 1
11 22 0 0 0 3.5E-05 0.01771 0.99232 1 1 1 1 1
12 24 0 0 0 3E-06 0.00234 0.22167 1 1 1 1 1
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Fig. 20a.  PCI across intact vaginal mucosa and de-epithelialised mucosa by means of heat (heat de-epithelialisation) 
reached steady state respectively after 16 and 12 h 
                             Chapter 2: Vaginal mucosa                                            64 
           
6
4
 
0 4 8 12 16 20 24
0
50
100
150
200
250
0.5 mM MDY-19
0.5 mM PCI
Bar=SEM
Time (h)
F
lu
x
 r
a
te
 (
p
m
o
le
s
.c
m
-2
.m
in
-1
)
The mean flux values of MDY-19 and PCI compared at different concentrations and 
temperatures (20 °C and 37 °C) are shown in Figs. 21-24 and the AUC/24 h (average 
flux over 24 h) of these figures are shown as column bars in Fig. 25.  The AUCs of the 
mean flux values of MDY-19 and PCI increased with an increase in concentration and 
temperature (20 °C to 37 °C).  The times to steady state are shown in Figs. 
(21a,22a,23a,24a). The AUCs of the mean flux values of 1 mM MDY-19 and PCI at 37 
°C were the highest.   
 
 
 
 
 
 
 
 
 
 
  
 
 
 AUC/24 h of 0.5 mM MDY-19: 117.13 ± 12.01 pmoles.cm-2.min-1 
 AUC/24 h of 0.5 mM PCI: 131.75 ± 11.88 pmoles.cm-2.min-1 
 
Fig. 21.  Overall mean flux values at 37 ˚C of 0.5 mM MDY-19 and PCI across intact 
vaginal mucosa. 
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Bonferroni test; variable DV_1 (MDY-19)
Error: Within MS = 2612.4, df = 495.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
23.178 62.81 88.4724 106.898 117.802 132.116 142.065 151.324 157.435 165.407 169.182 177.348
1 2 0.00098 0 0 0 0 0 0 0 0 0 0
2 4 0.00098 0.31694 0.0001 0 0 0 0 0 0 0 0
3 6 0 0.31694 1 0.0849 0.00013 0 0 0 0 0 0
4 8 0 0.0001 1 1 0.36822 0.00776 8.4E-05 3E-06 0 0 0
5 10 0 0 0.0849 1 1 0.50442 0.01579 0.00098 1.5E-05 2E-06 0
6 12 0 0 0.00013 0.36822 1 1 1 0.35587 0.01742 0.0033 5.4E-05
7 14 0 0 0 0.00776 0.50442 1 1 1 0.67756 0.19119 0.00738
8 16 0 0 0 8.4E-05 0.01579 1 1 1 1 1 0.28012
9 18 0 0 0 3E-06 0.00098 0.35587 1 1 1 1 1
10 20 0 0 0 0 1.5E-05 0.01742 0.67756 1 1 1 1
11 22 0 0 0 0 2E-06 0.0033 0.19119 1 1 1 1
12 24 0 0 0 0 0 5.4E-05 0.00738 0.28012 1 1 1
Bonferroni test; variable DV_1 (PCI)
Error: Within MS = 3280.2, df = 484.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
16.0809 47.9187 81.7305 114.521 135.149 151.956 166.277 180.002 188.937 199.825 196.906 203.12
1 2 0.13419 0 0 0 0 0 0 0 0 0 0
2 4 0.13419 0.06984 0 0 0 0 0 0 0 0 0
3 6 0 0.06984 0.09831 1.9E-05 0 0 0 0 0 0 0
4 8 0 0 0.09831 1 0.01937 4.3E-05 0 0 0 0 0
5 10 0 0 1.9E-05 1 1 0.16841 0.001 1.6E-05 0 0 0
6 12 0 0 0 0.01937 1 1 0.42969 0.02288 0.00027 0.00096 5.7E-05
7 14 0 0 0 4.3E-05 0.16841 1 1 1 0.07636 0.197 0.02406
8 16 0 0 0 0 0.001 0.42969 1 1 1 1 1
9 18 0 0 0 0 1.6E-05 0.02288 1 1 1 1 1
10 20 0 0 0 0 0 0.00027 0.07636 1 1 1 1
11 22 0 0 0 0 0 0.00096 0.197 1 1 1 1
12 24 0 0 0 0 0 5.7E-05 0.02406 1 1 1 1
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
       Fig. 21a.  0.5 mM MDY-19 and PCI reached steady state at 16 h 
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 AUC/24 h of 0.75 mM MDY-19: 124.00 ± 13.76 pmoles.cm-2.min-1 
 AUC/24 h of 0.75 mM PCI: 172.21 ± 14.93 pmoles.cm-2.min-1 
 
Fig. 22.  Overall mean flux values at 37 ˚C of 0.75 mM MDY-19 and PCI across 
intact vaginal mucosa 
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Bonferroni test; variable DV_1 (MDY-19)
Error: Within MS = 4049.0, df = 451.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
12.64 33.445 63.248 89.405 113.37 134.98 158.13 171.69 184.97 202.16 212.97 221.68
1 2 1 0.01973 4E-06 0 0 0 0 0 0 0 0
2 4 1 1 0.00432 1E-06 0 0 0 0 0 0 0
3 6 0.01973 1 1 0.02252 2.4E-05 0 0 0 0 0 0
4 8 4E-06 0.00432 1 1 0.07331 6.9E-05 0 0 0 0 0
5 10 0 1E-06 0.02252 1 1 0.08957 0.00212 2.5E-05 0 0 0
6 12 0 0 2.4E-05 0.07331 1 1 0.55911 0.02329 0.00012 2E-06 0
7 14 0 0 0 6.9E-05 0.08957 1 1 1 0.10725 0.00599 0.0004
8 16 0 0 0 0 0.00212 0.55911 1 1 1 0.20518 0.02336
9 18 0 0 0 0 2.5E-05 0.02329 1 1 1 1 0.56037
10 20 0 0 0 0 0 0.00012 0.10725 1 1 1 1
11 22 0 0 0 0 0 2E-06 0.00599 0.20518 1 1 1
12 24 0 0 0 0 0 0 0.0004 0.02336 0.56037 1 1
Bonferroni test; variable DV_1 (PCI)
Error: Within MS = 3856.5, df = 484.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
18.079 57.992 102.5 140.33 170.62 195.62 217.31 237.37 252.78 264.53 270.95 277.05
1 2 0.16002 0 0 0 0 0 0 0 0 0 0
2 4 0.16002 0.04821 0 0 0 0 0 0 0 0 0
3 6 0 0.04821 0.26571 1.9E-05 0 0 0 0 0 0 0
4 8 0 0 0.26571 1 0.00191 1E-06 0 0 0 0 0
5 10 0 0 1.9E-05 1 1 0.02629 3.2E-05 0 0 0 0
6 12 0 0 0 0.00191 1 1 0.10019 0.00102 1.4E-05 1E-06 0
7 14 0 0 0 1E-06 0.02629 1 1 0.4608 0.02257 0.00323 0.00042
8 16 0 0 0 0 3.2E-05 0.10019 1 1 1 0.70052 0.16952
9 18 0 0 0 0 0 0.00102 0.4608 1 1 1 1
10 20 0 0 0 0 0 1.4E-05 0.02257 1 1 1 1
11 22 0 0 0 0 0 1E-06 0.00323 0.70052 1 1 1
12 24 0 0 0 0 0 0 0.00042 0.16952 1 1 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Fig. 22a.  0.75 mM MDY-19 and PCI respectively reached steady state at 18 and 16 h 
Chapter 2: Vaginal mucosa                                            68 
           
6
8
 
0 4 8 12 16 20 24
0
100
200
300
1 mM MDY-19
1 mM PCI
Bar=SEM
Time (h)
F
lu
x
 r
a
te
 (
p
m
o
le
s
.c
m
-2
.m
in
-1
)
 
 
 
 
 
 
 
 
 
 
 
 
 AUC/24 h of 1 mM MDY-19: 172.25 ± 21.28 pmoles.cm-2.min-1 
 AUC/24 h of 1 mM PCI: 188.08 ± 24.09 pmoles.cm-2.min-1 
 
Fig. 23.  Overall mean flux values at 37 ˚C of 1 mM MDY-19 and PCI across intact 
vaginal mucosa 
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Bonferroni test; variable DV_1 (MDY-19)
Error: Within MS = 6777.5, df = 506.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
43.471 93.692 138.49 167.87 181.55 196.11 212.16 224.85 228.59 233.34 229.13 235.1
1 2 0.21444 2E-06 0 0 0 0 0 0 0 0 0
2 4 0.21444 0.56804 0.001 2.2E-05 0 0 0 0 0 0 0
3 6 2E-06 0.56804 1 0.76054 0.04918 0.00114 3.4E-05 1.1E-05 3E-06 9E-06 1E-06
4 8 0 0.001 1 1 1 0.61908 0.05634 0.02528 0.00862 0.02247 0.00569
5 10 0 2.2E-05 0.76054 1 1 1 0.73109 0.38321 0.15906 0.34824 0.11287
6 12 0 0 0.04918 1 1 1 1 1 1 1 1
7 14 0 0 0.00114 0.61908 1 1 1 1 1 1 1
8 16 0 0 3.4E-05 0.05634 0.73109 1 1 1 1 1 1
9 18 0 0 1.1E-05 0.02528 0.38321 1 1 1 1 1 1
10 20 0 0 3E-06 0.00862 0.15906 1 1 1 1 1 1
11 22 0 0 9E-06 0.02247 0.34824 1 1 1 1 1 1
12 24 0 0 1E-06 0.00569 0.11287 1 1 1 1 1 1
Bonferroni test; variable DV_1 (PCI)
Error: Within MS = 6970.1, df = 462.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
42.057 104.06 156.68 202.04 218.8 226.13 236.84 241.62 239.54 231.12 237.54 241.15
1 2 0.04132 0 0 0 0 0 0 0 0 0 0
2 4 0.04132 0.24056 6E-06 0 0 0 0 0 0 0 0
3 6 0 0.24056 0.7978 0.04035 0.00864 0.0007 0.00021 0.00036 0.00279 0.00059 0.00024
4 8 0 6E-06 0.7978 1 1 1 1 1 1 1 1
5 10 0 0 0.04035 1 1 1 1 1 1 1 1
6 12 0 0 0.00864 1 1 1 1 1 1 1 1
7 14 0 0 0.0007 1 1 1 1 1 1 1 1
8 16 0 0 0.00021 1 1 1 1 1 1 1 1
9 18 0 0 0.00036 1 1 1 1 1 1 1 1
10 20 0 0 0.00279 1 1 1 1 1 1 1 1
11 22 0 0 0.00059 1 1 1 1 1 1 1 1
12 24 0 0 0.00024 1 1 1 1 1 1 1 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
           Fig. 23a.  1 mM MDY-19 and PCI respectively reached steady state at 10 and 8 h 
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 AUC/24 h of 1 mM MDY-19: 77.88 ± 10.00 pmoles.cm-2.min-1 
 AUC/24 h of 1 mM PCI: 51.96 ± 9.30 pmoles.cm-2.min-1 
 
 
Fig. 24.  Overall mean flux values at 20 ˚C of 1 mM MDY-19 and PCI across intact 
vaginal mucosa 
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Bonferroni test; variable DV_1 (MDY-19)
Error: Within MS = 1603.7, df = 462.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
17.665 19.382 38.347 55.635 71.481 82.669 94.307 105.77 114.74 126.98 137.21 140.96
1 2 1 1 0.0009 0 0 0 0 0 0 0 0
2 4 1 1 0.00214 0 0 0 0 0 0 0 0
3 6 1 1 1 0.00938 2.8E-05 0 0 0 0 0 0
4 8 0.0009 0.00214 1 1 0.12261 0.00063 1E-06 0 0 0 0
5 10 0 0 0.00938 1 1 0.56073 0.00549 5.1E-05 0 0 0
6 12 0 0 2.8E-05 0.12261 1 1 0.51068 0.01514 2.8E-05 0 0
7 14 0 0 0 0.00063 0.56073 1 1 1 0.01159 6.3E-05 7E-06
8 16 0 0 0 1E-06 0.00549 0.51068 1 1 0.9541 0.02003 0.00358
9 18 0 0 0 0 5.1E-05 0.01514 1 1 1 0.63243 0.167
10 20 0 0 0 0 0 2.8E-05 0.01159 0.9541 1 1 1
11 22 0 0 0 0 0 0 6.3E-05 0.02003 0.63243 1 1
12 24 0 0 0 0 0 0 7E-06 0.00358 0.167 1 1
Bonferroni test; variable DV_1 (PCI)
Error: Within MS = 282.54, df = 462.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7} {8} {9} {10} {11} {12}
14.711 31.079 45.767 53.074 56.219 57.504 61.076 64.152 66.266 68.304 68.437 74.249
1 2 0.00053 0 0 0 0 0 0 0 0 0 0
2 4 0.00053 0.00394 0 0 0 0 0 0 0 0 0
3 6 0 0.00394 1 0.27198 0.0853 0.00192 3.8E-05 2E-06 0 0 0
4 8 0 0 1 1 1 1 0.15663 0.0201 0.0021 0.0018 1E-06
5 10 0 0 0.27198 1 1 1 1 0.38326 0.06113 0.05372 6.1E-05
6 12 0 0 0.0853 1 1 1 1 1 0.20076 0.17844 0.00033
7 14 0 0 0.00192 1 1 1 1 1 1 1 0.02048
8 16 0 0 3.8E-05 0.15663 1 1 1 1 1 1 0.36738
9 18 0 0 2E-06 0.0201 0.38326 1 1 1 1 1 1
10 20 0 0 0 0.0021 0.06113 0.20076 1 1 1 1 1
11 22 0 0 0 0.0018 0.05372 0.17844 1 1 1 1 1
12 24 0 0 0 1E-06 6.1E-05 0.00033 0.02048 0.36738 1 1 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Fig. 24a.  1 mM MDY-19 and PCI respectively reached steady state at 18 and 16 h 
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Fig. 25.  The mean AUC/24h of MDY-19 and PCI at different concentrations, over a 
24 h period 
 
The normalised, mean flux values of 0.5, 0.75 and 1 mM MDY-19 and PCI over the 24 h 
period, at 37 °C are shown in Fig. 25 and 26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Fig. 26.  The normalised flux values of 0.5, 0.75 and 1 mM MDY-19 (37 °C )  
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  Fig. 27.  The normalised flux values of 0.5, 0.75 and 1 mM PCI (37 °C) 
 
The intra-experiment variation for the peptides was 43.4 % the inter-experiment variation 
was 43.1 %. 
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2.5  Discussion 
HIV is spreading rapidly especially in sub-Saharan Africa and Southeast-Asia.  The 
usage of condoms and the teaching of altered sexual behaviour, however, seem to be 
ineffective and therefore new prophylactic strategies are being investigated.  The use of 
microbicidal vaginal formulations, which have the advantage that women can take 
control of their own safety, are being investigated (Garg et al., 2001).  Cationic peptides 
have activity against malaria parasites, and viruses (including HIV, HSV, influenza A 
virus and vesicular stomatitis virus).  These properties make them promising candidates 
as new therapeutic agents (Powers and Hancock, 2003).  Where antibiotics only have 
activity against bacteria, cationic peptides have a wide range of activities against 
bacteria, fungi, enveloped viruses and eukaryotic parasites.  The pharmacological 
applications of peptides to treat infections are therefore receiving much interest, because 
they have an enormous attraction as potential therapeutic agents (Hancock, 2001).  
 
Even though aging and estrogen deficiencies may influence vaginal-cervical epithelial 
paracellular permeability, previous studies have shown that postmenopausal vaginal 
mucosa can successfully be utilised as an in vitro model to predict in vivo permeation 
(Viljoen et al., 2005; Gorodeski, 2001).       
 
MEA-5, MDY-19 and PCI readily penetrated vaginal mucosa.  MDY-19 had a 
significantly (p<0.05) higher flux rate than MEA-5 (Fig. 16), commensurate with its 
smaller molecular size (weight).  This may also possibly be explained by precipitation of 
MEA-5 at 20 ˚C.  Further test could not be conducted with MEA-5, since EMPRO 
stopped the production of this compound.    
 
Novel microbicides may be coupled to the transport peptide MDY-19 to be transported 
transmucosally or into cells.  Although the increased size of a MDY-19/microbicide 
complex may decrease mucosal permeability, this could possibly be offset by the 
addition of an appropriate surfactant-containing permeation enhancer.  Even though the 
peptides readily penetrated the vaginal mucosa, the surfactant used in this study further 
enhanced the AUC of MDY-19 by approximately 1.3 times (Fig. 17).                                           
 
De-epithelialisation mimics the situation when integrity of vaginal epithelium is breached 
due to disease or local trauma.  De-epithelialisation of the vaginal mucosa significantly 
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(p<0.05) increased the permeability of all three peptides (MEA-5, MDY-19 and PCI) over 
their controls.  This supports the premise that the main barrier is located in the 
epithelium and it may have possible implications for increased in vivo uptake of 
microbicides as well as HIV by traumatised vaginal mucosa.  It is in keeping with the 
finding that other sexually transmitted diseases e.g. genital herpes, chlamydia infection, 
trichomoniasis (ulcerative and non-ulcerative) are known to cause disruption of the 
vaginal epithelium and can increase HIV transmission 3- to 10-fold (Fleming and 
Wasserheit, 1999; Stratton and Alexander, 1993).  Initially two methods e.g. mechanical 
and heat de-epithelialisation were used to establish the most effective and convenient 
method to remove epithelium from the vaginal mucosa.  The MEA-5 peptide was used to 
evaluate these two de-epithelialisation methods.  Although it was not more effective, 
overall de-epithelialisation by heat appeared to be a more convenient method.  It was 
therefore used for mucosal de-epithelialisation of the peptides MDY-19 and PCI.  
Interestingly, 1 mM MEA-5 (at 20 ˚C) did not reach a steady state (prolonged the lag 
time) when the vaginal tissue was de-epithelialised by means of mechanical and heat 
stripping, but heat de-depithelialisation decreased the lag time of 0.75 mM MDY-19 and 
PCI (37 ˚C).   
 
Precipitation of the peptides MDY-19 and PCI on the vaginal mucosa during the 
permeability experiments at room temperature (20°C) and at a concentration of 1 mM 
was noticed.  For this reason, permeability studies of MDY-19 and PCI were repeated at 
concentrations of 1 mM, 0.75 mM and 0.5 mM in PBS buffer, at a temperature of 37 ˚C.   
 
The permeability of 1 mM MDY-19 and PCI at 37 °C were significantly (p<0.05) higher 
than at 20 °C.  At 37 °C the AUCs of the overall mean flux values of MDY-19 and PCI 
increased with concentration according to well-established diffusion theory.  At room 
temperature, the AUCs of 1 mM MDY-19 is 1.5x higher than 1 mM PCI and at 37 °C the 
AUC of 1 mM PCI is 1.1x higher than the corresponding value found for 1 mM MDY-19.  
This may be explained as follows.  PCI has a less overall positive charge than MDY-19 
since it contains less of the basic acid, arginine.  At high concentrations (1 mM) and 
lower temperatures precipitation of PCI may occur, since it is less water-soluble than 
MDY-19 and therefore the flux values of the PCI across vaginal tissue were decreased.  
The solubility of PCI in water however increased with an increase in temperature (20-37 
°C), leading to less precipitation on the vaginal tissue, which in turn yields in higher flux.  
Chapter 2: Vaginal mucosa                                            76 
           
7
6
 
The foregoing combined with the fact that PCI are more lipid soluble than MDY-19 may 
explain why at 37 °C, 1 mM PCI‟s permeability is higher than MDY-19.  The normalised, 
mean flux values of MDY-19 and PCI (Figs. 26 and 27) varied with concentration and 
may possibly be explained by the precipitation of the two peptides at higher 
concentrations, especially at 1 mM.  However, these findings may also indicate that the 
flow-through diffusion system‟s ability to predict permeability of test compounds is 
influenced by the concentration and the solubility of the test compound.  Further studies 
are therefore necessary to determine the exact influence of different concentrations of 
the test compound on the flow-through diffusion system‟s ability to predict permeability.     
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Chapter 3: Skin tissue  
3.1  Summary  
The objectives of the skin tissue study were to determine the permeability of different 
terbinafine hydrochloride formulations through human skin and to measure the 
respective concentrations of each formulation within the skin tissue.  A further objective 
of the study was to investigate the effects of increased temperature on in vitro 
permeability of tritiated water across human skin. 
 
Relatively little information is available in the literature about the concentration of 
terbinafine in tissues.  A possible reason could be due to a lack of availability of an 
analytical method (Yeganeh and McLachlan, 2000).  Since the skin is the main target for 
topical antifungal drug treatment, terbinafine‟s clinical efficacy can be determined by 
evaluating the concentration of the drug at its target site.  The permeation of three 
commercial available 1 % (10 mg/ml) terbinafine hydrochloride formulations and three 
terbinafine hydrochloride solutions of 10, 20 and 30 mg/ml through human skin was 
determined using our in vitro flow-through diffusion system.  The terbinafine retained in 
the exposed skin was extracted and analysed.  The terbinafine from the different 
formulations readily diffused into the skin tissue. However, no flux values for any of the 
terbinafine hydrochloride formulations through the skin into the acceptor fluid were 
found.  The mean terbinafine concentrations in the skin after 24 h exposure to the three 
commercial available formulations were 3.589, 1.590 and 4.219 µg/ml respectively.  The 
mean terbinafine concentration in the skin exposed to the 10 mg/ml PBS/Methanol 
solution was higher than those from the three commercial formulations.  Terbinafine 
seems to accumulate in skin, rather than to diffuse through the skin into the acceptor 
compartment.  These unique pharmacokinetic properties of terbinafine may enhance its 
efficacy as topical antifungal and reduce systemic side effects.  The in vitro model used 
in the present study may possibly be expanded into a model with the potential to assess 
bioequivalence of different formulations.  
 
There has been relatively little investigation of the effect of temperature on skin 
permeation compared to other methods of penetration enhancement.  Increasing the 
temperature of the skin and its environment may well provide the potential for 
overcoming the barrier properties of the stratum corneum and this prompted us to 
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investigate the effects of increased temperature on in vitro permeability of the chemical 
marker tritiated water across human skin.  The results of this temperature study 
demonstrated the temperature-dependency of water flux rates across skin tissue.  An 
increase of 5 ºC caused a significant increase in flux values of tritiated water across skin.  
The average flux for tritiated water across skin at 37 ºC was on average double those at a 
temperature of 32 ºC.  This in vitro temperature model may therefore be useful for 
predicting flux rates at higher temperatures and to investigate temperature as a potential 
enhancer of transdermal delivery.   
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3.2  Introduction 
3.2.1  Topical administration of drugs 
Percutaneous administration of drugs offers many advantages compared to traditional 
drug delivery methods e.g. oral delivery and injections.  Firstly, compared to oral 
delivery, it avoids gastrointestinal drug metabolism (since it circumvents the hepatic first-
pass effect), reduces elimination by the liver, provides less chance of an over- or 
underdose, allows easy termination (e.g. removing the drug from the skin) and permits 
both local and systemic treatment of conditions.  Secondly, the pain, fear and the 
possibility of infections associated with injections, often results in low patient compliance.  
Transdermal drug transport seems to be an answer to some of these problems.  The 
research on methods to increase absorption of drugs transcutaneously constitutes a 
huge area of pharmaceutical research.   
 
Although topical drugs are usually applied at a convenient site, the target for the drug 
action may be local (e.g. cortisone creams, analgesics) or systemic (e.g. scopolamine to 
prevent motion sickness).  Regardless of the target, all transcutaneous drugs that 
penetrate the skin and enter the vascular system will have some systemic effects.   
 
For a drug to be a successful topical agent, it has to have efficacy at the target site and 
also have the ability to reach that site.  This may involve delivery via the systemic 
circulation and direct penetration.  The topical agent consists of a vehicle or base, which 
often contains an active ingredient.  Possible vehicles include: lotions, creams, gels, 
patches, ointments and pastes.  The clinical effect is achieved through direct transport to 
the tissue or by systemic absorption and redistribution (Vaile and Davis, 1998).  The 
clinical efficacy of the formulation therefore depends on the ability of the vehicle to 
release the drug which then must penetrate the stratum corneum. The diffusion and 
partitioning processes are a succession of steps and the slowest event will determine the 
rate of local drug availability (Higuchi, 1960). 
 
One of the functions of the skin is to act as a diffusional barrier.  The skin has metabolic 
activity and some of the topically administered drugs are metabolised during skin 
diffusion.  The metabolic activity of the skin should therefore be kept in mind when 
developing transdermal drug formulations (Martin et al., 1987).   
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Various sources are used for obtaining human skin, including cosmetic surgery and 
amputations.  Skin from a wide variety of animal species is used for in vitro and in vivo 
studies e.g. pigs, rats, guinea pigs, snakes and rabbits.  Although animal and synthetic 
skin models provide a good indication of the diffusion characteristics of chemicals, it 
does not necessary reproduce the complex nature of the stratum corneum of human skin 
(Katritzky et al., 2006). 
 
Skin penetration studies play an important role in the selection of drugs for dermal or 
transdermal application.  Therefore, the choice of predictive in vitro penetration models is 
very important and the use of especially human skin to evaluate penetration properties 
of candidate drugs can be a useful tool (Schmook et al., 2001).  
  
3.2.2  Skin 
The skin is an extensive organ covering the exterior of the body and varies in thickness, 
colour and the presence of hairs, glands and nails.  It regulates heat and water loss from 
the body and protects the body from the penetration of harmful chemicals or 
microorganisms, including agents applied to the skin.  The human skin also plays a role 
in the absorption and blockage of radiation, temperature regulation, sensory perception 
and immunological surveillance.  It therefore helps us to withstand a considerable range 
of environmental challenges.  It has a surface area of approximately 2 m2 and receives 
about a third of the body‟s blood circulation (MacKie, 1987).  Since it is the biggest organ 
(that of an average adult male weighs 4.5 to 5 kg) and easily accessible, it offers great 
opportunities for the administration of therapeutic compounds (Williams, 2003).   
 
Skin (in vivo) is metabolically active and in a state of continual regeneration.  It has 
immunological and histological responses to different chemicals.  Most transdermal drug 
delivery studies tend to use in vitro skin, due to ethical and experimental difficulties.  It 
should be kept in mind that skin from in vitro studies serves only as a model and data 
obtained cannot always be translated directly to the in vivo-situation, since some of the 
abovementioned active processes are lost in these studies.   
 
The skin is composed of three layers: an outer layer of epithelial cells called the 
epidermis, middle layer of connective tissue called the dermis, and a variable inner layer 
called the hypodermis (Figs. 28 and 29).  
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Fig. 28. (Silverthorn, 1998)  
(a) The different layers of the skin 
(b) Epidermis 
(c) Basement  membrane and the connection between epidermis and dermis    
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Fig. 29.  Histology of human skin (By courtesy of Prof. IOC Thompson)  
 
3.2.2.1  Epidermis 
The epidermis, the outermost part of the skin, is a continually renewing, stratified, 
squamous epithelium.  It varies in thickness from around 0.06 mm on the eyelids to 
around 0.8 mm on the load-bearing areas of the skin.  Marcello Malpighi (1628-1694), 
who believed that it was a gelatinous membrane, first described the epidermis and he 
divided it into an inner layer of viable cells (now known as the stratum malphigii) and an 
outer layer of anucleated keratinised cells (stratum corneum).   
 
The epidermis consists of four histologically distinct layers, which represent the stages of 
maturation of keratin by keratinocytes: the stratum basale or germinativum, stratum 
spinosum, stratum granulosum and the outermost layer the stratum corneum (Fig. 29).  
Some literatures describe a fifth layer, the stratum lucidum, but this layer is usually 
considered the lower layer of the stratum corneum (Williams, 2003).  
 
It does not contain any blood vessels and therefore molecules have to permeate to the 
dermis to be cleared or taken up by the systemic circulation.  The main cell of the 
epidermis is the keratinocyte, which produces the protein keratin.  Keratins are high-
molecular-weight polypeptide chains and are the major constituent of the stratum 
corneum.  The stratum corneum comprises keratin (65 %), along with soluble proteins 
Stratum corneum 
Stratum granulosum 
Stratum spinosum 
Stratum basale/ 
germinativum 
Epidermis 
Dermis 
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(10 %), amino acids (10 %), lipids (10 %) and cell membranes (5 %).  The keratinocytes 
are tied to each other by an extensive system of desmosomes (Fig. 28b).  As these cells 
mature, they synthesize numerous keratin fibres and secrete a hydrophobic phospholipid 
matrix that acts as the skin‟s main waterproofing agent.  By the time the older 
keratinocytes are pushed to the surface of the epidermis by newer cells, their cytoplasm 
is thick with keratin fibres.  At this point the cells die and their nuclei and organelles 
disappear.  The mats of keratin fibres that remain behind are still linked to each other by 
the protein fibres of the desmosomes.  Dispersed between the keratinocytes are the 
melanocytes, the cells that produce melanin, and the cells of Langerhans, which have a 
defensive function (Williams, 2003).  
 
The stratum corneum seems to be the main permeability barrier and provides an 
incredibly effective barrier to penetration, even though it is merely 15-20 µm thick 
(Hadgraft, 2001b).  It comprises densely packed disc-like keratinocytes, which are 
anucleate keratinised cells, and separated by multi-cellular lipid bilayers which function 
as cement (Joshi and Jaideep, 2002).  These lipid bilayers consist of regions of 
ceramides, fatty acids, cholesterol, cholesterol esters and triglycerides and form regions 
of semi crystalline gel and liquid crystal domains.  The lipids form long lamellae parallel 
to the corneocyte surfaces.  Inside the lamellae, at physiological temperatures, the lipids 
are arranged in bilayers consisting of ordered, crystalline phases on both sides of a 
narrow, central band of fluid lipids.  The stratum corneum resembles a „brick and mortar‟ 
structure, analogous to a wall, and this highly ordered construction makes the stratum 
corneum impermeable to many drugs.  It forms the rate-controlling barrier for diffusion 
for almost all compounds (Barry, 2001). 
 
Most of the molecules penetrate through skin via the intercellular micro route and many 
of the transdermal enhancement techniques are aimed at disrupting this layer‟s 
molecular architecture.  This layer is also lipophilic and unionised drugs penetrate the 
stratum corneum more readily, while the rest of the epidermis is more hydrophilic (Singh 
and Roberts, 1994).  A drug that exhibits both hydrophilic and lipophilic characteristics 
will therefore have optimal penetration. 
 
The epidermis does not contain any blood vessels or lymph nodes, but does contain a 
large number of nerve endings.  Between the epidermis and the underlying layer of 
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connective tissue is an acellular basement membrane.  The cells of the epidermis and 
fibres of the dermis are anchored to each other by protein fibres that run throughout the 
basement membrane (Fig. 28c). 
 
3.2.2.2  Dermis 
The dermis is the layer below the epidermis.  It is typically 3-5 mm thick and composed 
of a network of connective tissue, which consists primarily of collagen fibres embedded 
in a mucopolysaccharide gel (Wilkes et al., 1973). 
 
The dermis, in contrast with the epidermis, does contain blood vessels.  The blood 
vessel supply plays an essential role in the regulation of body temperature whilst also 
delivering oxygen and nutrients to the tissue and removing toxins and waste products.  
The blood flow is responsible for removing molecules that have permeated the outer skin 
layers.  This ensures a concentration gradient, and therefore a driving force, between 
the applied formulation on the skin surface and the vasculature.  It also contains 
lymphatic vessels, nerve endings, pilosebaceous units (hair follicles and sebaceous 
glands) and sweat glands (eccrine and apocrine).  The lymphatic flow seems to play a 
bigger role with the clearance of larger molecules (Williams, 2003).  Hair follicles are 
present over the entire body surface, except over the load-bearing areas and on the lips.  
The sebaceous glands are found together with the hair follicles and secrete sebum that 
plays a role in maintaining the skin‟s pH at approximately 5 (Williams, 2003).  
 
This layer is often viewed as consisting of essentially gelled water and therefore provides 
a minimal barrier to the delivery of most polar drugs.  The dermal barrier properties are 
more pronounced when delivering lipophilic compounds (Williams, 2003).  
 
3.2.2.3  Hypodermis 
The hypodermis is the deepest layer of the skin.  This subcutaneous fat layer forms the 
bridge between the overlying dermis and the underlying body organs.  It serves as an 
insulator of the human body, protects it against physical shock and provides a reservoir 
of high-energy molecules.  In most areas of the body, it is a few millimetres thick, but in 
some areas, e.g. the eyelids, it is absent.  The hypodermis contains blood vessels and 
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nerves (Williams, 2003).  Below the hypodermis is the subcutaneous tissue, which forms 
the internal boundary of the skin. 
 
3.2.3  Processes of percutaneous absorption of drugs 
Percutaneous absorption of a topically applied drug involves a sequence of individual 
transport processes.  A drug molecule has three possible pathways through skin tissue: 
appendageal (through hair follicles with associated sebaceous glands or via sweat 
ducts), inter- and transcellularly (Byl, 1995). 
 
The area available for diffusion through skin appendages is almost negligibly small 
(approximately 1 %) (Barry, 2001).  This pathway may be important for ions and large 
polar molecules.  If a drug follows the transcellular pathway, the drug crosses the skin by 
directly passing through the phospholipid membranes and the cytoplasm of the dead 
keratinocytes that constitute the stratum corneum.  Since the drug must pass through 
several lipophilic membranes of the different cells (lipid bilayers) and the hydrophilic 
cytoplasm, only a few drugs have the chemical properties to penetrate the skin through 
this method.  Drugs that follow the intercellular route must pass through the small spaces 
between the cells of the skin.  The drugs have to follow a tortuous route between the 
cells and the diffusion path of most chemicals penetrating the skin is approximately 400 
µm, although the thickness of the stratum corneum is only 15-20 µm.  The intercellular 
spaces contain a mixture of ceramides, free acids (and their esters), cholesterol (and its 
sulfate).  The lipids are arranged into structured bilayers and the reasons for the 
impermeability of the skin are due to the combined effect of the tortuous route that the 
compounds have to follow and the repeated partition and diffusion across these lipid 
bilayers (Hadgraft, 2001a; Flynn, 1996).  Once diffusion through the stratum corneum 
has taken place, the molecules permeate the dermis and are absorbed by the capillary 
plexus and transported into the circulating bloodstream (Hadgraft and Lane, 2005).  For 
many years it was thought that percutaneous drugs all entered the dermal capillary 
network and reached the central blood compartment only to return to the local area 
above which they were applied.  However, it now appears that there is a system of local 
delivery separate from systemic delivery via the central blood compartment (Byl, 1995).  
As mentioned the molecule follows a tortuous route and has to cross, sequentially and 
repeatedly, a number of hydrophilic and lipophilic domains.  The time necessary to reach 
Chapter 3: Skin tissue                                                86 
           
8
6
 
Cmax is approximately 10 times longer than that when the equivalent oral administration 
is given (Heyneman et al., 2000). 
 
The transmembrane diffusion process is passive in nature, requiring a concentration 
differential as the driving force and each molecule requires kinetic energy to effect a net 
movement down this gradient.  The lipid-water partitioning characteristics of the 
permeant play an important role in its penetration.  Drugs that are either extremely 
hydrophilic or extremely hydrophobic are poorly absorbed, since the skin is a 
heterogeneous membrane.  Molecular size plays a role in penetration of the skin and so 
does the pH of the vehicle (Payne-James et al., 1992).  The pH of the skin is 
approximately 4-5 and seems to have a good buffer capacity.  Formulations used on the 
skin should therefore preferably have a pH between 4 and 7 (Hadgraft, 2001b).  Most 
drugs are weak acids or weak bases which dissociate to various degrees depending on 
the pH of the formulation used and the pH of the membrane through which it must 
diffuse.  Other physiochemical properties of a drug include solubility/melting point and 
the state of ionisation, since the skin behaves as a lipophilic membrane.  The governing 
factor for which pathway the permeant will follow when it diffuses through the tissue, is 
the partition coefficient.  There is an inverse relationship between the permeant flux and 
its molecular weight.  Smaller molecules diffuse through the skin tissue at a faster rate 
than larger molecules.  Topical medication is usually applied in an aqueous formulation 
and the permeant from the formulation should thus be somewhat watersoluble (Williams, 
2003; Heyneman et al., 2000).  Another significant factor that influence percutaneous 
diffusion is the number of functional groups on the drug that are able of hydrogen 
bonding.  The diffusion coefficients of the permeant decreases as the number of 
hydrogen bonding groups increase until three groups are present.  With a further 
increase of hydrogen bonding groups, there is little effect.  It seems that this effect is 
related to the ability of the permeant to form a hydrogen bond with the polar head groups 
of the ceramides (Hadgraft, 2001b).  
 
Permeability of the skin is also influenced by age, disease, the appearance of skin 
appendages (e.g. hair follicles, aprocrine sweat glands, erector pili muscles, sebaceous 
glands), the nature of its physiochemical condition (e.g. thickness, lipid structure, 
membrane capacity), as well as the viscosity and the extent of cross-linking of the 
collagen (Wester and Maibach, 1991).  Hydration of the stratum corneum plays a vital 
Chapter 3: Skin tissue                                                87 
           
8
7
 
role.  The amount of water in the stratum corneum increases the permeability of this 
layer to hydrophilic drugs.  It is possible for the stratum corneum to absorb three to five 
times its own weight in water, resulting in a two- to threefold enhancement in the 
permeability to water and other polar molecules (Byl, 1995). 
 
Transdermal drug delivery is often chosen to bypass hepatic metabolism, but it must be 
kept in mind that after drug penetration through the stratum corneum, substances may 
be subjected to metabolism by the viable epidermis.  Venkatesha et al. (1992) studied 
the cytochrome P450 (P450) content, the cytochrome reductase activity, the metabolism 
of a variety of P450 substrates and the presence and role of flavin-containing 
monooxygenase (FMO) in xenobiotic metabolism, in mouse skin, and compared it to 
those of liver. The cytochrome P450 content of skin was approximately 6.8 % of the liver 
P450 content. By comparison, cytochrome reductase activity in skin microsomes was 
high, being equivalent to approximately one-third of the liver microsomal enzyme activity. 
Skin microsomes metabolized several known P450 substrates and, depending upon the 
substrate used, the specific activity ranged from 2.5 to 13.4 % of the corresponding rates 
seen in liver microsomes.  Metabolism of a chemical may result in significant 
modification of the molecule in terms of reduced or increased pharmacological 
and/or toxicological activity (Wester and Maibach, 1983).  Examples of cutaneous 
metabolism of drugs include steroids (estradiol, progesterone, testosterone) and 
nitroglycerin.  Usually drug metabolism by the skin is less compared to the oral 
administration (Rohatagi et al., 1997; Zobrist et al., 2001).  Berner and John (1994) 
found regional variations in cutaneous metabolism which may cause differences in drug 
bioavailability.  Scrotal application of a testosterone transdermal formulation resulted in 
an increased systemic dihydrotestosterone concentration compared to non-scrotal 
application (Berner and John, 1994).  Some excipients (e.g. permeation enhancers) in 
formulations may affect skin metabolism.  This can be explained through the inhibition or 
induction of enzymatic activity by these chemicals (Berner and John, 1994).  Therefore, 
the formulation characteristics might be considered as a potential reason for inter- and 
intra-individual variations in metabolism and bioavailability of transdermally administered 
drugs.  The foregoing must be kept in mind when conducting in vitro permeability 
studies. 
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3.2.4  Predicting skin permeation of compounds 
Many efforts have been made to measure percutaneous absorption (Schnetz and 
Fartasch, 2002).  The permeation rates of compounds can be measured by employing or 
using: 
 In vivo drug release in live animals or human volunteers 
 Excised skin from human or animal sources in in vitro experiments 
 Synthetic model membranes as diffusion barriers in in vitro experiments    
(Cronin et al., 1999) 
 
Both human and animal skin in vitro models are used to predict percutaneous 
penetration in humans.  Skin from a wide range of animals has been suggested as a 
suitable replacement for human skin.  Pig and rat skin are most commonly employed 
(Katritzky et al., 2006).  Animal skin may provide a good indication of the diffusion 
characteristics of chemicals, but animal skin tends to be more permeable than human 
skin and it does not necessarily reproduce the complex nature of the human stratum 
corneum.  Excised human skin is therefore regarded as the „„gold standard” for in vitro 
penetration experiments (Barbero and Frasch, 2009).  Previous workers have 
demonstrated that pig skin is a good in vitro model for human skin, since it had 
permeability properties closer to humans than rodents.  Pig skin can only be stored for 2 
months before the barrier properties begin to deteriorate.  Frozen human skin retains its 
barrier properties for at least one year (Davies et al., 2004).  Human skin from various 
sources, including cosmetic surgery and amputations, has been used for the in vitro 
assessment of percutaneous penetration (Katritzky et al., 2006).   
 
Predicting skin permeation of compounds has advantages for the pharmaceutical, 
cosmetic and agrochemical fields, but the development of reliable mathematical models 
to predict the diffusion of drugs through skin remains a challenging objective.  Numerous 
attempts have been made to predict skin permeability coefficients.  Since experimental 
data for skin permeability are still relatively scarce, predictive models are usually based 
on the data set published by Flynn (1990) or subsets thereof.  The prediction of 
partitioning and diffusivity of compounds remains a challenge due to the complexity of 
skin structure and variability in skin lipid composition and thickness.  Changes in skin 
induced by solvents and permeants and the effects of metabolizing enzymes on 
permeants may also influence skin permeation of compounds.  
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Mechanistic and empirical modelings have been developed in an attempt to predict skin 
permeation of compounds (Yamashita and Hashida, 2003).  Both approaches certainly 
have their merits and have reached a relatively high level of sophistication, but 
unfortunately the heterogeneity of the data in terms of skin origin and experimental 
conditions, contribute to the variance in existing models.  Statistics demonstrate that 
some published models are based on nonsignificant parameters and this may diminish 
mechanistic insight and will lead to over-interpretation of the data (Geinoz et al., 2004).  
Mechanistic and empirical approaches should not be exclusive, but compensative in 
nature.  Ideally, empirical models should be used to compensate for uncertainties that 
mechanistic models overlook and yet-to-be-know relationships that mechanistic models 
cannot deal with (Yamashita and Hashida, 2003).  
 
3.2.4.1  Mechanistic analysis of skin permeation of drugs 
Mechanistic approaches provides information on understanding of skin permeation of 
compounds, such  as structure-permeability relationship, contribution of each barrier 
step, mechanisms of penetration enhancers and in vivo-in vitro relationships.  
Mechanistic approaches are also used to predict the time-dependent change of 
concentration of a compound in the layers of the skin e.g. the dynamics of skin 
penetration.  It also yields information about the additional factors influencing skin 
permeation e.g. the contribution of the various barriers or the effect of penetration 
enhancers (Yamashita and Hashida, 2003). 
  
3.2.4.1.1  Analysis based on simple diffusion models 
3.2.4.1.1.1  Fick’s diffusion law 
Compounds are thought to transfer through the skin by a predictable system of passive 
diffusion, which is defined by Fick‟s Law and the rate of permeation.  Diffusion for most 
low molecular weight substances seems to occur uniformly through the stratum 
corneum.  Fick‟s first law assume that the rate of transfer of the permeant through a unit 
area of a section tissue is proportional to the concentration gradient.  It is used to 
describe steady state diffusion and can be represented as follows: 
J = DKΔc/h        or      J = Cv /Cs,v    ·   D·Cs,m/H 
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Where: 
J is the flux per unit area  
D is the diffusion coefficient of skin 
K is the skin-vehicle partition coefficient 
Δc is the concentration difference across the skin 
H is the diffusional pathlength 
Cv is the drug concentration dissolved in the vehicle 
Cs,v and Cs,m are the solubility of the drug in the vehicle and in the barrier respectively 
Cv /Cs,v represents the degree of saturation of the drug in the formulation 
 
Often his equation is simplified when in vitro studies, such as the present study, are 
conducted.  The applied concentration (in the donor chamber) is much larger than the 
concentration under the skin (acceptor chamber).  The equation is then simplified to: 
J = kp·Capp 
Where: 
kp is a permeability coefficient (= KD/h). 
Capp is the applied concentration 
 
The second law is a mass-balance equation that is derived from the first law and 
boundary conditions are given to solve the equation (Yamashita and Hashida, 2003).  
 
3.2.4.1.1.2  Quantitative structure-permeability relationship (QSAR) 
QSAR methods are used to predict the permeability of compounds through skin by 
statistically relating the experimentally measured percutaneous penetration of a range of 
compounds to known physiochemical parameters.  The majority of QSAR studies were 
based on the analysis of homologous, series of compounds, until Flynn published a data 
set of human skin permeability for 94 compounds (Roy and Flynn, 1989; Anderson et al., 
1988b; Scheuplein, 1965).  Flynn also compiled 97 human skin permeability coefficients 
from 15 different literature sources, but these data showed a high degree of 
experimental errors due to inter-laboratory variability (Degim et al., 1998; Flynn, 1990).  
Flynn‟s studies showed that the skin permeability could be predicted by the permeants‟ 
octanol-water partition coefficient and molecular weight (Yamashita and Hashida, 2003; 
Flynn, 1990).  
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 It is important that all biological data are reproducible and consistently measured, when 
developing any QSAR.  It is therefore advisable to use the same protocol, type of skin, 
anatomical region, temperature, receptor medium and to measure the skin permeation in 
one laboratory, by the same researchers (Degim et al., 1998).  
 
3.2.4.1.2  Analysis based on heterogeneous diffusion models 
3.2.4.1.2.1  Development of heterogeneous diffusion models 
Due to the heterogeneity of the skin structure, the structure-permeability relationship 
model becomes more complex when a wide range of compounds, especially highly 
hydrophilic compounds are involved.  Skin is often considered to exist out of two layers 
namely the stratum corneum and aqueous viable layer.  Polar and nonpolar pathways 
exist in the former layer.  Therefore, the processes of drug absorption through the skin 
play an important role.  The permeability coefficient of polar compounds is independent 
of their oil-water partition coefficient.  These drugs follow the polar or aqueous pathway 
through the skin.  The highly lipophilic drugs have an almost constant permeability 
coefficient, since the more aqueous viable layer underneath the stratum corneum limits 
their permeation rate.  Due to mathematical simplicity, Fick‟s diffusion law cannot be 
used to analytically solve the permeants‟ mass-balance equation and therefore only the 
steady state portion of the permeation profile is analysed when using the heterogeneity 
model of skin (Anderson et al., 1988b).  
 
3.2.4.2  Empirical analysis of skin permeation of drugs 
Empirical modeling has the potential to overcome inaccuracies of mechanistic models 
caused by the existence of uncertainties and gives better predictions from the practical 
point of view.  Empirical approaches usually predict the steady state properties of skin 
permeation from molecular parameters such as molecular size and lipophilicity.  These 
two parameters (or slight variations, e.g. molecular volume) have been used repeatedly 
in predictive models and seem to affect the passive diffusion of drugs through any 
biological barrier to a large extent.  Various other descriptors (e.g. polarity, hydrogen-
bond donor acidity and hydrogen-bond acceptor basicity) have also been employed in 
models predicting skin permeability (Geinoz et al., 2004). 
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3.2.4.2.1  Linear empirical modeling for prediction of skin permeability 
This approach includes the selection of molecular or structural descriptors without 
mechanistic consideration (Yamashita and Hashida, 2003).  
 
3.2.4.2.2  Neural network modeling for prediction of skin permeability 
Artificial neural network (ANN) is a powerful model for non-linear modeling of complex 
causal-effect relationships.  It is an information-processing paradigm that is inspired by 
the biological nervous systems, such as the brain.  Application of ANNs includes 
structure-activity relationship analysis, structure-property relationship analysis, 
pharmacokinetic modeling and the design of formulation (Yamashita and Hashida, 
2003).  
 
3.2.5  Concentration gradient and supersaturation 
The concentration gradient is often considered as the main driving force for 
percutaneous diffusion.  Strictly, it should be the chemical potential gradient.  Fick‟s law 
state that the flux (J) should increase linearly with concentration until Capp reaches 
solubility limit.  When the solubility limit is reached, a further increase in concentration of 
the same drug in the same solution will result in the same flux (Hadgraft, 2001b).   
 
However, a drug solution can be supersaturated and this may enhance permeation 
through and uptake into, in vitro skin.  The supersaturated state may be produced by 
temperature changes, the uptake of water from the skin, the loss of a volatile solvent and 
the use of cosolvent mixtures.  A drug formulation in this state is innately unstable, but if 
the supersaturation state can be maintained for the duration of the administration, fluxes 
greater than those from a saturated solution can be accomplished.  Maintaining the 
supersaturated state of the drug can be accomplished by the addition of polymers such 
as hydroxypropylmethyl cellulose (HPMC), which can impart stability for many hours.  
The thermodynamic activity of the drug in the vehicle is increased above unity, thus 
enhancing the driving force for drug delivery and increasing skin permeation.  It is 
dependent on the nature of the compound, but the precise mechanism is not fully 
understood (Hadgraft, 2001b).  
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3.2.6  Methods to breach the skin barrier 
Scientists have looked at different means to enhance the transport of drugs through the 
skin and especially trying to decrease the barrier properties of the stratum corneum - the 
main barrier of the skin.  The barrier properties of the skin are primarily attributed to the 
intercellular lipid bilayers of the stratum corneum.  The ability of a drug to penetrate the 
skin is closely related to its molecular weight and its affinity for the stratum corneum 
(Akomeah et al., 2004; Joshi and Jaideep, 2002).  
 
Transdermal delivery is often only considered after a novel compound has been selected 
and shown to be active, but then was proven to be problematic for oral administration.  
The drugs that are available for transdermal formulation consequently seldom have ideal 
physicochemical properties for transdermal administration.  Redesigning of the chemical 
is often too expensive and time consuming, after the compound‟s toxicological, 
pharmacological and pre-formulation studies have already been conducted (Williams, 
2003).  
 
Many of the topically applied agents do not penetrate skin optimally (Wenkers and 
Lippold, 2000; Cordero et al., 1997; Singh and Roberts, 1994).  In order to overcome the 
significant barrier posed by stratum corneum (SC), several enhancement strategies are 
being explored to expand the number of drugs delivered through skin.  While product 
formulation may have a dramatic impact, not only on transcutaneous absorption rates, 
but also on depth of penetration into the underlying tissues, further optimisation may be 
desirable (Heyneman et al., 2000).  A number of approaches to enhance transport 
across skin and to expand the range of drugs delivered have been investigated (Guy 
and Hadgraft, 2003).  Despite intensive research during the last three decades, there are 
still limited transdermal products available on the market for transdermal transport.  
Those available are mainly low-molecular weight lipophilic drugs (Mw<500 Da).  
Expanding the range of topically available drugs, especially to include macromolecules, 
is primarily hindered by low skin permeability.  Strategies for transdermal drug 
absorption are primarily targeted at enhancing the permeability of the stratum corneum, 
the main barrier of the skin.  These strategies involve the selection of the correct drug or 
prodrug and chemical potential adjustment.  Hydration of the stratum corneum, chemical 
methods and increased temperature can also possibly be used.   
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Penetration enhancers may improve the percutaneous penetration of drugs by modifying 
the thermodynamic activity of the drug (e.g. changes in partitioning tendencies) or by 
altering the skin barrier properties (e.g. changes in fluidity of extracellular lipids) 
(Jantharaprapap and Stagni, 2007).  A good enhancer may also act by increasing the 
effective concentration of the drug in the vehicle.  Chemical enhancers include 
surfactants, solvents, lecithin gels, liposomes and submicron emulsions.  Surfactants 
may enhance partitioning by reducing the surface tension between the vehicle and the 
membrane surface and by influencing the barrier potential of the membrane (Barry and 
El Eini, 1976).   
 
Physical methods, e.g. iontophoresis, electroporation, magnetophoresis, 
photomechanical waves, sonophoresis and increased temperature are other options 
(Barry, 2001).  These techniques are based on two principles: enhancing skin 
permeability and/or providing driving force acting on the drug.   
 
3.2.6.1  Temperature 
It is an established fact that when skin is heated, its permeability increases and transport 
of a variety of chemical substances across this tissue is enhanced (Barry, 1983; Fritsch 
and Stoughton, 1963).  Even though the use of heat to enhance percutaneous 
absorption has been well documented, it has never been fully exploited as a means of 
aiding drug delivery across the skin (Blank et al., 1967).  There has been relatively little 
investigation of the effect of temperature on skin permeation compared to other methods 
of penetration enhancement.   
 
In order to understand the mechanism of permeation enhancement it is essential to 
investigate the effect of temperature on permeation, the cellular components (keratin, 
ceramides etc.) and the functions of the skin.  The Food and Drug Administration (FDA) 
recently produced an article describing the possibility of toxicity, due to the percutaneous 
absorption of topically applied material, as a result of the increased temperature and 
exposure to UV radiation associated with the sun (Lewis, 2002).  Consequently, 
increasing the temperature of the skin and its environment may well provide the potential 
for overcoming the barrier properties of the stratum corneum and warrants a systematic 
investigation.  This increased permeability has been attributed to an increased fluidity of 
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the stratum corneum intercellular lipids, which are thought to constitute the major barrier 
towards penetration of chemical substances across human skin (Tanojo et al., 1997).  
Furthermore, thermal energy increases the molecular diffusivity of the permeant 
molecules (Cagnie et al., 2003; Byl, 1995). 
 
3.2.7 Antifungals 
Superficial fungal infections are commonly encountered in the dermatologic practice.  It 
is second to acne the most common condition prompting dermatological care.  A rise in 
the frequency of fungal infections over the past few years has occurred in response of a 
combination of factors.  This include disease states such as AIDS, an aging population, 
the increase prevalence of diabetes mellitus, immunosuppression employed in 
transplantation or resulting from chemotherapy and advances in invasive surgical 
techniques which allow for opportunistic pathogen access.  Topical antifungals are 
generally considered as the first-line therapy for uncomplicated, superficial 
dermatomycoses due to their high efficacy and low potential for systemic adverse 
effects, unless the infection is widespread, covers an extensive area, or is resistant to 
initial therapy (Wolverton, 2007; Huang et al., 2004; Elewski and Smith, 2001; Jensen-
Pergakes et al., 1998).  
  
The three main classes of topical antifungals currently employed in the topical treatment 
of superficial fungal infections are the polyenes, azoles and allylamines/benzylamines.  
Other topical antifungal agents include morpholine derivates, hydroxypyridone, ciclopirox 
olamine and selenium sulphide (Katz, 2000; Jensen-Pergakes et al., 1998).   
 
The azoles are mainly fungistatic and can be subdivided into the imidazoles and the 
triazoles.  All azoles work by means of the same mechanism of action. It inhibits the 
cytochrome P450 dependent enzyme, lanosterole 14-α-demethylase, an essential 
enzyme in ergosterol synthesis (Katz, 2000).   
 
The topical polyenes, e.g. nystatin and amphotericin B, work by increasing cell 
membrane permeability by binding to ergosterol.  They have been in use since the 
1950‟s, but their use is limited by the fact that they have no significant activity against 
dermatophytes.  They are mainly used for the candidal inertrigo, candidal vaginitis and 
oral thrush (Katz, 2000).  
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The introduction of allylamine/benzylamine compounds in the 1980s has improved 
antifungal therapy, since these two classes exhibit fungicidal mechanisms of action by 
acting at an earlier stage of the metabolic pathway than the azoles.  They are a relatively 
new class of antifungal drugs and were inadvertently discovered during efforts to 
synthesize an active central nervous system compound.  Examples of this group of 
antifungal drugs include terbinafine, naftifine and butenafine.  They inhibit the enzyme 
squalene epoxidase, an enzyme required for ergosterol synthesis (Katz, 2000; Jensen-
Pergakes et al., 1998).  
 
All the topical antifungal agents mentioned may be effective, but the 
allylamine/benzalamine-type drugs are more potent in vitro and have a higher efficacy in 
vivo than the azole type antifungal agents in the treatment of dermatophytoses.  The 
allylamines/benzylamines are fungicidal while the azoles are primarily fungistatic against 
common dermatophytes.  The allylamines/benzylamines also exhibit a “reservoir” effect 
due to their highly lipophilic nature and therefore has the advantage that patients 
continue to improve after cessation of therapy.  This retention effect, together with a 
fungicidal activity, results in shorter duration of therapy and lower relapse rates in 
patients (Jensen-Pergakes et al., 1998).  
 
3.2.7.1  Terbinafine hydrochloride 
Terbinafine hydrochloride is classified as a synthetic allylamine antifungal.  It is the most 
representative of this new chemical class of antimycotic compounds.  Chemically, 
terbinafine is (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl) hept-2-en-4-yn-1-amine and 
the empirical formula is C21H25N (Figs. 30 and 31).  It is marketed for oral and topical use 
and is highly lipophilic and keratophilic, leading to high concentrations and efficient 
binding to the stratum corneum, sebum and hair follicles. It therefore reduces the 
probability of reinfection (Schuster et al., 1988) and tends to accumulate in skin, nails 
and fatty tissues (Hosseini-Yeganeh and McLachlan, 2002).  Terbinafine has a 
molecular mass of 291.43 g/mol and is typically administered orally (250 or 500 mg per 
day) or topically (10 mg/ml cream, gel, solution/spray or powder; applied one/twice daily) 
(James et al., 2007).  
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It has a broad spectrum of antifungal activity at relatively low concentrations.  Terbinafine 
is fungicidal against dermatophytes (of the genera trichophyton, epidermophyton and 
microsporum), moulds and certain fungi.  The activity against yeasts is fungicidal or 
fungistatic, depending on the species (Terbicil 1 % Cream® package insert by Aspen, 
2005).  Terbinafine inhibits ergosterol synthesis by inhibiting fungal squalene epoxidase, 
an enzyme that is part of the fungal cell wall synthesis pathway.  Squalene epoxidase is 
involved in the biosynthesis of 2,3-oxidosqualene from squalene and thereby inhibits 
biosynthesis of ergosterol, an essential component of the fungal cell membrane.  This 
leads to intracellular accumulation of squalene that is toxic to the fungal cell and results 
in rapid death.  Terbinafine‟s effects are selective for fungi, because its affinity for 
squalene epoxidase in fungal cells is 400 to 4000 times greater than in animal/human 
cells and it has few adverse reactions (Tanuma et al., 2000; Gupta and Shear, 1997).   
It is applied twice a daily when administered topically and is prescribed for fungal 
infections of the skin caused by trichophyton (e.g. T. rubrum, T. mentagrophytes, T. 
verrucosum, T. violaceum), mycrosporum canis and epidermophyton floccosum.  It is 
also indicated for yeast infections of the skin, principally those caused by candida 
albicans and pityriasis (tinea) vesicolor due to pityrosporum orbiculare (also known as 
malassezia furfur) (Terbicil 1 % Cream® package insert by Aspen, 2005; Brunton et al., 
2006).  Its site of action is within the stratum corneum and therefore terbinafine‟s local 
bioavailability in this most superficial layer of the skin is pertinent to its ultimate clinical 
efficacy in vivo (Balfour and Faulds, 1992; Faegermann et al., 1991). 
 
Terbinafine hydrochloride is a fine, white crystalline powder that is freely soluble in 
methanol and methylene chloride, soluble in ethanol and slightly soluble in water.  It is 
highly lipophilic and keratophilic (Gupta and Shear, 1997).  In a study by Tatsumi et al. 
(2002), the affinity to keratin powder was established.  Terbinafine showed a 96 % 
binding to the keratin.  The release of terbinafine from drug-preloaded keratin powder 
after 10-minute washings with saline at 37 ºC was 21.6 %.  Uchida and Yamaguguchi 
(1993) also reported that terbinafine showed a high rate of keratin binding when 
incubated in a buffer with 10 % keratin.  These authors found a binding of 88.4 %. 
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   Fig. 30.  Terbinafine (The Merck Index, 2001) 
 
drug terbinafine hydrochloride 
therapeutic category antifungal 
octanol/water partition coefficient 3.3 
pKa 7.1 
solubility water (1 in 160) 
alcohol (˃1 in 14) 
MW (g/mol) 327.9 
 
Fig. 31.  Physicochemical characteristics of terbinafine hydrochloride (Alberti et 
al., 2001b; Dollery et al., 1999) 
 
Topical therapy is often preferred to oral drug administration in the treatment of 
superficial fungal infections of the skin, since generally a high oral dose are necessary to 
reach a therapeutic drug concentration in the skin  which may lead to the increased risk 
of adverse reactions and drug interactions.  Usually, topical administration results in 
much lower and often undetectable plasma levels and the required concentration for 
antimycotic activity at the skin target site may be more efficiently achieved by topical 
administration (Alberti et al., 2001b).  
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Terbinafine undergoes extensive biotransformation in the liver, with the production of 
about 15 metabolites.  It is unknown whether or not there is significant skin metabolism 
of topically applied terbinafine (Dollery et al., 1999; FDA website). 
 
3.2.8  Tritiated water 
Tritiated water is a form of water in which the usual hydrogen atoms are replaced with 
tritium. In its pure form it may be called tritium oxide (3H2O).  In vitro transdermal tritiated 
water flux measurements are frequently used to evaluate skin barrier integrity for quality 
control purposes, so that any damaged tissues can be eliminated from subsequent in 
vitro studies (Meidan and Roper, 2008).  Hence, understanding how tritiated water flux 
values vary with respect to different variables such as anatomic site, temperature etc. is 
crucial within this quality control context (Meidan and Roper, 2008). 
  
3.2.9  Aim  
Dermal and transdermal drug delivery serve as an attractive alternative to conventional 
drug delivery methods.  Topical administration of drugs can be used to achieve systemic 
or local effects.  If the skin is the site of action, the effectiveness of a topical 
dermatological formulation depends on the bioavailability of the drug within this target 
organ.  The drug has to reach the target skin at the required concentration and achieve 
the desired therapeutic action, with minimal systemic exposure.  The barrier properties 
and the subsequent impermeability of the skin are a considerable problem in the delivery 
of active compounds both to and through skin.  The pharmaceutical industry is therefore 
investing ever increasing amounts of resources on the development of new products that 
are able to overcome the barrier properties of the skin (Akomeah et al., 2006).  Skin is a 
complex organ, which have a wider variety of cell types than the brain.  Even though the 
skin is very accessible for drug administration and research, some aspects of 
transdermal drug penetrations are still unknown.  The precise penetration route of 
chemicals and how this can be affected by formulations are still not fully established.   
 
Due to modern high-throughput technologies large numbers of potential drugs are 
produced by parallel synthesis and combinatorial chemistry.  The pharmaceutical 
industry therefore requires rapid and accurate methods to screen drug leads for tissue 
permeability potential in the early stages of drug discovery.  In vivo human dermal 
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studies are not always feasible due to the invasiveness of biopsies and the high costs.  
Even though mathematical models are available for the selection of appropriate 
transdermal drugs, these models are still ambiguous in predicting skin permeability 
(Moss et al., 2002).  Reliable in vitro models can be applied to determine permeation of 
the test compounds, which will help avoid the wasting of valuable resources on the 
development of drugs that are destined to fail in preclinical and clinical phases due to 
insufficient absorption properties. Well-designed and standardised in vitro models and 
studies may play an important role to enable the accurate prediction of the optimum 
choice of formulations and solvent type enhancers for in vivo percutaneous absorption 
(Moss et al., 2002; Alberti et al., 2001).  One would prefer to use human skin to evaluate 
the penetration properties of new candidate drugs, since in vitro studies using human 
skin to measure drug diffusion and metabolism, provide more accurate absorption data 
than animal skin studies (Schmook et al., 2000; Collier et al., 1991). 
   
Terbinafine hydrochloride is classified as a synthetic allylamine antifungal.  It is the most 
representative of this new chemical class of antimycotic compounds and has a broad 
spectrum of antifungal activity at relatively low concentrations.  It is marketed for oral and 
topical use and is highly lipophilic and keratophilic, resulting in high concentration in the 
stratum corneum, sebum and hair follicles and therefore reducing the probability of 
reinfection (Alberti et al., 2001; Schuster et al., 1988).  Ideally, a topical antifungal drug 
should be absorbed by the skin and achieve the desired therapeutic action with minimal 
systemic exposure.  Relatively little information is available in the literature about the 
concentration of terbinafine in tissues.  A possible reason could be due to a lack of 
availability of an analytical method (Yeganeh and McLachlan, 2000). 
  
Choosing the appropriate vehicle/formulation for a specific drug plays a critical role in the 
clinical efficacy of a dermatological topical drug. The formulation has to exhibit qualities 
such as optimised drug release and at the same time be able to facilitate drug transport 
across or into the skin.  The foregoing prompted the use of a flow-through diffusion 
system to determine the permeability of different terbinafine hydrochloride formulations 
through human skin and to measure the drug‟s concentrations within the skin tissue.  
Since the skin (stratum corneum) is the main target for topical antifungal drug treatment, 
terbinafine‟s clinical efficacy can be determined by evaluating the concentration of the 
drug at its target site.  The results will present a potential in vitro model for of evaluating 
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different formulations and may possibly be developed into a method for assessing the 
bioequivalence of alternative (generic) vehicles or formulations containing the same 
drug.   
 
A further objective of the study was to investigate the effects of increased temperature 
on in vitro permeability of tritiated water across human skin.  Tritiated water flux 
measurements are frequently used to evaluate barrier integrity of the skin. There has 
been relatively little investigation of the effect of temperature on skin permeation 
compared to other methods of penetration enhancement.  Increasing the temperature of 
the skin and its environment may well provide the potential for overcoming the barrier 
properties of the stratum corneum.  Establishing an in vitro model in which skin 
temperature can be controlled will therefore have the potential to investigate and predict 
the effect of increased temperature on in vivo skin.   
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3.3  Materials and Methods 
3.3.1  Skin tissue 
Skin specimens were obtained from excess tissue removed from 23 females, mean age 
43 ± 16 SD (range: 18-75) yr, during breast reduction procedures and abdominal plastic 
surgery at the Louis Leipoldt Hospital, Bellville, South Africa.  No specimens were 
obtained where there was clinical evidence of any disease that might have influenced 
the permeability characteristics of the skin. 
 
All skin specimens were immediately placed in a transport fluid after removal and kept at 
4 ºC.  The transport fluid consisted of a stock solution of Eagle‟s Minimum Essential 
Medium (MEM) without L-glutamine and sodium bicarbonate (Gibco, Paisley, Scotland), 
to which the latter as well as an antibiotic (penicillin/streptomycin, 100 IU/ml) and an 
antimycotic (amphotericin-B, 2.5 μg /ml) were added prior to using it for the transport of 
tissue specimens.  The skin tissue was transferred to our laboratory within 2 hours.  In 
the laboratory excess connective tissue was trimmed away using a forceps and scalpel.  
Specimens from each patient (10 x 10 mm) were snap-frozen in liquid nitrogen and 
stored at -85 ˚C.  Full thickness skin was obtained, since the presence of both the 
epidermis and dermis makes for a more realistic model for in vivo drug transport.  
Human skin was used since it is regarded as the „„gold standard” for in vitro penetration 
experiments (Barbero and Frasch, 2009).  Prior to use, the frozen samples were thawed 
and hydrated in PBS for 24 hours at 4 ºC. 
 
The study was approved by the Ethics Committee of Stellenbosch University and the 
Tygerberg Academic Hospital. Project number:  95/019 (resubmitted and approved on 
28/7/03).  
 
3.3.2 Terbinafine hydrochloride 
Terbinafine hydrochloride powder and three commercial terbinafine hydrochloride 10 
mg/ml formulations (Topical1, Topical2, and Topical3) were obtained from different 
pharmaceutical companies.  The manufacturer who provided some of the formulations 
do not want to be revealed and it was therefore one of the conditions I had to accept 
before receiving the formulations. Therefore no mention will be made to the 
manufacturer, trade names or batch numbers in this thesis.  Topical1 and Topical2 were 
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generic cream formulations (Topical1 was obtained from a local generic pharmaceutical 
company) and contained 1.0 % benzyl alcohol as preservative, while Topical3 was a gel 
formulation and had 0.5 % (m/m) benzyl alcohol as well as 10 % ethanol (96 %, v/v) as 
preservatives. 
 
Benzyl alcohol is a widely used low-risk preservative and fragrance additive in the 
pharmaceutical and cosmetic industry.  It is not only able to solvate strongly hydrophobic 
compounds such as terbinafine by forming micelles, but also able to maintain contact 
with aqueous solutions due to its moderate hydrophilicity, thus making it ideal for 
penetration through the stratum corneum (Mikulak et al., 1998).  The inclusion of benzyl 
alcohol in topical formulations has been shown to increase drug retention and 
accumulation within the skin significantly, whilst lack of binding in the dermis and 
metabolic biotransformation reactions within the epidermis aid the removal of the drug 
from the skin and ensure sink conditions (Peng and Nimni, 1999; Mikulak et al., 1998; 
Boehnlein et al., 1994; Barry et al., 1985).  
 
Methanol is a solvent that interferes with the skin‟s barrier function by exerting an effect 
on the stratum corneum‟s lipids and proteins (Hadgraft, 2001a; Goates and Knutson, 
1994).  It has the ability to extract lipids in the stratum corneum.  It removes lipids that 
are covalently bonded to the corneocyte envelope which leads to a decreased barrier 
function by the skin (Hadgraft, 2001b).  It is therefore known to cause rapid and 
irreversible damage to stratum corneum.  The extent of damage increase with contact 
time (Nangia et al., 1998; Dugard et al., 1984). 
 
Ethanol is commonly used as a solvent and permeation enhancer (Femenia-Font et al., 
2005; López-Pinto et al., 2005; Ho et al., 2004).  It extracts some of the lipids of the 
stratum corneum, but is a much milder solvent than methanol.  Ethanol consists of a 
short two carbon chain, which enable it to interact with and dissolve relatively non-polar 
molecules.  It also has a hydroxyl group, which gives ethanol the ability to interact with 
relatively polar molecules and to form hydrogen bonds.  Ethanol therefore has the ability 
to act as a solvent for organic molecules with a wide range of octanol/water partition 
coefficients (Van der Merwe and Riviere, 2005).  Its synergistic effect with other 
permeation enhancers has been widely studied (Gwak et al., 2004; Kim and Chien, 
1995).  Ethanol can exert its permeation enhancing activity by extracting lipids from the 
Chapter 3: Skin tissue                                                104 
           
1
0
4
 
stratum corneum to increase drug flux, increasing the lipid fluidity of the skin, effecting 
the putative pore pathway, enhancing drug solubility in stratum corneum lipids, changing 
stratum corneum hydration and altering the keratinised protein (Trommer and Neubert, 
2006).  As a solvent it can increase the solubility of the drug in the vehicle.  It is also 
feasible that the rapid permeation of ethanol or evaporative loss of this volatile solvent 
from the donor phase modifies the thermodynamic activity of the drug within the 
formulation.  Heard and Screen investigated this effect of ethanol further and showed the 
transit of the ethanol permeating through skin gave rise to co-transportation of the drug 
(the so called pull or drag effect) (Heard and Screen, 2008).   
 
3.3.3 Permeability experiments 
The human skin specimens were mounted in flow-through diffusion cells (exposed 
circular areas 0.196 ± 0.002 SD cm2) and permeation studies were performed on 7 
tissue replicates for each patient (Van der Bijl et al., 2006; Basson et al., 2005; Van der 
Bijl et al., 2003).  The skin was mounted between donor and acceptor compartments and 
the stratum corneum faced towards the donor compartment.  0.5 ml Topical1 was placed 
in the donor compartment of each flow-through diffusion cell and covered with adhesive 
tape to avoid evaporation.    
 
PBS at 32 ºC was pumped through the acceptor chambers at a rate of 1.5 ml/h and 
collected by means of a fraction collector, at 2-h intervals for 24 h.  Alternatively 0.5 ml 
(~ 5 mg) Topical2 and Topical3 were used.  The above experiments were repeated with 
terbinafine hydrochloride solutions (PBS/Methanol 1:1) of 10, 20 and 30 mg/ml 
respectively.  0.5 ml of the respective terbinafine hydrochloride solutions was added to 
the donor compartments of the flow-through diffusion cells and fractions were collected 
at 2-h intervals for a 24 h period.     
 
The terbinafine in the acceptor chambers was quantified by means of LC/MS analysis 
and terbinafine extractions of the exposed skin were conducted. 
 
For studying the effect of temperature on 3H2O flux rates, skin tissue was mounted in the 
flow-through diffusion cells, as previously described.  Prior to each permeability 
experiment, the thawed skin specimens were equilibrated for 10 min in PBS (pH 7.4) at 
32 or 37 ºC in the diffusion cells.  The PBS was then removed from the donor 
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compartment and replaced with 1.0 ml of PBS containing 1 µCi 3H-water (Amersham 
Laboratories, Little Chalfont, Amersham, UK).  Aliquots (100 l) were removed within 
minutes from each of the seven donor compartments for the determination of donor cell 
concentration at time zero.  A flow rate of 1.5 ml/h was maintained and fractions 
collected, by means of a fraction collector, at 2-h intervals.  Temperatures were 
controlled by using a circulator water bath.  Scintillation cocktail (10 ml) (PCS 
Scintillation Cocktail; Amersham Biosciences, Uppsala, Sweden) was added to each 
sample collected and the radioactivity (dpm) determined using a Beckman LS 5000TD 
liquid scintillation counter (Beckman Instruments, Fullerton, CA, USA).  The counting of 
the samples was continued until a 2-s value of 1 % was reached.  Quenching for each 
sample was automatically corrected in the counter.   
 
Intra- and inter-experiment variations were calculated for the terbinafine and 3H2O 
experiments (SD/mean x 100). 
 
3.3.4.1 Terbinafine extractions from skin 
After each 24 h transdermal diffusion experiment, the skin samples from the diffusion 
cells were recovered and wiped 3 times using a cotton cloth immersed in PBS to remove 
excess terbinafine from the surface of the skin.  The skin area (0.196 ± 0.002 SD cm2) 
exposed to the different terbinafine hydrochloride formulations were taken with a biopsy, 
cut into smaller sections, positioned in a glass homogeniser and grounded in 1 ml 
methanol.  The resulting solution was centrifuged for 10 min at 6500 rpm to eliminate 
suspended solids and impurities from the skin.  The terbinafine were then extracted with 
10 ml ethyl acetate and the extract was evaporated at 39 0C (Schmook et al., 2000).  1 
ml methanol was added to the residues and the solution was subjected to analysis by 
LC/MS (Liquid Chromatography/Mass Spectrometry).   
 
3.3.4.2  LC/MS determination of terbinafine 
The samples collected from the acceptor compartments of the perfusion apparatus over 
the 2-h sampling intervals, were analysed using LC/MS.  Determination was conducted 
under the following LC/MS conditions (Figs. 32-37): 
LC: Waters 2695 Seperatious Module (Alliance)  
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MS: Water Micromass, Quatro Micro EScl (Electrospray chemical ionisation).   
Column: Xterra Rp (18
5µm, 3 x 9 x 150 mm)  
Flow rate: 0.9 ml/min  
Mobile phase: Two solvents (50:50), A (MeOH) and B (0.1 % Formic H+ in deionised 
water). 
Retention time: 4.3 min 
LLOQ (lower limit of quantification): 0.0001 mg/ml   
There were a 6.7 % variation on the chromatographic area and a 0.61 % variation on the 
retention time (RT).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32.  Best cone voltage for terbinafine was at 30V 
  
Chapter 3: Skin tissue                                                107 
           
1
0
7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 33.  Best product ion was 141.21 m/z at collision energy of 15 
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 Fig. 34.  Parent scan of daughter ion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 35.  Calibration curve 1 
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Injection Number Area RT
1 566769.375 3.66
2 535695.063 3.76
3 472059.406 3.75
4 455136.000 3.75
5 560435.938 3.73
6 568797.438 3.72
7 505724.938 3.74
8 505089.719 3.72
9 522681.625 3.74
10 541672.563 3.73
11 547673.125 3.74
12 547160.000 3.72
13 568252.563 3.73
14 561737.875 3.72
15 561984.188 3.73
Mean 534724.654 3.73
SD 35799.897 0.02
RSD 0.0670 0.0061
% CV 6.70 0.61
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 36.  Calibration curve 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          Fig. 37.  Terbinafine Repeatability Analysis (5ppm) 
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3.3.4.3  Calculation of flux values 
Flux (J) values of 3H2O across skin were calculated by means of the relationship: J = 
Q/(A x t) (dpm x cm-2 x min-1), where Q = quantity of 3H2O crossing skin (dpm), A = skin 
area exposed (cm2) and t = time of exposure (min).  The trapezoid method of obtaining 
area under curve (AUC) was used. 
3.3.4.4  Steady state kinetics and statistical analysis of data 
Repeated measure ANOVA over all time periods and a Bonferroni multiple comparison 
procedure was used to determine steady state.  If at consecutive time periods p-values 
exceeded 0.05, these flux values do not differ significantly, therefore indicating steady 
state.  Non-linear regression analyses (third order polynomials) were performed using a 
GraphPad Prism, version 4, 2003 computer programme.  A F-test was used to compare 
entire curves (Harwood and Mishell, 2001).  A significant level of 5 % was used for all 
tests and comparisons. 
 
Chapter 3: Skin tissue                                                111 
           
1
1
1
 
3.4  Results 
3.4.1  Terbinafine hydrochloride  
No flux values for any of the terbinafine hydrochloride formulations (Topical1, Topical2, 
Topical3 or terbinafine hydrochloride solutions) through skin into the acceptor fluid were 
found.  Topical3 showed a significantly (p<0.05, ANOVA) higher mean drug 
concentration (4.219 μg/ml) in the skin than Topical2 (1.590 μg/ml).  The mean 
terbinafine concentration in the skin after exposure to Topical3 was higher than the skin 
exposed to Topical1 (3.589 μg/ml), but this difference was not significant (p>0.05).  The 
mean terbinafine concentrations in the skin after 24 h exposure to Topical1, Topical2 
and Topical3 were 3.589, 1.590 and 4.219 µg/ml respectively (Fig. 38).  Topical1 led to a 
significantly (p<0.05, ANOVA) higher mean terbinafine concentration in skin than 
Topical2.  The mean terbinafine concentrations in the skin after 24 h of exposure to the 
terbinafine hydrochloride solutions (PBS/Methanol 1:1) of 10, 20 and 30 mg/ml were 
42.640, 77.34 and 62.541 µg/ml respectively (Fig. 39).  The mean drug concentration of 
the skin exposed to 10 mg/ml terbinafine hydrochloride solution (PBS/Methanol 1:1) was 
11.880 times higher than the mean drug concentration of the skin exposed to Topical1 
(10 mg/ml) and 10.107 higher than the mean drug concentration of the skin exposed to 
Topical3 (10 mg/ml) (Fig. 40).  The mean drug concentration of the skin exposed to 20 
mg/ml terbinafine hydrochloride solution was almost 2 times (1.814) and 1.237 times 
higher than the mean drug concentration of the skin exposed to the 10 and 30 mg/ml 
solutions respectively. 
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Fig. 38.  Mean terbinafine concentrations in the skin after 24 h exposure to 
Topical1, Topical2 and Topical3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 39.  Mean terbinafine concentrations in the skin after 24 h exposure to 
terbinafine solutions of 10 mg/ml, 20 mg/ml and 30 mg/ml 
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Fig. 40.  Comparison between the mean terbinafine concentrations in the skin after 
24 h exposure to a 10 mg/ml terbinafine hydrochloride solution and Topical3 (10 
mg/ml) 
 
3.4.2  Tritiated water 
The results of this temperature study clearly demonstrated the temperature-dependency 
of water flux rates across skin tissue.  The overall mean flux values of water across 
human skin at 32 ºC and 37 ºC are shown in Fig. 41.  The increase of temperature 
caused the lag time to decrease from 16 to 12 h (Fig. 41b).  An increase of 5 ºC caused 
a significant (p<0.05) increase in flux values of tritiated water across skin.  The AUC of 
the overall mean flux values of tritiated water across skin at 37 ºC were 2.0 times that of 
the overall mean flux values of tritiated water across skin at 32 ºC (Fig. 41). 
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 AUC/24 h of 3H2O at 37 ºC: 447.96 ± 65.17 dpm.cm
-2.min-1 
 AUC/24 h of 3H2O at 32 ºC: 223.17 ± 21.37 dpm.cm
-2.min-1 
  
 Fig. 41.  Overall mean flux values of 3H2O across human skin at 32 ºC and 37 
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Bonferroni test; variable DV_1 (32 ºC)
Error: Within MS = 3615.8, df = 198.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7}
85.456 196.5 221.8 240.74 258.98 279.12 296.68
1 2 0 0 0 0 0 0
2 4 0 1 0.05754 0.0006 1E-06 0
3 8 0 1 1 0.24213 0.00246 1.4E-05
4 12 0 0.05754 1 1 0.1924 0.00353
5 16 0 0.0006 0.24213 1 1 0.21968
6 20 0 1E-06 0.00246 0.1924 1 1
7 24 0 0 1.4E-05 0.00353 0.21968 1
Bonferroni test; variable DV_1 (37 ºC)
Error: Within MS = 31322., df = 246.00
Cell No. Time (h) {1} {2} {3} {4} {5} {6} {7}
161.57 369.32 442.18 505.56 548.85 563.61 539.48
1 2 4E-06 0 0 0 0 0
2 4 4E-06 1 0.0105 0.00012 0.00002 0.00033
3 8 0 1 1 0.12977 0.03926 0.26017
4 12 0 0.0105 1 1 1 1
5 16 0 0.00012 0.12977 1 1 1
6 20 0 0.00002 0.03926 1 1 1
7 24 0 0.00033 0.26017 1 1 1
 
 
 
 
 
 
 
 
    
       
 
 
 
 
 
 
   Fig. 41b.  3H2O reached steady state at 12 h (temperature 37 ºC)   
 
The intra-experiment variations for terbinafine and 3H2O were respectively 30.1 and 26.2 
% and the inter-experiment variations were respectively 27.4 and 20.9 %. 
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3.5  Discussion  
3.5.1  Terbinafine hydrochloride    
In vitro human skin studies to measure drug diffusion and metabolism provide the most 
accurate absorption data, as compared with animal skin studies.  Therefore one would 
like to use human skin, as done in the present study, to evaluate penetration properties 
of new candidate drugs (Schmook et al., 2000; Collier et al., 1991).   
 
There is relatively little information available in the literature about the concentration of 
terbinafine in tissues.  A possible reason could be due to a lack of availability of an 
analytical method (Yeganeh and McLachlan, 2000).   This prompted us to use the flow-
through diffusion system to study the permeation of terbinafine hydrochloride across 
human skin and to determine the concentration of the drug in skin tissue. 
 
From the results of the present study, it was clear that terbinafine diffused into the skin 
along a concentration gradient, but interestingly, no flux values were found for 
terbinafine through skin into the acceptor compartment of the flow-through diffusion 
system.  This may be explained as follows.  Terbinafine hydrochloride is a highly 
lipophilic (octanol/water partition coefficient=3.3) and keratophilic compound. It has a 
relatively small molecular weight (327.9 g/mol) and it therefore readily diffused from its 
vehicle into the skin, but then accumulated in the skin (“reservoir effect”) rather than to 
diffuse into the hydrophilic acceptor compartment through which PBS was pumped.  This 
reservoir effect is in agreement with other authors (Tatsumi et al., 2002; Leyden, 1998; 
Uchida and Yamaguguchi, 1993).  
 
The extensive absorption of terbinafine into the skin and the maintenance of high 
concentrations in the skin for a considerable time after cessation of treatment, together 
with its fungicidal mode of action are of major relevance to its ability to achieve rapid 
anti-mycological and clinical response (Faergemann et al., 1995; Hill et al., 1990).  
These findings are in agreement with the results` obtained in other in vivo and in vitro 
studies.    
 
The findings of this study concur with data from a previous in vitro skin study, in which a 
comparison of the penetration properties of human skin or epidermis models with human 
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and animal skin was conducted.  The flux rate of terbinafine through human skin was 
below the detection limit of the study and therefore had the lowest flux rate of the four 
test compounds used in the study, but interestingly the skin concentration (µg/g) of 
terbinafine was the second highest of the four compounds (Schmook et al., 2001). 
 
Other authors demonstrated in an in vivo study that only 3-5 % of terbinafine (10 mg/ml 
cream) is absorbed into the systemic circulation after topical administration.  The skin 
penetration was a slow process, with the peak amount of substance appearing as 
metabolites in the urine only 2 to 3 days after administration (Jones, 1990; Hill et al., 
1992).  The results of the mentioned in vivo study may also explain why no terbinafine 
was detected in the acceptor compartment of this experiment, since in this study 
permeability of terbinafine hydrochloride was only studied over a 24 h period due to the 
degradation of the in vitro skin.   
 
Even though terbinafine undergoes first pass effect in the liver, it is unknown whether or 
not there is significant skin metabolism of topically applied terbinafine hydrochloride 
(FDA website).  Future studies with the flow-through diffusion could be used to evaluate 
the metabolism of drugs by skin tissue. 
 
An in vivo study of multiple-dose oral terbinafine (250 mg, 1x/day) showed a peak 
plasma concentration of 1.70 ± 0.77 µg/ml occurring 1.2 h post administration.  
Terbinafine distributed extensively to the peripheral body fluids and tissue, but had a 
slow redistribution back to the central plasma compartment.  The fungicidal 
concentrations in the skin were maintained for weeks to months after a course of 
treatment.  In the mentioned in vivo study terbinafine levels in the stratum corneum was 
1 µg/ml (Koavarik et al., 1995).  The findings of this in vivo study could be used to put 
the concentration of terbinafine found in skin exposed to Topical1, Topical2 and Topical3 
(3.589, 1.590 and 4.219 µg/ml respectively) into clinical perspective and illustrate the 
reservoir effect of terbinafine once again. 
 
The reservoir effect of terbinafine in skin may have significant clinical value, since the 
skin is the site of action for topical terbinafine. It is therefore important that after 
application of this antifungal drug, terbinafine reaches its minimum inhibitory 
concentration (MIC) in the skin and not necessary in the systemic circulation.  The 
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extensive absorption of terbinafine into the skin and the maintenance of high 
concentrations in the skin for a considerable time after cessation of treatment, together 
with its fungicidal mode of action are of major relevance to its ability to achieve rapid 
mycological and clinical response (Faergemann et al., 1995; Hill et al., 1990).  Diffusion 
of terbinafine mainly into the skin and not the systemic circulation may decrease 
unnecessary side effects and limit drug interactions with especially cytochrome P450 
enzyme inhibitors/inducers e.g. cimetidine, rifampicin and also with oral contraceptives, 
terfenadine, caffeine, cyclosporine (In: South African Medicines Formulary, 2003).  It 
may also be advantageous for patients breast-feeding and patients with gastrointestinal 
or hepatic dysfunction.  Topical administration and minimal drug plasma levels may 
therefore lead to greater patient convenience and possibly improving drug adherence.   
 
Budimulja et al. (2000) conducted an in vivo study in adult patients with tinea 
corporis/cruris.  The patients were treated with 1 % Lamisil Cream® once daily for 7 
days.  Rapid mycological cure were achieved and maintained for up to 7 weeks after 
completion of treatment.  Hill et al. (1992) also investigated the effect pharmacokinetics 
of 1 % Lamisil Cream®.  Treatment for 7 days also resulted in terbinafine still being 
detectable 7 days after cessation of therapy at fungicidal concentrations, showing the 
highly lipophilic and keratophilic properties of the drug.  
 
The administration of Topical3 led to a higher (P˃0.05) mean skin concentration (4.219 
µg/ml) than Topical1 (3.589 µg/ml) and a significantly (P<0.05) higher mean skin 
concentration than Topical2 (1.590 µg/ml) (Fig. 38).  The mean skin concentration after 
24 h exposure to Topical3 was respectively 1.2 and 2.7 times higher than Topical1 and 
Topical2.  All three commercial formulations used in this study had a concentration of 10 
mg/ml, but Topical3 contained 0.5 % (m/m) benzyl alcohol as well as 10 % ethanol (96 
%, v/v) as preservatives, where as Topical1 and Topical2 contained 1.0 % benzyl 
alcohol as a preservative.  The finding that Topical3 led to greater terbinafine penetration 
into the skin may be attributed to the combination of benzyl alcohol (0.5 %) and ethanol 
(10 %) in the gel formulation of Topical3, which enhanced the absorption of terbinafine in 
to the skin more efficiently than the 1.0 % benzyl alcohol cream formulation of the other 
two commercial formulations.  These results correlate well with an in vivo study done by 
Cramer et al. (2006), where the authors compared the skin penetration of two different 
commercial terbinafine hydrochloride formulations.   The gel formulation that contained 
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the combination of benzyl alcohol and ethanol as preservatives showed a significantly 
higher skin penetration than the cream formulation that contained only benzyl alcohol.  
 
In another in vivo study, single daily application of two 10 mg/ml terbinafine topical 
products with similar formulations to Topical 1, Topical2 and Topical3 were used and the 
skin concentrations of the respective formulations were compared using skin stripping.  
The topical formulation similar to Topical3 showed significantly faster skin penetration 
than the topical formulation similar to Topical1 and 2 (138 ± 16 vs. 121 ± 16 ng/cm2/min) 
(James et al., 2007).  The ratio between the in vivo skin concentrations achieved after 1 
day application of the two different formulations was 1.2.  Interestingly, the skin 
concentration ratio achieved in this in vitro study after 24 h application of Topical 1 and 
3, was also 1.2. 
 
Both Topical1 and Topical2 were 10 mg/ml cream formulations that contained 1.0 % 
benzyl alcohol as preservative, but the 24 h skin exposure to these two formulations led 
to a significantly higher mean terbinafine concentration in the skin exposed to Topical1.  
This interesting result may be attributed to the fact that the two formulations are 
manufactured by different pharmaceutical companies and may contain different 
ingredients, even though they are from similar pharmaceutical category.  The results 
demonstrate the importance of formulation for percutaneous absorption of topical drug 
preparations, as the quantity of applied terbinafine penetrating the skin varied 
significantly between the two formulations.  Different ingredients and solvents used in the 
formulation of drugs may change the partitioning and diffusion behaviour of the drugs 
into the stratum corneum, which is the main barrier of the skin (Rosado et al., 2003; Kai 
et al., 1990).  
 
With the exception of topical corticosteroids, the only means a generic company has to 
demonstrate bioequivalence of topical dermatologic product to an innovator‟s product is 
through comparative clinical trials with a bioequivalence endpoint (Sha et al., 1998).  
These clinical trials are time and money consuming.  In the case of topical 
corticosteroids, the demonstration of bioequivalence may be conducted by using the 
FDA vasoconstrictive protocol (FDA, 1995).  In vitro models to study the effects of 
different formulations and solvents on percutaneous drug absorption could improve the 
prediction of skin absorption in the pharmaceutical industry and may therefore save time 
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and resources.  The in vitro flow-through diffusion model used in the present study has 
shown that the formulation of topically applied terbinafine hydrochloride can have a 
considerable impact on the transdermal penetration of this antifungal compound. 
 
The results of the study are in correlation with Fick‟s law; the skin absorption rate of a 
penetrant in a mixture is proportional to the penetrant concentration (Dugard, 1977).  As 
expected, the mean drug concentration of the skin exposed to 20 mg/ml terbinafine 
hydrochloride solution was almost 2 times (1.814) higher than the mean drug 
concentration of the skin exposed to the solution with a lower concentration (10 mg/ml).  
This finding supports the well-established diffusion theory, but the 20 mg/ml solution also 
had a slightly higher (1.237 times) drug concentration than the tissue exposed to the 30 
mg/ml terbinafine hydrochloride solution (Fig. 39).  The lower drug concentration found in 
the skin exposed to a higher terbinafine hydrochloride solution may be explained by the 
saturated solubility of the terbinafine hydrochloride in the 30 mg/ml terbinafine 
hydrochloride solution, the instability of the saturated solution, the subsequent 
decreased thermodynamic activity, the formation of crystals on the exposed skin surface 
and saturation of the exposed skin tissue.  The absorption of a drug is invariant with 
concentration above the solubility limit of the specific drug (Hadgraft, 2001b).  It may 
therefore be assumed that the solubility limit of terbinafine hydrochloride in 
PBS/Methanol (1:1) is approximately 20 mg/ml.   
 
Chemicals that reduce the skin‟s ability to perform its barrier function are collectively 
known as penetration enhancers.  These substances cause the skin to become more 
permeable and they allow drug molecules to cross the skin at a faster rate.  A wide 
selection of chemical structures has been identified as penetration enhancers, of which 
methanol is one.  Methanol interferes with the skin‟s barrier function by exerting an effect 
on the stratum corneum‟s lipids and proteins (Hadgraft, 2001a; Goates and Knutson, 
1994).  It is known to cause rapid and irreversible damage to stratum corneum.  The 
extent of damage increases with the contact time (Nangia et al., 1998; Dugard et al., 
1984).  Ethanol is also commonly used as a solvent and permeation enhancer, but is a 
much milder solvent than methanol (Femenia-Font et al., 2005; López-Pinto et al., 2005; 
Ho et al., 2004).  This may explain why the mean drug concentration of the skin exposed 
to 10 mg/ml terbinafine hydrochloride solution (PBS/Methanol 1:1) was 10.107 times 
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higher than the mean drug concentration of the skin exposed to Topical3 (10 mg/ml, 1 % 
benzyl alcohol, 10 % ethanol) (Fig. 40).   
 
For dermatophytes the minimum inhibitory concentration (MIC) range for terbinafine in in 
vitro skin is 0.001 to 0.01 µg/ml, ≤ 0.05 to 2.0 µg/ml for dimorphic fungi, 0.05 to 1.56 
µg/ml for aspergilla, 0.1 to 0.4 µg/ml for sporothrix schenckii, 0.2 to 0.8 µg/ml for 
malasseziafurfur and it also exerts good activity against yeasts (MIC range: 0.1 to >100 
µg/ml) (Balfour and Faulds, 1992; Petranyi et al., 1987).  The in vitro MIC for some 
Candida species is 0.25 to 1 µg/ml and Trichophyton species 0.0039 to 0.078 µg/ml 
(Hazen, 1998).  Terbinafine displays a primary fungicidal action against dermatophytes, 
other filamentous fungi and sporothrix schenckii.  The concentrations of terbinafine 
found in skin exposed to Topical1, Topical2 and Topical3 were 3.589, 1.590 and 4.219 
µg/ml respectively that are all above the mentioned in vitro mentioned MICs and may put 
the drug concentrations found in this study into clinical perspective. 
 
Choosing the appropriate vehicle/formulation for a specific drug plays a critical role in the 
clinical efficacy of a dermatological topical drug. The formulation has to exhibit qualities 
such as optimised release of the drug and at the same time facilitates drug transport 
across or into the skin.  In vivo assessment of topical drug bioavailability may be 
expensive and may not always be easily accomplished.  A reliable in vitro model to 
assess preclinical formulations will therefore be very beneficial.  Such an in vitro model 
may serve as a tool to evaluate whether the presence of certain vehicle components 
may enhance percutaneous absorption (Alberti et al., 2001a).  
 
3.5.2  Tritiated water 
The results of the study clearly show a significant increase in flux rate of water across 
skin tissue when the normal temperature of skin is elevated from 32 ºC to 37 ºC (Fig. 
41).  The AUC/24 (average flux over 24 h) of tritiated water across skin at 37 ºC were 
double that of the overall mean flux values of tritiated water across skin at 32 ºC. 
 
The enhancement in percutaneous absorption due to the temperature increase is 
consistent to that reported by other authors (Clarys et al., 2001; Ogiso et al., 1998; 
Ohara et al., 1995).  These authors attributed the enhancement to an increase in the 
fluidity of stratum corneum lipids which might also lead to an associated increase 
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(expansion) in intercellular space, thus leading to the increase in epidermal permeability.  
Many of the earlier studies employed rat skin and/or donor solutions/gels containing 
penetration enhancers such as ethanol, propylene glycol and terpenes, which are known 
to disturb the intercellular lipid arrangement.  This does not allow the effect of 
temperature on skin permeation to be studied independently, making it difficult to 
differentiate the effect of temperature and/or chemical enhancers on either the polar 
and/or non polar pathways across the skin.  At low temperatures, the lipids are much 
more rigid and closely packed and this hinders the diffusion of the penetrant molecules 
across the stratum corneum.  With the aid of differential scanning calorimetry (DSC), 
thermal transitions of stratum corneum lipids has been shown to occur near 40, 65-70 
and 80-85 ºC (Lawson et al., 1998; Tanojo and Bouwstra, 1994; Knutson et al., 1985). 
 
The results of the present study are in agreement with a previous in vitro skin study 
where a two-fold increase in flux was observed for every 7-8 ºC rise in receptor 
temperature for all penetrants investigated (Tanojo et al., 1997).  
 
This calls for further investigation into the effect of increases in physiologically 
acceptable temperature on percutaneous absorption and dermal retention of a wide 
range of permeants. This is required especially when the regulatory authorities are 
becoming increasingly concerned about the possibility of toxicity from active agents or 
vehicle excipients, used in topical semisolids as a result of exposure to elevated 
temperature/UV radiation at the site of application. Increased temperatures may also be 
of importance in patients with fever. 
 
 
Chapter 4: Small intestine mucosa                                       123 
           
1
2
3
 
Chapter 4: Small intestine mucosa   
4.1  Summary 
The oral route still remains the most popular route to administrate new drugs, despite the 
extensive research on other routes of drug delivery.  In mammals/humans the jejunum is 
generally the major absorbing site for most drugs.  Approximately 90 % of all absorption 
of nutrients and drugs takes place in the small intestine.  This part of the small intestine 
also has the largest surface area and it is the site of the most active carrier-mediated 
transport in the gastrointestinal tract.  It was therefore decided to use jejunum mucosa 
for evaluating the small intestine permeability. 
 
Due to modern isolation technology and high throughput biological screen capability a 
reliable, high through put method for evaluating intestinal permeability is essential.  
Several methods have been proposed and investigated for in vitro evaluation and 
prediction of gastrointestinal permeability of drugs, but no official method is available at 
present due to certain limitations.  
 
The permeability of excised human jejunum mucosa to 4 different oral drugs, using our 
flow-through diffusion system, was investigated.  The 4 drugs were selected as 
representative model compounds of drug classes 1 (high solubility, high permeability) 
and 3 (high solubility, low permeability) according to the Biopharmaceutics Classification 
System (BCS).  Permeability values from our in vitro diffusion model were compared with 
in vivo gastrointestinal drug permeability and the BCS permeability classification.   
 
The flux rates of the 4 chosen test drugs were influenced by the length of the 
experiment.  Between the time periods 2-4 h and 4-6 h, AZT‟s mean flux values were 
respectively 1.8 and 2.0 times higher than didanosine and 2.3 and 2.2 times higher than 
enalapril. At these same time periods propranolol‟s mean flux values were respectively 
1.2 and 1.4 times higher than didanosine and 1.6 times higher than enalapril during the 
mentioned time periods.  Class 1 drugs showed a significantly higher flux rate across the 
jejunal mucosa compared to the class 3 drugs and these results are in line with their 
BCS classification.  The in vitro model has proved to be reliable to predict permeability of 
the class 1 and 3 drugs and also showed correlation with human in vivo data. 
 
Chapter 4: Small intestine mucosa                                       124 
           
1
2
4
 
The results of this study show that the permeability values of gastrointestinal mucosa 
obtained with the developed flow-through diffusion system are good predictors of BCS 
permeation classification and concurred with other in vitro studies.  Moreover, the 
proposed method allowed obtainment of good results for a wide variety of 
compounds/drugs. 
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4.2  Introduction 
4.2.1  Oral administration of drugs 
Regardless of the tremendous research on drug delivery methods in the last few 
decades, the oral route remains the most preferred route of administration of new drugs 
(Balimane et al., 2000).  More than 60 % of marketed drugs are oral products, despite 
some shortcomings (Masaoka et al., 2006).  The oral administration route is preferred 
due to its convenience, high patient compliance, less stringent production conditions and 
lower costs.  It is also considered safe, efficient and easily accessible, with minimal 
discomfort to the patient compared to other routes of administration.  Tremendous 
growth in the field of genomics and combinatorial chemistry, combined with advances in 
technological innovations led to vast numbers of potential drug candidates.  The 
screening of potential compounds for permeability/absorption, solubility, stability and 
biological activity is now one of the rate limiting processes in drug discovery.  The 
implementation of appropriate screening models is therefore essential for the design of 
an oral preparation.  These models must be able to accurately predict in vivo 
permeability, dissolution and absorption and must be cost-effective and exhibit a high 
capacity (Balimane et al., 2000).   
 
4.2.2  Small intestine 
4.2.2.1  Anatomy 
The human small intestine is approximately 2-6 m long and is divided into three areas 
namely the duodenum, jejunum and ileum.  These three sections comprise respectively 
5, 50 and 45 % of the length of the GIT (Ganong, 1995).  The small intestine is the 
principle site for absorption of nutrients and drugs.  Approximately 90 % of all absorption 
in the gastrointestinal tract occurs in the small intestinal region and the upper part of the 
small intestine is considered to have the higher capacity for drug absorption.  In 
mammals/humans the jejunum is generally the major absorbing site for most drugs.  The 
jejunum has the largest surface for absorption and is the site of the most active carrier-
mediated transport (Lennernäs, 2007).  The duodenum is the shortest segment and 
starts at the pyloric sphincter of the stomach and extends approximately 25 cm until it 
merges with the jejunum.  Duodenum means “twelve”, since it is roughly 12 fingers 
breadth in length.  The jejunum is approximately 2.5 m long and extends to the ileum.  
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Jejunum means “empty”, since this part of the small intestine is usually found empty at 
death.  The last portion of the small intestine is the ileum.  The ileum means “twisted”, 
measures approximately 3.6 m and joins the large intestine at the illeocecal sphincter.   
 
The small intestine fills much of the peritoneal cavity and its position is stabilised by the 
mesentery proper, a broad mesentery attached to the dorsal body wall.  The stomach, 
the large intestine, the abdominal wall and the pelvic girdle restrict movement of the 
small intestine during digestion.  Blood vessels, lymphatic vessels and nerves reach the 
segments of the small intestine within the connective tissue of the mesentery.  The 
primary blood vessels are branches of the superior mesenteric artery and the superior 
mesenteric vein (Martini, 2006; Tortora and Grabowski, 1993). 
 
4.2.2.2  Histology 
The walls of the small intestine are composed of four layers of tissue: mucosa, 
submucosa, muscularis externa and the serosa (Fig. 42). 
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Fig. 42.  Sectional views of layers of small intestine (Tortora and Grabowski, 1993)  
 
The mucosa is composed of the intestinal epithelium, lamina propria and muscularis 
mucosae.  The mucosa has a characteristic villous form in the whole of the small 
intestine, with short glands known as crypts of Lieberkühn between the villi, extending 
down to the muscularis mucosae.  The villi are finger-like projections of the lamina 
propria that is the connective tissue layer of the mucosa.  The villi tend to be longest in 
the duodenum and become shorter towards the ileum.  The mucosa and submucosa are 
thrown up into circularly arranged folds, called plicae circulars or valves of Kerkring, 
which are particularly numerous in the jejunum.  Plicae circulares are only found in the 
jejunum and ileum (Fig. 42). 
 
The epithelium of the mucosa consists of simple columnar epithelium or enterocytes, 
mucous/goblet cells, Paneth cells, stem cells and endocrine cells. The enterocytes are 
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responsible for digestion and absorption and cover the villi and crypts. The 
mucous/goblet cells, Paneth cells, stem cells and endocrine cells are dispersed between 
the enterocytes and their numbers and distribution vary in the different zones of the 
small intestine.  The proportion of goblet cells in the epithelium increases distally.  
Numerous microvilli are present at the luminal surface of the enterocytes and since the 
microvilli project from the epithelium‟s free border like the bristles on a brush, these 
epithelial cells are said to have a brush border.  The connection tissue of the lamina 
propria contains an arteriole, a venule, a capillary network and a lacteal, which is a 
lymphatic vessel (Fig. 43).  Nutrients and drugs pass through the epithelial cells covering 
the villus and then pass through the capillary walls and the lacteal to enter the blood and 
lymphatic fluid.  The entire epithelium of the intestine is replaced every 3 to 5 days.  
Another prominent feature of the small intestine is lymphoid aggregations known as 
Peyer‟s patches within the lamina propria.  These structures are associated with the 
function of the immune system (Martini, 2006; Tortora and Grabowski, 1993).  The 
muscularis mucosa, a layer of circular smooth muscle fibres, lies immediately beneath 
the mucosal crypts and separates the mucosa (lamina propria) from the submucosa.  
The submucosa is vascularised loose connective tissue containing larger blood vessels, 
lymphatic vessels and adipose cells as well as submucosal (Meissner‟s) plexuses. It 
extends into and forms the core of the plicae circulares.  Beneath the mass of 
submucosal glands is the muscularis externa, which is composed of an inner circular 
layer and an outer longitudinal layer of smooth muscle.  These two muscle types are 
responsible for peristaltic activity.  Between the two layers of smooth muscle is the 
myenteric plexus (plexus of Auerbach). The peritoneal aspect of the muscularis externa 
is invested by the loose collagenous serosal, which is lined on its peritoneal surface by 
mesothelium, that is identical in appearance to the mesothelium lining of the pleura. 
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Fig. 43.  Enlarged villus showing lacteal and capillaries (Tortora and Grabowski, 
1993)  
 
If the small intestine was a simple tube with smooth walls it would have had a total area 
of roughly 3300 cm2, but the surface area for digestion and absorption is increased to a 
factor of more than 600 (2 million cm2) due to the plicae and the forest of villi and 
microvilli (Martini, 2006; Tortora and Grabowski, 1993).  
 
4.2.3  Functions of the GIT 
The GIT has several important functions such as the absorption and metabolism of 
nutrients and drugs, secretion and it acts as an efficient barrier to digestive enzymes and 
potentially hazardous bacteria and toxins.  The enterocytes and colonocytes of the 
epithelial layer of the GIT maintain a balance between absorption and protection and this 
subsequently affects the permeability of drugs, while the gut-associated lymphoid tissue 
(GALT) is the largest immunological tissue in the body.   
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The human body plays host to 1014 bacteria of which most are located in the GIT.  The 
microflora in the lumen of the GIT forms a complex ecosystem and plays an important 
role in the normal physiology of the body.  Different regions of the GIT contain different 
compositions and concentrations of microflora e.g. the stomach and jejunum contain few 
bacteria due to the lower pH and inhibitory action by bile/pancreatic secretion.  The 
colon contains a much higher concentration of bacteria due to a higher pH, the 
abundance of nutrients and decreased peristalsis (Lennernäs, 2007).  
 
4.2.3.1  Metabolism 
The small intestine plays a significant role in the metabolism of orally administered 
drugs, although it is regarded as an absorptive organ (Lin et al., 1999).  Metabolic 
pathways include both phase I and II reactions (Kaminsky and Zhang, 2003).  Most drug-
metabolising enzymes that are present in the liver are also found in the small intestine, 
but at lower levels (Lin et al., 1999).  The importance of the small intestine‟s metabolising 
enzymes arises from their location in the epithelial cells (enterocytes) and may result in 
the reduced systemic uptake of drugs.  Examples of the enzymes include 
aminopeptidase A, alkaline phosphatase, cytochrome P-450 and UDP-
glucuronosyltransferase (Bohets et al., 2001).  Clinical studies have shown that the small 
intestine contributes substantially to the overall first-pass cytochrome P450-mediated 
metabolism of drugs.  In addition to oxidative metabolism by cytochrome P450, 
hydrolysis is also an important phase I reaction in the biotransformation of ester-
containing drugs. Carboxylesterase is involved in the hydrolysis of a variety of ester- and 
amide-containing endogenous compounds. Carboxylesterases are important in both the 
inactivation of drugs and in the activation of prodrugs and are widely distributed in many 
tissues, including the intestines (Zhang et al., 2002; Satoh and Hosokawa, 1998). 
 
4.2.3.2  Absorption 
4.2.3.2.1  Site of absorption 
Drugs are absorbed throughout the GIT.  Absorption of drugs throughout the GIT varies 
with location.  The stomach is the first site for drug release and absorption.  The pH of 
the stomach in the fasted state usually lies in the range of pH 1-3.  After a meal the pH, 
increases to values up to 7 due to the buffering effects of the food.  For drugs that are 
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highly soluble at a gastric pH, complete dissolution can occur in the stomach, but for 
weak acids little dissolution will occur in the stomach, while high dissolution will occur in 
the small intestine due to this region‟s higher pH.  Poorly soluble neutral compounds 
have slow dissolution in the gastric region and often dissolution is not completed before 
the drug reaches the first absorptive sites in the small intestine.  For poorly soluble weak 
bases, solubility is likely to be higher in the stomach than elsewhere in the GIT.  This 
may result in supersaturation, but precipitation of the drug is hindered by bile 
components as the drug moves out of the stomach into the higher pH of the small 
intestine (Dressman et al., 2007).  The pH of the small intestine is 7-7.8 (Bajpai et al., 
2003).  In the fasted state, it may be below neutral (pH 6-6.5) (Dressman et al., 1990).  
The proximal small intestine‟s pH is influenced more by food intake than the pH of the 
distal regions. 
 
Generally, the upper part of the small intestine is considered to have a higher capacity 
for drug absorption than the lower part.  This is due to an increase in tightness of the 
epithelium in the distal intestinal area, as well as a decrease in total surface area.  The 
luminal pH of the different areas also plays a role.  In mammals/humans the jejunum is 
generally the major absorbing site for most drugs.  It has the largest surface area and it 
is the site of the most active carrier-mediated transport in the gut (Kasim et al., 2004; 
Sun et al., 2002).  The villous structures in the upper intestine enlarge the surface area 
of the intestine membrane.  Villous structures of the jejunum amplify the area four-fold 
compared to the colon and two-fold compared to the ileum.  It seems that this area is 
relatively leaky and therefore contributes to the high permeability of hydrophobic drugs in 
the upper intestinal membrane.  However, some drugs have been reported to exhibit 
high permeability even to the lower part of the intestine (ileum and colon) (Balimane et 
al., 2000).  Generally, the permeability of the colonic membrane is much lower than that 
of the small intestine, but some drugs are known to be absorbed from the colon.   
 
4.2.3.2.2  Absorption and solubility 
The epithelial cells lining the gastrointestinal tract are the major barrier to absorption of 
many orally administered drugs (Jackson, 2005).  They are a heterogeneous population 
of cells that include enterocytes/absorptive cells, goblet cells that secrete mucin, 
endocrine cells, Paneth cells, M cells, tuft cells and cup cells (Madara and Trier, 1987; 
Carr and Toner, 1984).  Enterocytes make up 90 % of the cells in the epithelium and are 
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responsible for the majority of the absorption of both nutrients and drugs in the small 
intestine.  The epithelial membrane controls the transport of both low and high 
permeability compounds regardless of the transport mechanism in vivo (Lennernäs, 
2007).  It is highly polarised with distinct apical and basolateral membranes that are 
separated by tight junctions (Balimane et al., 2000).  The basolateral surface faces the 
bloodstream and the apical surface faces the intestinal lumen.  The membranes around 
the intestinal cells are lipid bilayers containing proteins (e.g. receptors and carrier 
molecules).   
 
The mucus layer at the surface of the intestinal epithelium exhibits a rate-limiting barrier, 
especially against the absorption of highly permeable drugs.  The thickness of the mucus 
layer varies in different luminal segments (Winne and Verheyen, 1990).  The mucous gel 
layer consists of a three-dimensional network of glycoproteins and the extracellular 
matrix comprises tight junctions, which function is regulated by different transmembrane 
and intracellular proteins (Ho et al., 2004).   
 
The small intestine‟s primary source of solubilisation is the bile components.  The bile 
salt conjugates, phospholipids and cholesterol combine (additionally with lipolysis 
products in the fed state) to create mixed micelles that can solubilise lipophilic molecules 
and correlations have been established for solubilisation by mixed micelles as a function 
of logP for neutral compounds (Dressman et al., 2007).  
 
The rate and extend of drug absorption from a solid dosage form during its transit 
through the small and large intestine depends on several factors: drug release and 
dissolution kinetics, stability and binding properties in the lumen, gastrointestinal transit 
time and intestinal permeability (Lennernäs, 2007).  Permeation of compounds across 
the intestinal membrane is a complex and dynamic process.  Two fundamental 
processes determine oral drug absorption: the drug‟s solubility or dissolution rate in 
gastrointestinal fluids and its gastrointestinal permeability through the lipid bilayers of the 
epithelial cells lining the intestinal wall.  However, the permeability of a drug is not a 
simple two-step process of solubilisation and diffusion, but rather consists of a variety of 
complex molecular events (Pleuvry, 2005).   
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4.2.4  Different types of permeation routes 
Most drugs have to cross membranes to exert their pharmacological effect.  It is 
generally accepted that the main barrier to drug absorption is formed by the intestinal 
epithelium.  Several routes can be followed to cross the epithelium and the type of route 
depends on the physicochemical properties of the drug.  Drugs can cross the lipophilic 
membrane of the GIT by mechanisms such as passive diffusion (paracellular and 
transcellular), carrier-mediated process (facilitated and active) and endocytosis.  The two 
passive transport routes entail either the transport of a compound through the cell 
membranes of the enterocytes (transcellular) or via the tight junctions between the 
enterocytes (paracellular) (Balimane et al., 2000).  80-95 % of commercial drugs are 
absorbed primarily by passive diffusion (Mandagere et al., 2002; Steinberg et al., 1996).   
 
4.2.4.1  Lipophilic and transcellular 
When a drug follows passive transcellular transport, it diffuses through the highly 
lipophilic membranes of the GIT epithelium.  This is the predominant route for lipophilic 
compounds (Lennernäs et al., 1997).  The diffusion processes are governed by Fick‟s 
law of diffusion (Martinez et al., 2002).  Transcellular passive diffusion is the most 
significant transport mechanism for intestinal drug absorption and the rate of transport is 
determined by the physicochemical properties of the epithelium, as well as the properties 
of the drug (lipophilicity) (Taub et al., 2002). 
 
4.2.4.2  Paracellular and hydrophilic 
Generally hydrophilic molecules that are not recognised by a carrier are not able to 
partition into the lipophilic intestinal membrane and thus permeate the membrane 
through the paracellular route.  Hydrophilic molecules permeate the intestinal wall 
through the paracellular route located at the tight junctions.  The available surface area 
for paracellular intestinal absorption has been estimated to be about 0.01 % of the total 
surface area of the small intestine (Madara and Pappenheimer, 1987). 
 
Paracellular permeation is mainly determined by the size and the number of pores at the 
tight junctions between the cells.  Permeation is also influenced by the size and the 
charge of the drug (Mälkiä et al., 2004).   There are aqueous channels through which 
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small water-soluble molecules can pass.  The ordered lipid bilayers make it impossible 
for these aqueous channels to be wide enough to admit drug molecules larger than 
approximately 200 Da or 0.4 nm (Martinez et al., 2002; Balimane et al., 2000; Pade and 
Stavchansky, 1997).  Tight junctions restrict the transport of hydrophilic molecules via 
the paracellular pathway.  The intestinal epithelium is composed of intercellular 
junctional complexes that varying tightness along the length of the gastrointestinal tract.  
The tightness of the intercellular junctional complex can be characterised in a leaky to 
tight epithelium by measuring transepithelium electrical resistance (TEER).  The 
epithelium in the jejunum is relatively leaky, whereas the epithelium in the colon is 
tighter. 
 
Larger compounds consequently take the transcellular route, which is also the main 
transport route for hydrophobic molecules.  Therefore, drugs intended for oral 
administration must be sufficiently hydrophilic to dissolve in gastrointestinal fluid, but 
they must also possess sufficient hydrophobic character to undergo passive transport 
across the intestinal epithelia.  It has been suggested that molecules limited to the 
paracellular route have lower absorption characteristics, whereas those using 
transcellular routes have better absorption characteristics (Pade and Stavchansky, 
1997). 
   
4.2.4.3  Active and other transport processes 
Active transport processes require specific binding of the drug to a transporter protein 
and my entail transport into either the cells or efflux out of the cells (Mälkiä et al., 2004).  
A few larger molecules are transferred across the intestinal membrane by a process 
called pinocytosis.  During pinocytosis the cell membrane invaginates to form a vesicle 
around the extracellular molecule and transport it into the cell or to the other side 
(Pleuvry, 2005).  Other influx and efflux mechanisms (via carriers) also exist. 
 
4.2.5  Physicochemical properties of permeants 
Factors such as the log P, hydrogen bonding, solute charge, electrostatics of lipid 
bilayers, solute size and order of the partition phase describe and influence drug 
partitioning into cell membranes.  The permeability of the drugs varies as function of 
surface area to volume ratio and regional pH effects on ionisation (Mälkiä et al., 2004). 
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The driving force for diffusion across the apical and basolateral membranes of the 
enterocytes is the soluble drug concentration gradient and for ionisable drugs this varies 
with the pKa, the pH and the pH profile between the intestinal compartments 
(Hendriksen et al., 2003).     
 
4.2.6  Predicting intestine permeation of compounds 
The pharmacokinetic profile of a drug is dependent on the drug‟s ability to cross 
biological membranes.  The permeability characteristics of compounds therefore affect 
its absorption, distribution and elimination (Mälkiä et al., 2004).  It is estimated that 
approximately 40 % of the failures in drug development programs during clinical phases 
are due to problems in pharmacokinetics and drug delivery (Kennedy, 1997). 
 
The absorption of an orally administered compound depends on many different 
parameters, such as the chemical structure of the drug, permeability of the intestine 
brush border membrane (BBM), intestinal motility, gastrointestinal transit times, fluid 
volume, bile salt composition, enzyme systems, food and the physiological state of the 
human intestinal tissue.  It is therefore clear that the absorption of a drug by the intestine 
is a complex process (Oulianova et al., 2007; Martinez et al., 2002).  
 
It is important that the limiting factor to intestinal absorption can be modelled when using 
in vitro models to predict in vivo performance.  Release of the active compound and 
absorption must occur within the available transit time.  The drug must be released 
before reaching the absorptive site of the GIT and must be stable in the luminal fluids 
(Dressman and Reppas, 2000).  The physicochemical properties of an orally 
administered drug are generally the major determinants of intestinal permeability.  This 
includes molecular size and shape, pKa, lipophilicity (log P/log D), charge/ionisation and 
hydrogen bonding properties.  Solubility of the compound in the intestinal tract is an 
extremely important factor that dictates the dissolution characteristics of the drug and 
eventually influences the bioavailability of the compound.  Even though the underlying 
driver for solubility in the gastrointestinal fluids is the aqueous solubility of the drug, the 
solubility of the drug in the GIT may be influenced by pH profile, solubilisation via 
naturally occurring surfactants and food components, as well as complex formation with 
food and native components of the gastrointestinal contents (Dressman et al., 2007).  
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4.2.6.1  In vitro methods 
Good oral availability is dependent on maximum intestinal permeability and maximum 
solubility/dissolution of the drug at the site of absorption.  The extent of in vivo 
absorption can therefore be predicted based on in vitro permeability and solubility 
measurements.  The research of intestinal permeability represents an essential part in 
the prediction of the oral bioavailability of any new drug candidate (Trapani et al., 2004).  
Due to the multiple processes involved in drug absorption in the intestine, it is often 
difficult to use just one in vitro model to accurately predict the in vivo permeability 
characteristics (Balimane et al., 2000).  Different in vitro methods exist to assess the 
intestinal permeability of potential drug candidates.  Each in vitro method has its distinct 
advantages and disadvantages.  General advantages of in vitro techniques for 
assessment of permeability are that it is less labour and cost-intensive compared to in 
vivo animal studies.   
 
The successful application of in vitro models to predict drug absorption across the 
intestinal mucosa depends on how closely the in vitro model mimics the in vivo intestinal 
epithelium characteristics.  Since it is very difficult to develop a single in vitro system that 
can simulate all the conditions existing in the human intestine, various in vitro systems 
are presently used as decision-making tools in early drug discovery. 
 
4.2.6.1.1  Animal tissue 
Excised animal tissue models have been used since the 1950s to explore the 
mechanism of absorption of nutrients from the intestine.  Animal intestinal tissues consist 
of essentially the same kind of endothelial cells than humans.  Various animal species 
are used for screening the permeability of newly discovered drugs, even though there 
are marketed interspecies differences across animal species such as in vivo drug 
solubility, gastric transit time, intestinal permeability, diet, pH differences and species-by-
formulation interactions (Martinez et al., 2002; Quastel, 1961).   
 
4.2.6.1.2  Everted gut technique 
Wilson and Wiseman (1954) introduced the everted gut technique in the 1950s to study 
the transport of sugars and amino acids from the mucosal to serosal side of the intestine. 
Everted sacs are usually prepared from rat intestine by quickly removing the intestine 
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form the decapitated animal, flushing it with a saline solution, everting it over a glass rod, 
filling it with fresh oxygenated culture medium and then dividing it into sacs (2-4 cm).  
The sacs (mucosal side outside) are submerged in a culture medium containing the drug 
of interest and accumulation of the drug in the inner compartment is measured.  Under 
optimal conditions the sacs remain viable for up to 2 hours. 
 
Advantages of this technique include that the sample volume on the serosal side is 
relatively small and drugs therefore tend to accumulate faster, it is relatively inexpensive 
and regional differences in drug absorption can be compared.  The small volume inside 
the sac (serosal side) may however be a disadvantage, since sink conditions may be lost 
with well-absorbed chemicals.  Other disadvantages include that compounds have to 
cross all the layers (including the muscle layer) of the small intestine instead of just the 
intestinal mucosa, the lack of active blood and nerve supply that can lead to a rapid loss 
of viability and everting the intestinal tissue may lead to morphological damage, causing 
misleading results (Bohets et al., 2001; Wilson and Wiseman, 1954).  
 
4.2.6.1.3  In vitro transport across intestinal segment  
This in vitro method was first demonstrated by Ussing and Zerahn, using an Ussing 
chamber and it has been proved useful for investigations of in vitro transport and 
metabolism.  This method engages the isolation of intestinal tissues, cutting it into strips 
of appropriate size and clamping it on a suitable device.  The permeability of a 
compound is measured based on the appearance of drug in the serosal side of the 
chamber, rather than the disappearance of drug at the mucosal side (Ungell et al., 1998; 
Ussing and Zerahn, 1951). 
 
4.2.6.1.4  Isolated membrane vesicles 
Membrane vesicles were first used in transport studies reported by Hopfer et al. (1973) 
and since then it has been used extensively in transport characterisation studies 
(Waclawski and Sinko, 1996; Sinko et al., 1995; Madara and Trier, 1987).  Brush border 
membrane vesicles can be isolated and prepared from humans and various animal 
species by either conducting intestinal scrapings or from isolated enterocytes.   
 
The membrane vesicles prepared from intestinal tissues provide the flexibility of 
examining the interaction of drugs to a specific membrane of interest (e.g. brush border 
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membrane vs. basolateral membrane of enterocytes).  Vesicles offer an opportunity to 
study the properties of drugs, nutrient transport at cellular level and allow a complete 
manipulation of solute environment both inside and outside of the vesicle.  It is possible 
to isolate the transporter proteins that are specifically expressed on either the brush 
border or the basolateral side of the membranes.  
 
Unfortunately, prepared vesicles are not 100 % pure and generally contain other 
membrane or organelle fragments.  The process of isolation of vesicles often leads to 
damage of the transporter proteins and enzymes.  A sensitive analytical method is 
required for this method of permeability study, since the volume of the vesicles is 
extremely small (Balimane et al., 2000).  
 
4.2.6.1.5  Artificial membranes 
Artificial membranes, such as the Parallel Artificial Membrane Permeability Assay 
(PAMPA) system, mimics passive diffusion of the intestine and offer a potentially high 
throughput approach for the assessment of drug absorption potential, since the majority 
of drugs are mainly absorbed through passive transport.  It consists of a filter-supported 
lipoid membrane in a 96-well microtitre plate format and has gained acceptance by 
several pharmaceutical industries.  Each well is divided into a donor and acceptor 
chamber, separated by a microfilter disc.  Unfortunately, it is impossible to maintain sink 
conditions during this type of permeation experiments, due to the very small volume of 
the donor and acceptor compartments.  It is a static method and, may reduce drug 
permeation rate and lead to its underestimation.  It is therefore continuously subjected to 
new studies for further improvement and optimization (Corti et al., 2006).  
 
4.2.6.1.6  Cell-based 
Cell culture models for drug absorption are based on the assumption that passage of 
drugs across the intestinal epithelium (a monolayer of cells) is the main barrier for drugs 
to reach the portal circulation.  Varieties of cell monolayer models that mimic in vivo 
intestinal epithelium in humans have been developed e.g. Caco-2, HT-29, T-84, MDCK 
and LLC-Pk1 cells (Taub et al., 2002; Balimane et al., 2000).  
 
Caco-2 cells are the most advanced and frequently used cell model to predict small 
intestine drug permeability and absorption (Borchardt, 1995; Artursson et al., 1994; 
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Rubas et al., 1993).  Caco-2 cells are derived from human colon cancer cells 
(adenocarcinoma) that undergo spontaneous enterocytic differentiation in culture and 
can be cultivated to spontaneously differentiate into a monolayer of polarised cells.  
Although they are derived from a colon cancer, they acquire many features of absorptive 
intestinal cells during culture.  They are grown on a semipermeable porous filter, and 
when they reach confluency the cell polarity, tight junctions, transporters, enzymes and 
microvilli are established.  For transport experiments, test compounds are typically 
added to the apical side of the monolayer and appearance in the basolateral 
compartment is measured.  
 
During the last 5 to 10 years there has been a tremendous growth in the use of Caco-2 
cells for the screening of intestinal drug absorption and it has found wide acceptance as 
an intestinal permeability model.  The predictability and utility of this model have been 
demonstrated many times; by many investigators and recently this permeability 
screening tool have been automated (Chong et al., 1997; Artursson and Karlsson, 
1991).  A fully automated Caco-2 cell system allows much greater throughput (500 to 
2000 compounds studies per month), without a proportional increase in resources.  The 
use of 24-well monolayer (cell surface area 0.33 cm2) coupled with the use of LC/MS 
significantly reduced the amount of compound (no more than 50 μg) required to perform 
permeability experiments with this model (Balimane et al., 2000).  
 
However, its use as a high throughput-screening tool is limited by several factors.  Caco-
2 monolayers are considered a good model for compounds that are transported via the 
transcellular pathway, which usually include compounds with moderate lipophilicity.  
Therefore the permeation of more hydrophilic compounds that typically follow the 
paracellular route is often underestimated.  Artursson et al. (1997) reported that the 
expression of the paracellular transport route, active transport routes and efflux systems 
is different in Caco-2 cell lines compared to the human intestine.  Paracellular passage is 
not modelled well with low molecular weight, hydrophilic compounds (e.g. ranitidine, 
atenolol, furosemide, hydrochlorothiazide, etc.).  This type of drugs shows poor diffusion 
in this cell model despite adequate absorption (greater than 50 % of dose) in humans.  A 
great percentage of new drug candidates with poor aqueous solubility cannot be 
evaluated in this model, since the use of organic cosolvents is limited in this model.  The 
integrity of tight junctions is easily compromised by commonly used organic solvents 
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(e.g. methanol, ethanol, PG, PEG, etc.) even at a minute concentration (more than 1-2 
% v/v).  Other shortcomings include the possibility of microbial contamination, being 
labour intensive, high costs, relatively high inter-experiment and inter-laboratory 
variations and long cell growth cycles (Corti et al., 2005).  The preparation of a fully 
functional cell monolayer generally requires a 3-week cell culture period with eight to 
nine laborious cell feedings.  To increase experimental efficacy alternative cell lines have 
been introduced, requiring less than a week of culture by modifying both the coating 
material and growth media (Balimane et al., 2000; Lentz et al., 1998; Chong et al., 
1996).   
 
Caco-2 cells are also known to over express the P-glycoprotein efflux system and this 
may result in the underestimation of the absorption of some compounds.  Nonspecific 
drug binding to plastic devices may further lead to this underestimation of permeability. 
Huge variations in the results obtained from Caco-2 cell studies are documented in the 
literature.  This variability may be attributed to factors such as cell passage number, 
culture time, type of support and medium (Trapani et al., 2004).  Despite these 
limitations and drawbacks, Caco-2 cell model is the most widely used intestinal cell 
culture models at present and it is providing valuable information to the decision making 
process in early drug discovery (Balimane et al., 2000).  
 
Tavelin et al. (1999) recently developed a new cell model that originates from foetal rat 
intestine.  The cell line is called 2/4/A1 and exhibits similar passive absorption (passive 
transcellular and paracellular drug transport) than the human jejunum.  This immortalised 
cell line forms viable, differentiated monolayers with tight junctions, brush border 
membrane enzymes, as well as the transporter proteins.  Since the tight junctions in the 
Caco-2 cell line appear unrealistically tighter than the tight junctions in the endothelial 
cells in human intestine, the 2/4/A1 cells were proposed as a better model to study 
passively transported compounds via the paracellular route.  Due to its lack of functional 
expression of active transport and efflux systems, the 2/4/A1 cell line only holds promise 
for characterisation of the passive absorption of drugs (Mälkiä et al., 2004).  
 
Madin-Darby canine kidney (MDCK) cells are another cell type used as a model to 
evaluate the intestinal transport characteristics of compounds.  MDCK cell lines are 
derived from dog kidney.  The distal tubular part of the nephron are used to differentiate 
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into columnar epithelial cells and to form tight junctions (like Caco-2 cells) when cultured 
on semipermeable membranes (Irvine et al., 1999; Cho et al., 1989).  The advantage of 
these cells is that they form tight junctions after a culture time of only 3 days (Bohets et 
al., 2001).  
 
4.2.6.2  In situ methods 
In situ perfusion involves the use of intestinal segments/sacs of animals (rats, rabbits, 
pig, dog, frog and monkey) and sometimes humans, to study the permeability and 
absorption kinetics of drugs (Trapani et al., 2004).  In situ experiments for studying 
intestinal drug absorption involve the perfusion of a drug solution through isolated 
cannulised intestinal segments.  The hydrodynamics of the buffer flow through the 
intestinal segments may influence the absorption characteristics of the drugs.  This 
technique uses the difference in inlet and outlet flow concentration to calculate the 
permeability.  Absorption is assessed based on the disappearance of drug from the 
intestinal lumen.  Drug absorption will therefore be overestimated if the drug extensively 
accumulates in the intestinal tissue or if significant drug metabolism occurs (Balimane et 
al., 2000).  
  
The advantages of the in situ system compared to in vitro techniques include the 
presence of an intact blood and nerve supply in the experimental animals and the 
barriers that compounds have to cross to reach the portal blood circulation are identical 
in the in situ and in vivo situation (Balimane et al., 2000).  Drug absorption in different 
regions of the small intestine can also be evaluated.  Various modifications of the 
perfusion technique exist: single pass perfusion (Amidon et al., 1981), recirculating 
perfusion (Tsuji et al., 1978), oscillating perfusion and the closed loop method (Doluisio 
et al., 1969).  This methodology is found to be highly accurate for predicting the 
permeability of passively transported compounds, however the use of a scaling factor 
has been recommended for predicting permeability of carrier-mediated compounds 
(Lennernäs, 1998).  
 
Despite its advantages, the use of single pass perfusion method is severely limited due 
to high costs, as it requires a large number of animals to get statistically significant 
absorption data and relatively high amounts of test compounds are required to perform 
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studies (>10 mg), which is not feasible in early drug discovery.  It therefore shows low 
potential for high throughput screening strategies.  Furthermore, the surgical 
manipulation of intestine combined with anaesthesia may cause significant changes in 
the blood flow to the intestine and may have an effect on the absorption rate of the test 
compounds (Balimane et al., 2000; Uhing and Kimura, 1995).   
 
4.2.6.3  In vivo methods 
In vivo methods for evaluation of drug absorption are commonly used, even though it is 
extremely time and resource intensive due to experimental animal work and bioanalysis 
of a large number of samples.  It is based on the similarity of the composition of epithelial 
cell membranes of mammals and the fact that absorption is essentially an interaction 
between the drug and the biological membrane.  These studies should be performed 
with caution due to potential species differences that may affect the drug absorption 
such as pH, GI motility, transit time and differential distribution of enzymes and 
transporters.  Comparison of AUC (plasma concentration vs. time curve) values after 
intravenous, oral and intraportal (or intraperitoneal) administration can often indicate the 
absolute extent of in vivo drug absorption.  This method is able to differentiate well 
absorbed compounds from reduced bioavailable compounds (Balimane et al., 2000).  
 
4.2.6.4  In Silico methods 
In silico methods are based on computational or virtual screenings of physico-chemical 
properties (such as lipophilicity, H bonding capacity, molecular size, polar surface area 
(PSA) and quantum properties) of drugs to predict their oral absorption potential.  A 
variety of computational models exists, due to the increase in computer resources over 
the past decades.  The in silico predictive models minimise the time consuming steps of 
synthesis and safe time by enabling screening of drug candidates prior to synthesis.  
These methods are very attractive, since intestinal absorption can be predicted before 
the synthesis of compounds, but at present their predictive power is unsatisfactory 
compared to experimental models (Corti et al., 2006; Balimane et al., 2000).  
 
To develop reliable and valid computational methods it is important that the quantitative 
structure-activity relationship (QSPR) models should be based on experimental data that 
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were obtained from a diverse set of compounds with respect to their properties (e.g. 
physicochemical and pharmacological) and chemical structures.  At present, most 
reports involve in silico modelling studies performed on compounds closely related in 
structure, thus making the model ineffective when applied to a wider structurally and 
diverse data set (Balimane et al., 2000).  
 
Lipinski and co-workers (2001) developed one of the best-known computational models 
to predict intestinal absorption form molecular properties.  It is based on the 
physicochemical properties of 2200 drug candidates that had entered clinical phase II 
trials.  They formulated a simple rule, taking into account hydrogen boding, molecular 
weight and lipophilicity.  This so-called rule-of-five (ROF) states that a compound is likely 
to have limited oral bioavailability due to low intestinal epithelial permeability or solubility 
if it generates two or more alerts.  The ROF is produced if the number of H-bond donors 
or acceptors in a compound exceeds 5 and 10 respectively; the molecular weight 
exceeds 500, or the lipophilicity expressed as the logarithm of the octanol-water partition 
coefficient (log P) exceeds 5.  Weaknesses of the ROF include that it does not apply to 
compounds that are subject to active transport processes.  It is mainly built on 
compounds with a high intestinal absorption and it gives relatively rough and sometimes 
false predictions (Bohets et al., 2001; Lipinski et al., 2001).  
 
Absorption is a very complex process that cannot be estimated accurately from structure 
alone.  Several companies have therefore attempted to combine parameters that affect 
intestinal absorption in commercial available packages (Bohets et al., 2001).  
  
4.2.6.5  Summary 
Using in silico methods to predict intestinal permeability is attractive because of their 
high throughput capacity, minimum usage of resources and manpower and 
reproducibility to predict passive drug transport.  However, they are often limited in 
scope and do not take into account physiological factors such as drug-membrane 
interactions, that can completely override the physicochemical properties of potential 
drugs.  This lack of real physiological conditions leads to predictions based only on the 
chemical properties of the drug and thus making it vulnerable to false predictions 
(Balimane et al., 2000).   
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Due to modern isolation technology and high throughput biological screen capability a 
reliable, high through put method for evaluating intestinal permeability is essential.  Many 
researchers have attempted to predict the oral absorption of drugs by using animal 
studies and different in vitro, in vivo and in situ models for drug permeability (Oulianova 
et al., 2007).  These systems have presented a compromise either between high 
throughput with low predictive potential or low throughput with high predictive potential 
(Youdim et al., 2003).   
 
4.2.7  Biopharmaceutics Classification System (BCS)  
BCS was introduced in the mid-1990s to function as a scientific framework for classifying 
active pharmaceutical ingredients, based upon their aqueous solubility and intestinal 
permeability.  The Biopharmaceutics Classification System (BCS) classifies drugs in to 
four different classes according to their aqueous solubility and intestinal permeability 
characteristics (rate-limiting biopharmaceutical factors).  The classes are as follows: 
 Class 1: High solubility, high permeability 
 Class 2: Low solubility, high permeability 
 Class 3: High solubility, low permeability 
 Class 4: Low solubility, low permeability (WHO website (b)) 
 
The dissolution of the active pharmaceutical ingredient (API) combined with the 
permeability and solubility properties of an API are the three major factors that govern 
the rate and extent of drug absorption from an immediate release (IR) solid dosage form.  
With respect to dissolution properties, IR dosage forms can be categorised as having 
“very rapid”, “rapid”, or “not rapid” dissolution characteristics (WHO website (a); 
HHS/FDA Guidance for Industry, 2000).  Depending on the classification, the oral 
availability of the compound may be expected to rely heavily on the formulation and 
manufacturing method, e.g. class 2 (low solubility, high permeability) or mostly 
dependent on the permeability properties, e.g. class 3 (highly solubility, low 
permeability). 
 
The FDA issued a guidance for the industry in 2000 on waivers of in vivo bioavailability 
and bioequivalence studies based on the BCS (HHS/FDA Guidance for Industry, 2000).  
These industry guidelines classify under which circumstances bioavailability and/or 
bioequivalence studies may be replaced/waived (not considered necessary for product 
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approval) by in vitro bioequivalence testing.  On the basis of solubility and permeability of 
the API and dissolution characteristics of the dosage form, the BCS approach therefore 
provides an opportunity to waive in vivo pharmacokinetic bioequivalence testing for 
certain categories of IR products.  A biowaiver is allowed for drugs with high solubility 
and high permeability (class 1 compounds) and that are formulated in solid IR oral 
formulations.  These IR compounds are candidates for in vitro assessment of 
bioequivalence, as long as they are stable in the gastrointestinal tract and have a wide 
therapeutic index (Lennernäs, 2007).  Instead of conducting expensive and time 
consuming in vivo studies, an in vitro test could therefore be adopted as the surrogate 
basis for the decision as to whether the two pharmaceutical products are equivalent.  
This can reduce time and costs during the development process and reduce 
unnecessary drug exposure to healthy volunteers in bioequivalence studies (FDA 
Guidance for Industry, 2000). 
 
4.2.7.1  Class boundaries  
4.2.7.1.1 High solubility 
A drug is considered highly soluble when the highest dose recommended by World 
Health Organisation (WHO) (if the drug appears on the WHO Model List of Essential 
Medicines) or highest dose strength available on the market as a oral solid dosage form 
(if the drug does not appear on the WHO Model List of Essential Medicines) is soluble in 
250 ml or less of aqueous media over the pH range of 1.2 to 6.8.  The pH-solubility 
profile of the API should be determined at 37 ± 1°C in aqueous media.  A minimum of 
three replicate determinations of solubility at each pH condition is recommended.  Initial 
recommendations in the BCS Guidance suggested that the solubility should be 
measured over a pH range of 1.2 to 7.5.  Successive scientific discussions and 
publications suggested that a pH range of 1.2 to 6.8 is more appropriate (HHS/FDA 
Guidance for Industry, 2000).  
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4.2.7.1.2  High permeability 
A drug is considered highly permeable when its extent of absorption in humans is 85 % 
or more based on a mass balance determination, or in comparison to an intravenous 
comparator dose.  Initial recommendation in the BCS Guidance suggested an absorption 
value of >90 % as a prerequisite for classification as highly permeable.  However, 
successive scientific discussions and scientific publications suggested lowering the 
criteria to 85 % absorption.  Acceptable test methods for permeability determination of 
the drug substance include: 
1) in vivo intestinal perfusion in humans, or 
2) in vitro permeation, using excised human or animal intestinal tissue 
When one of these two alternative methods is used for permeation studies, suitability of 
the methodology should be demonstrated, including determination of permeability 
relative to the permeability of a reference compound whose fraction dose absorbed has 
been documented to be at least 85 %.  Supportive data can be provided by the following 
additional test methods: 
1) in vivo or in situ intestinal perfusion, using animal models, or 
2) in vitro permeation across a monolayer of cultured epithelial cells (e.g. Caco-   
 2), using a method validated, using APIs with known permeabilities 
 
In vivo, in situ animal models or in vitro models (cell lines) are only considered 
appropriate for passively transported drugs.  The data from either of the two latter 
methods would not be considered acceptable on a standalone basis (HHS/FDA 
Guidance for Industry, 2000; WHO website (a)).  
 
A considerable amount of human permeability data exist.  This database has played an 
important role in classifying drugs in specific BCS categories, which can be used to set 
bioequivalence standards for drug product approval.  Since these permeability data are 
expensive and time consuming, alternative models for prediction of drug absorption and 
permeability are needed and explored.  The BCS Guidance lists in vitro permeation 
using excised human intestinal tissue as one possible permeability classification tool.   
 
4.2.7.1.3  Rapidly dissolving  
A drug product is considered to be rapidly dissolving when >85 % of the labelled amount 
of drug substance dissolves within 30 minutes using United States Pharmacopeia (USP) 
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apparatus I (basket, 100 rpm) or II (paddle, 50 rpm) in a volume of < 900 ml buffer 
solutions (HCl or simulated gastric fluid, pH 4.5 buffer and pH 6.8 buffer or simulated 
intestinal fluid) (HHS/FDA Guidance for Industry, 2000).  
 
4.2.8  Drugs 
Examples of drugs that are already BCS classified were obtained from Aspen 
Pharmacare (South Africa), for the permeability study (Fig. 44): 
Class 1 (high solubility, high permeability): 
 Zidovudine 
 Propranolol HCl 
Class 3 (high solubility, low permeability): 
 Didanosine 
 Enalapril Maleate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 44.  Drugs obtained from Aspen Pharmacare (South Africa), with their BCS 
classification 
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Class 1 and 3 drugs were selected, since dissolution is rate limiting to absorption in the 
case of class 2 and 4 drugs.  Official apparatus for in vitro drug dissolution testing are 
already available and formal guidelines already exist, which provide useful 
recommendations for their correct use (FDA Guidance for Industry, 1997).  Solubility 
screening is relatively routine and techniques ranging from simple turbidity-based 
measurements to true equilibrium solubility measurements are well established (Ingels 
and Augustijns, 2003; Saha and Kou, 2002; Krishna et al., 2001).  It is well documented 
that low dissolution/solution issues can be surmounted by the incorporation of 
cosolvents, surfactants, or complexation agents into the transport buffer to aid 
solubilisation (Takahashi et al., 2002; Yamashita et al., 2000).  The earlier studies on 
vaginal and skin permeation showed that the permeability barriers of biological 
membranes can be overcome by formulation, chemical enhancers and increased 
temperature.  It was therefore beyond the scope of this study to examine class 2 and 4 
drugs.  The absorption of class 1 drugs is rapid and complete, with extents of absorption 
>85 %.  Permeation across the intestinal membrane is the rate limiting step of the 
absorption process for class 3 drugs. 
 
4.2.8.1  Zidovudine (AZT) 
Zidovudine or azidothymidine (AZT, also called ZDV) was the first approved antiretroviral 
drug and is still widely used for treatment against HIV and human T-cell 
immunodeficiency virus (HIV-I and -II).  Its chemical formula is C10H13N5O4 (3‟-azido-3‟-
deoxythymidine) and it has a molecular mass of 267.24 g/mol (Figs. 45 and 49).  
 
Like other reverse transcriptase inhibitors, AZT works by inhibiting the action of reverse 
transcriptase, the enzyme that HIV uses to make a DNA copy of its RNA.  The viral 
double-stranded deoxyribonucleic acid (DNA) is subsequently spliced into the DNA of a 
target cell, where it is called a provirus.  The azido group increases the lipophilic nature 
of AZT, allowing it to easily cross cell membranes by diffusion and thereby to cross the 
blood-brain barrier.  Cellular enzymes convert AZT into the effective 5'-triphosphate 
form.  Previous studies have shown that the termination of the formed DNA chains is the 
specific factor in the inhibitory effect (Brunton et al., 2006).  
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The main limitation to therapeutic effectiveness of AZT is its dose dependent 
haematological toxicity.  It is rapidly absorbed from the gastrointestinal tract with a peak 
plasma concentration of 1.2 µg/ml, at 0.8 h.  It is also rapidly metabolised to the inactive 
glucuronide, with a mean elimination half-life (t1/2) of 1 h, thus necessitating frequent 
administration of large doses to maintain therapeutic drug levels (Thomas and 
Panchagnula, 2002).  Since AZT has a narrow therapeutic index, side effects occur 
frequently. AZT is absorbed rapidly and almost completely, which leads to very high 
initial plasma concentrations and consequently high incidences of toxicity.  
 
Huang et al. previously reported that zidovudine permeates the intestine by a Na+ 
/nucleoside carrier (Huang et al., 1994).  An in vitro, brush border membrane vesicle 
(BBMV) study by Oulianova et al. (2007) confirmed these results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
        
   Fig. 45.  Zidovudine (The Merck Index, 2001)  
 
4.2.8.2  Propranolol hydrochloride 
Propranolol hydrochloride is a commonly used non-selective ß-blocker that is prescribed 
in the management of hypertension, myocardial infarction, angina pectoris, 
phaeochromocytoma and cardiac arrhythmias.  Its chemical formula is C16H21N02.HCl 
and it has a molecular mass of 295.81 g/mol (Figs. 46 and 49). 
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Propranolol is almost completely absorbed after oral administration (>90 %).  Peak 
plasma concentrations are reached within 1-2 h after administration of a single dose.  
Propranolol is almost completely metabolised in the liver and the main metabolites are 
metabolised by cytochrome P450.  The half-life is about 4 h.  The pKa value of 
propranolol is approximately 9.5 and it is highly soluble at a pH of 7.2.  It has a solubility 
of 0.1 g/ml water and has two polymorphic forms (Brunton et al., 2006).   
 
Propranolol is predominantly absorbed by a passive diffusion (transcellular) mechanism 
and has a high partition coefficient (Trapani et al., 2004; Yamashita et al., 1997).  
Solubility will therefore not be the rate-limiting step in the absorption process in the GIT.  
Factors influencing permeability in vitro versus in vivo will be limited, since propranolol is 
a highly lipophilic and since it is transported transcellularly.  The high permeability is in 
line with the reported high oral absorption (>90 %) (Vogelpel et al., 2004).  
 
It is often used as a marker in permeability studies, because of the foregoing properties.  
It has neither affinity for cellular efflux or influx systems and is highly soluble in aqueous 
buffers (Motz et al., 2007). 
 
 
 
 
 
 
 
 
                                 
 
 
   Fig. 46.  Propranolol (The Merck Index, 2001)  
 
4.2.8.3  Didanosine 
Didanosine (2‟-3‟-dideoxyinosine, ddI) is a reverse transcriptase inhibitor and used in 
combination with other antiretroviral drug therapy as part of highly active antiretroviral 
Chapter 4: Small intestine mucosa                                       151 
           
1
5
1
 
therapy (HAART).  Its chemical formula is C10H12N403 and has a molecular mass of 
236.23 g/mol (Figs. 47 and 49). 
 
Didanosine is a nucleoside analgue of the purine nucleoside inosine.  It differs from 
other nucleoside analogues, because it does not have any of the regular bases.  
Instead, it has hypoxanthine attached to the sugar ring.  Within the cell, ddI is 
phosphorylated to the active metabolite 2‟,3‟-dideoxyadenosine-5‟-triphosphate (ddATP) 
by cellular enzymes.  The active metabolite inhibits viral reverse transcriptase and acts 
as chain terminator of the proviral DNA.  Like other anti-HIV nucleoside analogs, it acts 
as a chain terminator by incorporation and it inhibits viral reverse transcriptase by 
competing with natural dATP (Brunton et al., 2006).  
 
Its oral bioavailability is 40 %, but it is variable and dose-dependent.    Didanosine has a 
t1/2 of 1.4 ± 0.3 h and its metabolic pathways have not been fully evaluated in humans.  
The water solubility of didanosine is approximately 30 mg/ml when the pH is below the 
pKa of 9.1 and the solubility increases to >400mg/ml when the pH exceeds 10 
(Anderson et al., 1988a).  Even though didanosine has good solubility, poor intestinal 
permeability may hinder oral absorption of the drug.  It has weak acid stability and is 
easily damaged by the stomach acid.  Therefore, the original formula approved by the 
FDA was chewable tablets that included an antacid buffering compound to neutralize 
stomach acids (Brunton et al., 2006).  
 
 
 
 
 
 
 
                   
                              
 
 
Fig. 47.  Didanosine (The Merck Index, 2001)  
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4.2.8.4  Enalapril Maleate 
Enalapril (L-proline, 1-[N-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-(S)) maleate is an 
angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension 
and some types of chronic heart failure.  Enalapril maleate is the maleate salt of 
enalapril, the ethyl ester of a long-acting angiotensin converting enzyme inhibitor, 
enalaprilat.  Its chemical formula name is C20H28N2O5.C4H4O4 and molecular mass is 
492.52 g/mol (Figs. 48 and 49).   
 
Enalapril maleate was the first member of the group of ACE inhibitors known as the 
dicarboxylate-containing ACE inhibitors and can be administered orally and 
intravenously.  The drug acts by inhibiting the conversion of angiotensin I to angiotensin 
II (a powerful vasoconstrictor). 
   
Enalapril maleate has an oral bioavailability of about 60 % (not reduced by food).  
Enalapril has a half-life of only 1.3 hours, but enalaprilat has a plasma half-life of about 
11 hours, due to the tight binding to ACE.  As a prodrug, enalapril is metabolised through 
hepatic metabolism to the active form enalaprilat by various esterases.  Enalaprilat is the 
active metabolite responsible for the therapeutic action.  It is a dipeptide with a proline 
peptide bond and can exist as rotamers.  The interconversion between cis- and trans-
configurations may lead to poor chromatographic properties and prevents generation of 
a single sharp peak for quantitative analysis (Lee et al., 2003). 
  
 
 
 
  
 
 
 
 
 
    
   Fig. 48.  Enalapril maleate (The Merck Index, 2001)  
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Drugs AZT propranolol HCl 
therapeutic category antiviral anti-hypertensive, 
antianginal, 
antiarrhythmic 
octanol/water partition 
coefficient 
1 3.26 
pKa 9.68 9.5 
solubility  water (1 in 40) 
 alcohol (1 in 14) 
 
 water (0.1 g/ml) 
 alcohol (1 in 20) 
 
Practically insoluble in: 
 ether, benzene, ethyl  
     acetate 
 
MW (g/mol) 267.24 295.81 
 
Drugs didanosine enalapril maleate 
therapeutic category antiviral anti-hypertensive 
octanol/water partition 
coefficient 
0.043  Cis isomer: -0.46 
 Trans isomer: -0.65 
 
pKa 9.1 pKa1 3.0 
pKa2 (25°) 5.4  
solubility  water (1 in 40) 
 alcohol (1 in 1) 
 
 water (high: 25 mg/ml) 
 alcohol (80 mg/ml) 
 
MW (g/mol) 236.23 492.52 
 
Fig. 49.  Physicochemical characteristics of AZT, propranolol HCl, didanosine, 
enalapril maleate (Brunton et al., 2006; The Merck Index, 2001; Dollery et al., 1999) 
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4.2.9  Aim 
Due to modern high-throughput technologies, large numbers of compounds are 
produced by parallel synthesis and combinatorial chemistry.  The pharmaceutical 
industry therefore requires rapid and accurate methods for screening drugs leads for 
intestinal permeability potential in the early stages of drug discovery (Hamalainen and 
Frostell-Karlsson, 2004).  Approximately 50 % of all investigational new drugs fail in pre-
clinical and clinical phases of development due to inadequate absorption, distribution, 
metabolism, excretion and/or toxicity (Hamalainen and Frostell-Karlsson, 2004).  This 
may be decreased by applying efficient in vitro screening methods earlier in the 
discovery process.  It is important to decide as early possible on the most promising 
compound and physical formulation for the intended route of administration.  Reliable in 
vitro models can be applied to determine permeation of the test compounds, which will 
help avoid the wasting of valuable resources on the development of drugs that are 
destined to fail in preclinical and clinical phases due to insufficient absorption properties.  
Several methods have been proposed and investigated for in vitro evaluation and 
prediction of gastrointestinal permeability, but no official method is available at present 
due to certain limitations (Corti et al., 2006).  The BCS allows a biowaiver for solid, IR, 
oral formulations with high solubility and high permeability (class 1 compounds). These 
IR compounds are candidates for in vitro assessment of bioequivalence, as long as they 
are stable in the gastrointestinal tract and have a wide therapeutic index (Lennernäs, 
2007).    
 
The aim of the study was to investigate the permeability of excised human small 
intestine mucosa to 4 different oral, dosage drugs using our flow-through diffusion 
system.  The 4 drugs were selected as representative model compounds of drug classes 
1 (high solubility, high permeability) and 3 (high solubility, low permeability) according to 
the Biopharmaceutics Classification System (BCS).  Furthermore, the objectives of the 
study were to determine the suitability of our in vitro diffusion model to evaluate and 
predict in vivo gastrointestinal drug permeability and to compare it with the BCS 
permeability classification.  Also to establish a standard procedure of determining drug 
permeability class that may potentially be used for the establishment of drug product 
bioequivalence standards.   
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4.3  Materials and Methods 
4.3.1  Small intestine mucosa 
Six human jejunal specimens were obtained from excess tissue removed from 2 female 
and 4 male patients, mean age 43 ± 9 SD (range:33-54) yr, following various surgical 
procedures at Tygerberg Hospital, Bellville, South Africa.  No specimens were obtained 
where there was clinical evidence of any disease that might have influenced the 
permeability characteristics of the intestine. 
 
All jejunal specimens were immediately placed in a transport fluid after removal and kept 
at 4 ºC.  The transport fluid consisted of a stock solution of Eagle‟s Minimum Essential 
Medium (MEM) without L-glutamine and sodium bicarbonate (Gibco, Paisley, Scotland), 
to which the latter as well as an antibiotic (penicillin/streptomycin, 100 IU/ml) and an 
antimycotic (amphotericin-B, 2.5 μg/ml) were added prior to using it for the transport of 
tissue specimens.  The intestine tissue was transferred to our laboratory within 2 hours.  
At the laboratory the serosal, muscularis externa and excess connective tissue were 
trimmed away using a forceps and scalpel.  Specimens from each patient were snap-
frozen in liquid nitrogen and stored at -85 ˚C.  The frozen mucosal specimens were 
equilibrated in PBS (pH 7.4) for 30 min at room temperature to thaw completely prior to 
the start of each experiment, after which they were carefully cut into 5 X 5 mm 
specimens, so as not to damage the epithelial surfaces. 
 
The Ethics Committee of Stellenbosch University and the Tygerberg Academic Hospital 
approved the study.  Project number:  95/019 (resubmitted and approved on 28/7/03). 
 
4.3.2  Drugs 
Examples of drugs that are already classified (BCS) as high and low permeability drugs 
(class 1 - high solubility, high permeability and class 3 - high solubility, low permeability) 
were supplied by Aspen Pharmacare (South Africa): 
Class 1: 
 Zidovudine 
 Propranolol HCl 
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Class 3: 
 Didanosine 
 Enalapril Maleate 
 
4.3.3  Permeability experiments 
The specimens of jejunal mucosa were mounted in flow-through diffusion cells (exposed 
circular areas 0.039 cm2) and each permeation study was performed on 7 tissue 
replicates from each patient (Van der Bijl et al., 2003).  The mucosal tissue was mounted 
between the donor and acceptor compartments and the epithelial/mucosal side faced 
towards the donor compartment.  Tissue disks were equilibrated for 10 min in PBS (pH 
7.4) at 37 ºC in both the donor and acceptor compartments of the diffusion cells before 
each permeability experiment started.   This step was followed by the removal of the 
PBS from the donor compartment and the addition of 0.5 ml of PBS containing 5 mg/ml 
zidovudine, propranolol hydrochloride, didanosine or enalapril maleate.  The drug-
containing PBS solutions were prewarmed to 37 ºC.  
 
The donor compartments were covered with adhesive tape to prevent evaporation.  
Some patients‟ samples were investigated from 0-6 h, while other patients‟ tissues were 
used from 6-24 h.  The reasons for this division were mainly to safe consumables and 
money.  PBS at 37 ºC was pumped through the acceptor chambers at a rate of 1.5 ml/h 
and collected by means of a fraction collector, at 2-h intervals for the 6 h experiment and 
at 6-h intervals for the 6-24 h experiment.  The total time of the 2 experiments was 24 h.  
The zidovudine, propranolol, didanosine or enalapril in the acceptor chambers was 
quantified by means of LC/MS analysis. 
 
Intra- and inter-experiment variations were calculated for the AZT, propranolol, 
didanosine and enalapril experiments (SD/mean x 100). 
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4.3.4  LC/MS detection of zidovudine, propranolol, didanosine 
and enalapril 
Permeant-containing effluent samples, collected from the acceptor compartment of the 
perfusion apparatus over the 2-24 h sampling intervals were analysed using a LC/MS.  
Determination was conducted under the following LC/MS conditions: 
LC: Waters 2695 Separations Module (Alliance)  
MS: Waters API Quattro Micro, electrospray positive 
 
The standards of the four selected drugs were dissolved in the same PBS as the drug 
containing samples collected from the flow-through diffusion system to prevent matrix 
suppression.  Fresh or new standards were made for each experiment and all the 
samples were analysed on one day.  Standards were also injected before and after the 
sample analyses to monitor variation between different days. 
 
The coefficient of determination was better than 0.99 for all the analytes (R2) and the 
reproducibility of 6 injections from standards from 6 different vials were better than a % 
RSD of 2 % for all analytes. 
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min
1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0
%
0
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F1:MRM of 2 channels,ES+
268.1 > 127
3.466e+005
EP_Tyg_080326_7 AZT MRM1
5.03
Compound name: AZT MRM1
Coefficient of Determination: R^2 = 0.998111 
Calibration curve: -25.3586 * x^ 2 + 7957.62 * x + 477.551
Response type: External Std, Area
Curve type: 2nd Order, Origin: Exclude, Weighting: Null, Axis trans: None
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4.3.4.1  Zidovudine (AZT)  
Column: Waters Xbridge C18 3.5 µm, 2.1 x 50 mm 
Mobile phase: Solvent A: 0.01 % trifluoro acetic acid, Solvent B: acetonitrile 
Injection volume: 10 µl; Retention time: 5.03 min; Flow rate: 0.35 ml/min 
Gradient: Start at 100 % solvent A, hold for 0.5 min, followed by a linear gradient to 100 
% B over 7.5 min, hold at 100 % B for 1 min followed by re-equilibration to initial 
conditions. 
MS conditions: Two MRM transitions were monitored, the primary at 268.1>127 at a 
collision energy of 20 eV and Cone voltage of 15 V, and the second 268.1>142.1 at a 
collision energy of 10 eV and Cone voltage of 15 V conditions.  The calibration curve 
and chromatogram of AZT are shown in Figs. 50 and 51. 
 
 
 
 
 
 
 
 
 
Fig. 50.  Calibration curve of AZT 
 
 
 
 
 
 
 
 
 
 
 
Fig. 51.  Chromatogram of AZT 
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min
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0
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F1:MRM of 2 channels,ES+
260.2>183
1.356e+006
EP_Tyg_080415_90  Smooth(Mn,1x3) Propanolol
7.55
Compound name: Propanolol
Coefficient of Determination: R 2^ = 0.998992 
Calibration curve: -464.892 * x 2^ + 45211.6 * x + 12282.7
Response type: External Std, Area
Curve type: 2nd Order, Origin: Include, Weighting: Null, Axis trans: None
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4.3.4.2  Propranolol 
Column: Waters Atlantis dC18 3 µm, 2.1 x 150 mm 
Mobile phase: Solvent A: 1 % formic acid, Solvent B: acetonitrile 
Injection volume: 4 µl; Retention time: 7.55 min; Flow rate: 0.2 ml/min 
MS conditions:  Two MRM transitions were monitored, the primary at 260.2>116 at a 
collision energy of 15 eV and Cone voltage of 18 V, and the second 260.2>183 under 
the same conditions.    
HPLC Gradient: Start at 95 % solvent A, hold for 0.5 min, followed by a linear gradient to 
100 % B over 1.5 min, hold at 100 % B for 2 min followed by re-equilibration to initial 
conditions.  The calibration curve and chromatogram of propranolol are shown in Figs. 
52 and 53. 
 
 
 
 
 
 
 
 
 
 
Fig. 52.  Calibration curve of propranolol 
 
 
 
 
 
 
 
 
 
Fig. 53.  Chromatogram of propranolol 
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Compound name: Didanosine
Correlation coefficient: r = 0.990101, r 2^ = 0.980301
Calibration curve: 2534.72 * x + 7686.92
Response type: External Std, Area
Curve type: Linear, Origin: Include, Weighting: Null, Axis trans: None
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Didanosine
4.3.4.3  Didanosine 
Column: Waters Xbridge C18, 2.1 x 50 mm 
Mobile phase: Solvent A: 0.01 % TFA acid, Solvent B: acetonitrile 
Injection volume: 4 µl; Retention time: 4.69 min; Flow rate: 0.35 ml/min 
Gradient: Start at 100 % solvent A, hold for 0.5 min, followed by a linear gradient to 20 % 
B over 3.5 min and another linear gradient to 100 % B over 1.5 min, hold at 100 % B for 
0.5 min, followed by re-equilibration to initial conditions. 
MS conditions: One MRM transition was monitored 237>137 a collision energy of 15 eV 
and Cone voltage of 15 V.  The calibration curve and chromatogram of didanosine are 
shown in Figs. 54 and 55. 
  
 
 
 
 
 
 
 
 
 
Fig. 54.  Calibration curve of didanosine 
 
 
 
 
 
 
 
 
 
 
 
Fig. 55.  Chromatogram of didanosine 
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Compound name: Enalapril MRM2
Coefficient of Determination: R^2 = 0.998630 
Calibration curve: -134.385 * x^ 2 + 37775.1 * x + 27563.4
Response type: External Std, Area
Curve type: 2nd Order, Origin: Exclude, Weighting: Null, Axis trans: None
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4.3.4.4  Enalapril 
Column: Waters Atlantis dC18 3 µm, 2.1 x 150 mm 
Mobile phase: Solvent A: 1 % formic acid, Solvent B: acetonitrile 
Injection volume: 5 µl; Retention time: 8.33 min; Flow rate: 0.2 ml/min 
Gradient: Start at 95 % solvent A, hold for 0.5 min, followed by a linear gradient to 100 % 
B over 3.5 min, hold at 100 % B for 2 min, followed by re-equilibration to initial 
conditions. 
MS conditions: Two MRM transitions were monitored, the primary at 376.9>234.1 at a 
collision energy of 20 eV and Cone voltage of 15 V, and the second 376.9>303.2 under 
the same conditions.  The calibration curve and chromatogram of propranolol are shown 
in Figs. 56 and 57. 
 
 
 
 
 
 
 
 
 
Fig. 56.  Calibration curve of enalapril 
 
 
 
 
 
 
 
 
 
 
Fig. 57.  Chromatogram of enalapril 
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4.3.5  Calculation of flux values 
The flux values (J) across the membranes were calculated by means of the following 
relationship: J = Q/(A x t), where Q is the quantity of substance crossing membrane (in 
µg), A is the membrane area exposed (in cm2) and t is the time of exposure (in min).  
The trapezoid method of obtaining area under curve (AUC) was used. 
 
4.3.6  Steady state kinetics and statistical analysis of data 
Repeated measure ANOVA over all time periods and a Bonferroni multiple comparison 
procedure was used to determine steady state.  If at consecutive time periods p-values 
exceeded 0.05, these flux values do not differ significantly, therefore indicating steady 
state. Repeated measures ANOVA, Bonferroni multiple comparison procedures and a 
Bootstrap test were performed for comparative purposes.  A significant level of 5 % was 
used for all tests and comparisons. 
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4.4  Results 
The overall mean flux values of zidovudine, propranolol, didanosine and enalapril across 
human small intestine mucosa versus a 24 h period were investigated in two 
sections/time periods.   
 
There are relative correspondences between the mean flux measures of the two groups 
at 6 h, but since these are essentially two groups, the analysis for each time period was 
done separately and not as one.  During each time period a repeated measures ANOVA 
was done among the four different test drugs‟ (zidovudine, propranolol, didanosine and 
enalapril) mean flux values across intestine mucosa over time. 
 
During the first time period (0-6 h) there were significant interactions (F(9, 141)=3.553 
with p=0.0005) among the four drugs‟ flux values and time, indicating that the drugs 
caused different mean flux values across the mucosa over time (Fig. 58).  A Bonferonni 
corrected multiple comparisons method was used to compare the interactions (e.g. 
mean flux values over time).  The mean flux values for AZT were not significantly higher 
(p>0.05) than propranolol for time 2-6 h, but was significantly higher than didanosine and 
enalapril for time 2-6 h. 
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   AUC/6 h for AZT: 7.83 ± 1.36 µg.cm-2.min-1 
   AUC/6 h for Propranolol: 4.88 ± 0.37 µg.cm-2.min-1 
   AUC/6 h for Didanosine: 4.05 ± 0.24 µg.cm-2.min-1 
   AUC/6 h for Enalapril: 3.09 ± 0.54 µg.cm-2.min-1 
 
Fig. 58.  Overall mean flux values of AZT, propranolol, didanosine and enalapril 
across the intestinal mucosa 
 
 
  
Chapter 4: Small intestine mucosa                                       165 
           
1
6
5
 
0 4 8 12 16 20 24
0
5
10
15
20
AZT
Propranolol
Didanosine
Enalapril
Bar=SEM
Time (h)
F
lu
x
 (
µ
g
.c
m
-2
.m
in
-1
)
Similar repeated measures ANOVA was done among the different drugs‟ flux values 
over time to compare the mean flux values across the intestine mucosa among the four 
drugs for time 6-24 h (Fig. 59).  Over this time period there was also significant 
interaction (F(9, 297)=3.2667, p=0.00083), but none of the drugs‟ mean flux values was 
significantly different from the others at each time point using a Bonferroni correlated 
multiple comparisons procedure.  AZT, propranolol and didanosine reached steady state 
at 6 h, whereas enalapril reached steady state at 12 h (Fig. 59b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
   AUC/18 h for AZT: 9.59 ± 1.45 µg.cm-2.min-1 
   AUC/18 h for Propranolol: 11.07 ± 1.38 µg.cm-2.min-1 
   AUC/18 h for Didanosine: 7.44 ± 0.79 µg.cm-2.min-1 
   AUC/18 h for Enalapril: 11.40 ± 1.17 µg.cm-2.min-1 
 
Fig. 59.  Overall mean flux values of AZT, propranolol, didanosine and enalapril 
across the intestinal mucosa   
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Cell No. TREATMENT TIME {1} {2} {3} {4} {5}
1 AZT 0 0.032 0.033 0.000 0.001
2 AZT 6 0.032 1.000 1.000 1.000
3 AZT 12 0.033 1.000 1.000 1.000
4 AZT 18 0.000 1.000 1.000 1.000
5 AZT 24 0.001 1.000 1.000 1.000
TREATMENT TIME {6} {7} {8} {9} {10}
6 Propranolol 0 0.002 0.000 0.000 0.001
7 Propranolol 6 0.002 1.000 1.000 1.000
8 Propranolol 12 0.000 1.000 1.000 1.000
9 Propranolol 18 0.000 1.000 1.000 1.000
10 Propranolol 24 0.001 1.000 1.000 1.000
TREATMENT TIME {11} {12} {13} {14} {15}
11 Didanosine 0 0.019 0.000 0.001 0.000
12 Didanosine 6 0.019 1.000 1.000 1.000
13 Didanosine 12 0.000 1.000 1.000 1.000
14 Didanosine 18 0.001 1.000 1.000 1.000
15 Didanosine 24 0.000 1.000 1.000 1.000
TREATMENT TIME {16} {17} {18} {19} {20}
16 Enalapril 0 0.041 0.000 0.000 0.000
17 Enalapril 6 0.041 0.411 0.000 0.000
18 Enalapril 12 0.000 0.411 1.000 1.000
19 Enalapril 18 0.000 0.000 1.000 1.000
20 Enalapril 24 0.000 0.000 1.000 1.000
Bonferroni test; variable DV_1 (AZT, Propranolol, Didanosine, Enalapril)
Probabilities for Post Hoc Tests
Error: Between; Within; Pooled MS = 63.088, df = 422.45
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 59b.  AZT, propranolol and didanosine reached steady state at 6 h, whereas 
enalapril reached steady state at 12 h 
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The mean flux values for AZT, propranolol, didanosine and enalapril across the intestinal 
mucosa are shown as column bars for the time periods 2-4 and 4-6 h in Fig. 60. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 60.  Mean flux values of AZT, propranolol, didanosine and enalapril across the 
intestinal mucosa at different time periods 
 
Between the time (h) periods 2-4 and 4-6 AZT‟s mean flux values were respectively 1.8 
and 2.0 times higher (p˂0.5) than didanosine and 2.3 and 2.2 times higher (p˂0.5) than 
enalapril.  Between both the time periods 2-4 and 4-6 h AZT‟s mean flux values were 1.4 
times higher (p>0.5) than propranolol and didanosine‟s mean flux values were 
respectively 1.3 and 1.1 times higher (p>0.5) than enalapril during the mentioned time 
periods.  Propranolol‟s mean flux values were respectively 1.2 and 1.4 times higher than 
didanosine and 1.6 higher than enalapril during both the 2-4 and 4-6 h time periods 
(p>0.05). 
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Similar repeated measures ANOVA and a Bonferroni corrected multiple comparisons 
method as previously mentioned, as well as a Bootstrap test were used to compare the 
interactions (e.g. mean flux values over time) for the class 1 and 3 drugs (Fig. 61).  The 
mean flux values of the class 1 drugs across intestine mucosa were significantly 
(p<0.05) higher than for the class 3 drugs from time period 2-6 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   AUC/6 h for class 1: 6.35 µg.cm-2.min-1 
   AUC/6 h for class 2: 3.63 µg.cm-2.min-1 
 
Fig. 61.  Mean flux values over time (0-6 h) for the class 1 and 3 drugs 
 
The intra-experiment variations for AZT, propranolol, didanosine and enalapril were 
respectively 57.9, 48.7, 46.4 and 56.0 % and the inter-experiment variations were 
respectively 41.0, 26.4, 22.2 and 20.6 %.  
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4.5  Discussion 
Several methods have been proposed and investigated for in vitro evaluation and 
prediction of gastrointestinal permeability of drugs, but no official method is available at 
present due to certain limitations (Corti et al., 2006).   
 
The flux rates of the 4 chosen test drugs were significantly influenced by the length of 
the experiment.  Steady state fluxes were obtained for all 4 permeants that diffused 
across the intestinal mucosa during the 6-24 h period.  The steady state fluxes for AZT, 
propranolol and didanosine were obtained after 6 h and for enalapril it was reached after 
12 h.   
 
Even though didanosine has the smallest molecular weight (236.23 g/mol) of the 4 
compounds, this compound had the second lowest AUC during the first 6 h (Fig. 58) and 
lowest AUC between 6-24 h (Fig. 59), which correlates well with its BCS classification as 
a class 3 drug.  Although the oral bioavailable delivery of didanosine has been 
extensively studied, the exact reasons for its limited oral bioavailability remain unknown.  
Didanosine has weak acid stability and it‟s in vivo bioavailability is incomplete and 
erratic, even when it is administered with antacids.  The mean fraction available is 43 %, 
with a range of 16-54 % (Knupp et al., 1991).  Once-daily didanosine doses lead to 
significant reductions in bioavailability in comparison to the same amount given twice 
daily, suggesting the involvement of a saturable process (Drusano et al., 1992).  The low 
and variable absorption of didanosine can be partially attributed to the first-pass 
elimination of didanosine by the liver, presumably by a purine nucleoside phosphorylase 
(PNP) enzyme.  Presystemic metabolism in the intestinal wall does not contribute 
significantly to the first-pass elimination of didanosine, but degradation of unabsorbed 
didanosine by the intestinal flora in the lower intestinal tract may possibly be involved 
(Bramer et al., 1993).  Consistent with this possibility, other authors have shown that the 
intestinal permeability of didanosine, that is a relatively hydrophilic molecule (Fig. 49), is 
low.  The main route for diffusion of didanosine through gastrointestinal epithelium is via 
paracellular transport and it is regionally dependent, decreasing significantly in the 
terminal ileum and proximal ascending colon (Sinko et al., 1997; Sinko and Hu, 1996; 
Sinko et al., 1995).  Although these studies suggest that slow absorption coupled with 
degradation in the lower intestine may play a role, the exact reason for the low and 
variable oral bioavailability of didanosine remains to be conclusively identified. 
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The mean flux values for AZT, propranolol, didanosine and enalapril across the intestinal 
mucosa are shown as column bars for the time periods 2-4 and 4-6 h in Fig. 60.  It was 
decided to choose these specific time periods to compare mean flux values of the 4 
chosen compounds, since the small intestinal transit time is generally considered to 
range between 3.5 and 4.5 h (Dressman and Krämer, 2005; Yu et al., 1996).  The 
mentioned time periods are before the four drugs reached steady state.  AZT, 
propranolol and didanosine reached steady state after 6 h and enalapril after 12 h.  
AZT‟s mean flux values between the time (h) periods 2-4 and 4-6 were respectively 1.8 
and 2.0 times higher (p<0.05) than didanosine and 2.3 and 2.2 times higher (p<0.05) 
than enalapril.  AZT has a higher molecular weight (267.24 g/mol) compared to 
didanosine (236.23 g/mol), but it showed a higher mean flux rate than didanosine for 
both the 0-6 h and 6-24 h period experiments.  Both AZT and didanosine reached steady 
state at 6 h.  Huang et al. previously reported that AZT permeates the intestine by a Na+ 
/nucleoside carrier (Huang et al., 1994).  An in vitro, brush border membrane vesicle 
(BBMV) study by Oulianova et al. (2007) confirmed these results.  Sinko et al. (1997; 
1995) ruled out a significant carrier-mediated absorption of didanosine through rat 
intestinal brush border membrane vesicles, even though transporters are known to play 
an important role in the disposition of didanosine in other tissues.  The carrier system 
involved with AZT absorption, may therefore explain its higher permeability rate across 
the small intestine. 
 
Both AZT and propranolol HCl belong to BCS class 1, but interestingly AZT‟s mean flux 
values between the time (h) periods 2-4 and 4-6 AZT‟s were during both time periods 1.4  
higher (p>0.5) than propranolol.  AZT is absorbed by carrier mediated transport, 
whereas propranolol is predominantly absorbed by a passive diffusion mechanism.   
 
The results of the present study concur with other in vitro and in vivo studies that showed 
that propranolol HCl has a high partition coefficient (Trapani et al., 2004; Yamashita et 
al., 1997).  Factors influencing permeability of propranolol HCl in vitro versus in vivo will 
be limited, since propranolol HCl is transported transcellularly and neither has affinity to 
cellular efflux or to influx systems (Vogelpoel et al., 2004; Pade and Stavchansky, 1998).  
The high permeability is in line with the reported high oral absorption (>90 %) and BCS 
classification as a class 1 drug (Vogelpel et al., 2004).  The results are in contrast with 
other authors that found that propranolol had a high affinity for negatively charged 
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components of tissue, due to its cationic structure and therefore had a low permeability 
in vitro.  It seems that the flow-through diffusion system used in the present study were 
able to overcome this problem by having a constant flow of buffer and concentration 
gradient between the acceptor and donor compartments.  It therefore does not exhibit 
the problem of an unstirred waterlayer. 
 
During time periods 2-4 and 4-6 h the mean flux values of didanosine were very similar 
to enalapril.  Didanosine‟s mean flux values were respectively 1.3 and 1.1 times higher 
(p>0.5) than enalapril during the mentioned time periods, which correlate well with the 
same BCS classification of these two test drugs as class 3.   
 
Enalapril maleate is an amino acid ester prodrug and the transport of enalapril maleate 
in rats and Caco-2 cells has been shown to be a combination of both passive and active 
processes, involving a carrier-mediated peptide transport system (Li et al., 2006; 
Friedman and Amidon, 1989a;b).  From the results obtained in the 0-6 h period mean 
flux graph (Fig. 58), it was clear that the order of the AUC‟s of the 4 drugs studied during 
this time period were AZT > propranolol > didanosine > enalapril.  Enalapril reached 
steady state last (Fig. 59b), but at the end of the 24 h period enalapril exhibited the 
highest mean flux rate across intestinal mucosa even though it has the highest molecular 
weight (492.52 g/mol) of the four test drugs.  The high, mean end flux of enalapril 
despite its initial low mean flux rate, may be explained by the combination of passive and 
active processes.   
 
The BCS Guidance considers the use of excised human intestinal tissue as an 
acceptable test method for determination of permeability of drugs.  Supportive data can 
be provided by in vitro permeation across Caco-2 cells.  It is considered by some to be 
the „gold standard‟ technique (Hamalainen and Frostell-Karlsson, 2004).  Caco-2 cells 
possess many qualities of enterocytes.  Cell cultured monolayers tend to be “flat”, 
whereas the human jejunum is highly folded.  This difference does not appear to 
dramatically affect the correlation of drug transport for passively diffused compounds 
utilizing transcellular routes, since the brush-border region of enterocytes appears to be 
responsible for the vast majority of drug absorption (Press and Grandi, 2008).  Similar to 
Caco-2 cell model the flow-through diffusion model used in the present study require 
small quantities (mg) of compound.   
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Although the Caco-2 cell culture model is commonly accepted and used for the 
screening of potential drug candidates to predict intestinal absorption, many 
shortcomings remain associated with this model.  Compared to Caco-2 cells the present 
in vitro assay does not have the drawbacks such as long cell growth cycles, high costs, 
the absence of mucus, no cellular heterogeneity, tightness of epithelium (therefore less 
permeable than human intestinal epithelium), thickness of unstirred waterlayer and the 
possibility of microbial contamination (Ingels and Augustijns, 2003; Wikman et al., 1998).  
Other advantages of the present in vitro model include that regional differences in 
intestinal absorption can possibly be studied, the collected samples are analytically 
clean and species differences with respect to intestinal absorption characteristics can 
also possibly be determined.  The present model offers the possibility to study 
bidirectional transport and the effect of specific transport inhibitors.  Generally drug 
candidates with poor aqueous solubility cannot be evaluated in the Caco-2 cell model, 
since the use of organic cosolvents is limited in this model.  The integrity of tight 
junctions is easily compromised by commonly used organic solvents.  The results from 
the previously described vaginal mucosa and skin tissue study show that the in vitro 
diffusion model used in the present study can overcome this problem and the effects of a 
chemical enhancer can successfully be studied using the present model.  Other 
disadvantages of the Caco-cells include the absence of CYP3A4 and the variable 
expression of metabolic enzymes and transporter enzymes (Bohets et al., 2001; Barthe 
et al., 1999; Hidalgo, 1996).  Future studies with the in vitro flow-through diffusion 
system should therefore investigate the exact presence and influence of CYP3A4, 
metabolic enzymes and transporter enzymes. 
   
The mean flux values of the class 1 drugs (AZT and propranolol) over the 0-6 h periods 
of the experiment were significantly (p<0.05) higher than the permeability results from 
class 3 drugs (didanosine and enalapril) (Fig. 61).  By comparing the permeability results 
of this study with the BCS classification, it may be possible that the present in vitro 
system may have future usefulness for the permeability prediction of class 1 and 3 drugs 
in humans.  The results of this study show that the permeability/flux values obtained with 
the developed flow-through diffusion method are good predictors of the small intestine 
permeability to passively and carrier mediated absorbed drugs in humans.  The 
proposed method allowed obtainment of good results for both high permeability and low 
permeability compounds and drugs that are absorbed by passive transcellular diffusion 
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and by transport-mediated drug absorption.  Other authors only found a correlation 
between human in vivo and in vitro permeability for drugs absorbed by passive 
transcellular diffusion and a considerable deviation for transport-mediated drug 
absorption (Usansky and Sinko, 2005; Sun et al., 2002; Lennernäs et al., 1997).  The in 
vitro model has proved to be reliable to predict permeability and also showed correlation 
with human in vivo data.  Such a model may potentially facilitate drug discovery and 
development, as well as regulatory standards for marketed products.  This could reduce 
costs and time during the development process and reduce unnecessary drug exposure 
to healthy volunteers.  However, only limited amount of experiments could be conducted 
due to financial restrictions.  Further permeability studies with this model are therefore 
necessary to enlarge the set of flux values of already BCS classified drugs, so that clear 
flux value margins can be established for the specific BCS classes.  These established 
flux value ranges will help to accurately classify the permeabilities of future test 
compounds.  An in-depth investigation of pH influence, formulations for the solubilisation 
of the test compounds and an adequate further enlargement of the set of drugs will be 
necessary to better evaluate the actual permeability predictive power of the present flow-
through diffusion system.    
  
The BCS allows a biowaiver for solid, IR oral formulations with high solubility and high 
permeability (class 1).  These IR compounds are candidates for in vitro assessment of 
bioequivalence as long as they are stable in the gastrointestinal tract and have a wide 
therapeutic index (Lennernäs, 2007).  Instead of conducting expensive and time 
consuming in vivo studies, an in vitro test could therefore be adopted as the surrogate 
basis for the decision as to whether the two pharmaceutical products are equivalent.  
This can reduce time and resources during the development process and reduce 
unnecessary drug exposure to healthy volunteers in bioequivalence studies (FDA 
Guidance for Industry, 2000).  In view of the above considerations and the results found 
in the present study, it can be concluded that the flow-through diffusion system may 
have potential usefulness for future in vitro BA/BE determinations. 
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Chapter 5:  General discussion and conclusions 
Human vaginal tissue was used to test the in vitro flow-through diffusion model‟s 
suitability to evaluate the permeability of vaginal mucosa to three different peptides and 
to evaluate it‟s value to examine test conditions such as different temperatures and 
concentrations, removal of epithelium and the use of a surfactant.  It has been 
demonstrated that the de-epithelialisation of the vaginal mucosa increased the 
permeability of all three peptides tested in the study.  This supports the premise that the 
main epithelial barrier is located in the epithelium and may have possible implications of 
increased microbicide, as well as HIV uptake in vivo.  Furthermore, the results of the 
study show the concentration- and temperature dependency of flux rates of peptides 
across vaginal mucosa.  This should be taken into consideration for determining 
optimum diffusion conditions for in vitro permeability studies.  Decreased mucosal 
permeability could possibly be offset by the addition of an appropriate surfactant-
containing permeation enhancer. The results has demonstrated that the effects of 
concentration, temperature, de-epithelialisation and permeation enhancers on vaginal 
permeability  can successfully be studied with the in vitro flow-through diffusion model of 
the present study. 
 
Human skin tissue was utilised to assess the in vitro flow-through diffusion model‟s 
ability to evaluate the permeability of skin to terbinafine hydrochloride and tritiated water.  
The test conditions that were investigated included the use of different formulations and 
concentrations, and the effect of different temperatures on the permeability of skin to 
tritiated water.   
 
Terbinafine from different formulations readily diffused into skin tissue, but no flux values 
through skin into the acceptor fluid were observed with any of the terbinafine 
hydrochloride formulations.  This reservoir effect of terbinafine has clinical value, since 
the accumulation of terbinafine in the skin tissue reduce systemic absorption.  The 
results of this in vitro study concur with other in vivo and in vitro studies.  The in vitro 
model used in the study has predictive values for in vivo studies and has demonstrated 
that the uptake of terbinafine and potential other drugs by the skin can be determined by 
this model.  It may therefore serve as a prospective method for assessing the 
bioequivalence of alternative (generic) vehicles or formulations containing the same drug 
and for the comparison of potential penetration enhancers.  Predicting skin permeation 
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of compounds has many advantages for the pharmaceutical, cosmetic and agrochemical 
fields. 
   
Furthermore, the results of the study show the concentration and formulation 
dependency of the absorption of terbinafine by skin tissue.  This should be taken into 
consideration for determining optimum diffusion conditions for in vitro and in vivo 
permeability studies.  In vivo assessment of topical drug bioavailability may be expensive 
and also is not always easily accomplished and a reliable in vitro model to assess 
preclinical formulations will be very beneficial.   
 
Increasing the normal skin temperature from 32 to 37 ºC significantly increased the 
permeated amount of tritiated water through human skin.  The in vitro flow-through 
diffusion system has the potential to serve as a tool to study application of heat as a 
penetration enhancer and may potentially be used for predicting flux rates across human 
skin at higher temperatures.   
 
The results from the gastrointestinal study show that the permeability values obtained 
with the flow-through diffusion system are good predictors of BCS permeability 
classification.  This correlation existed for drugs that are absorbed by passive 
transcellular and paracellular diffusion, as well as by transport-mediated drug absorption. 
 
The BCS allows a biowaiver for solid IR oral formulations with high solubility and high 
permeability (class 1). These IR compounds are candidates for in vitro assessment of 
bioequivalence as long as they are stable in the gastrointestinal tract and have a wide 
therapeutic index (Lennernäs, 2007).  Instead of conducting expensive and time 
consuming in vivo studies, an in vitro test could therefore be adopted as the surrogate 
basis for the decision as to whether the two pharmaceutical products are equivalent.  
This can reduce time and costs during the development process and reduce 
unnecessary drug exposure to healthy volunteers in bioequivalence studies (FDA 
Guidance for Industry, 2000).  In view of the above considerations and the results found 
in the present study, it can be concluded that our flow-through diffusion system has 
potential usefulness for future in vitro BA/BE determinations.  The proposed method was 
tested on 4 drugs that belong to either BCS class 1 or 3.  Considering the widely 
differing chemical and physical properties of drugs, further validation of the above in vitro 
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model using all 4 BCS classes, larger number of drugs and different formulations is 
warranted.  Further permeability studies with this model are necessary to enlarge the set 
of flux values of already BCS classified drugs, so that clear flux value margins can be 
established for the specific BCS classes.  These established flux value ranges will help 
to accurately classify the permeabilities of future test compounds. 
 
Caco-2 cells are the most advanced and frequently used cell model to predict small 
intestine drug permeability and absorption, despite several disadvantages (Borchardt, 
1995; Artursson et al., 1994; Rubas et al., 1993).  Despite its frequent use and value to 
predict intestinal permeability the Caco-2 cell model has been shown to have high intra- 
and inter-experiment variations (>20 %).  The in vitro flow-through diffusion system used 
in the present study also showed high variation (especially with the peptide studies), but 
despite of this, the model also showed that valuable information can be obtained from its 
usage.  However, it must be remembered that the high intra- and inter-experiment 
variations are a shortcoming of the present in vitro flow-through diffusion system.   
 
Generally drug candidates with poor aqueous solubility cannot be evaluated in the Caco-
2 cell model, since the use of organic cosolvents is limited in the Caco-2 cell model.  The 
integrity of tight junctions is easily compromised by commonly used organic solvents.  
The results from the previously described vaginal mucosa and skin tissue study show 
that the in vitro flow-through diffusion model used in the present study can overcome this 
problem and the effects of a chemical enhancer can be successfully studied using this 
flow-through diffusion model.  Another drawback of the Caco-2 cells is that it cannot be 
used to evaluate the permeability of different intestinal regions, where as the flow-
through diffusion system has the possibility to that.  A further advantage of the present in 
vitro flow-through model is that the biological membrane‟s architecture is preserved and 
closely mimics the in vivo situation.  Compared to the Caco-2 cells, the flow-through 
diffusion system has the same potential for automation and it does not have the 
disadvantages of poor paracellular passage modelling, labour intensity, high costs and 
long cell growth cycles. The flow-through diffusion system has the potential to develop in 
to a simple, rapid, economic and highly-reproducible permeability method.   
 
The major advantages of all the above experiments are that because they were all 
performed in the same apparatus under standardised conditions, relative comparisons of 
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data were not subject to interlaboratory variations.  The absorption of drugs by different 
intestinal regions can potentially be studied and it may also be a useful method to 
compare the permeability values across species.  Since the flow-through diffusion 
system has a constant flow of buffer, it does not have the problem of an unstirred water 
layer in the acceptor and donor wells, like other in vitro models.  The amounts of drug 
required for the study are relatively small (milligram quantity) and the collected samples 
are analytically clean, which facilitates quantitative analysis.   
 
In conclusion, the results presented in this thesis show that valuable information can be 
obtained from the in vitro flow-through diffusion model, leading to the intelligent selection 
of suitable compounds for enhanced tissue permeability.  The permeability values 
obtained with the developed flow-through diffusion system are good predictors of in vivo 
permeation and concurred with other in vitro studies.  The results show that the 
continuous flow-through diffusion system can effectively be utilised to investigate 
different test conditions (de-epithelialisation of mucosal surfaces, chemical enhancers, 
temperature, permeant concentration and formulation) on the permeability of different 
compounds/drugs.  It seems that the in vitro flow-through diffusion model used in the 
present study have the potential to overcome some of the problems and limitations 
demonstrated by other in vitro techniques. It may potentially serve as a future tool for 
pharmaceutical companies to predict the diffusion characteristics of new drugs and 
different formulations across different biological membranes and may serve as a 
prospective method for assessing the bioequivalence of alternative (generic) vehicles or 
formulations containing the same drug/compound.   
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Chapter 6:  Future studies 
Areas for future research include: 
 
 Future studies with the in vitro flow-through diffusion system should investigate 
the exact presence and influence of metabolic enzymes and transporter 
enzymes.  Furthermore, “apical to basal” studies must be compared with “basal 
to apical” transports to determine the role of carrier-mediated transport of carrier-
mediated efflux mechanism involved with the present in vitro assay.     
 
 It was beyond the scope of the study to look at the effect of pathophysiological 
conditions and drug treatment on membrane permeability and the transport 
systems, but it will be an important aspect to investigate in follow-up studies, 
since transporter systems are affected by these variables. 
 
 Additional studies are necessary to determine the exact influence of different 
concentrations of the test compound on the flow-through diffusion system‟s ability 
to predict permeability.  These studies may include the utilization of a 
mathematical model.  
 
 Further permeability studies with this model are necessary to enlarge the set of 
flux values of already BCS classified drugs, so that clear flux value margins can 
be established for the specific BCS classes.  These established flux value ranges 
will help to accurately classify the permeabilities of future test compounds. 
 
 The following method for the determination of steady state was used: Repeated 
measure ANOVA over all time periods and a Bonferroni multiple comparison 
procedure was used to determine steady state.  If at consecutive time periods p-
values exceeded 0.05, these flux values do not differ significantly, therefore 
indicating steady state.  It was found in this study that flux values at steady state 
still increased (non-significantly) over the rest of the experiment for most of the 
test conditions.  It is therefore suggested that future studies should be done with 
the same data to develop a mathematical model that will be able to predict the 
max flux rate for the studied compounds. 
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 Further research and more data sets are needed to define and optimize the 
investigated experimental conditions. 
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